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Human granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cytokine 
that controls the normal production and functional activation of myeloid blood cells and has been 
implicated in diseases including myeloid leukemia, asthma and arthritis. GM-CSF mediates its 
effects by binding to specific cell surface receptors expressed on responsive cells. GM-CSF 
binds to a ligand-specific α-subunit (GMRα) with low affinity, and high affinity binding and 
signal transduction is achieved by the recruitment of the common β chain (hβc) to the GM-
CSF:GMRα complex. Despite GM-CSF’s central role in normal hematopoiesis, inflammation 
and disease, the mechanism of assembly and composition of the activated GM-CSF receptor 
(GMR) complex was unknown prior to this body of work. 
 
Using both cell surface expressed receptors and soluble extracellular domains of the GMR, the 
receptor assembly required for the activation of the GMR is shown here. The hβc was shown to 
form a functional dimer in activated cell surface expressed GMR using a functional assay for 
receptor homodimerization where the extracellular and transmembrane regions of the hβc were 
fused to the cytoplasmic domain of the functionally homodimeric erythropoietin receptor (EPO-
R).  
 
A previously unreported and uncharacterised interspecies interaction between exogenous hβc 
and endogenous mouse βc was revealed when the human GMR (hGMR) was expressed in 
mouse cell lines. This interspecies interaction was responsible for dramatically influencing 
hGMR signalling events, including assembly and activation, in a misleading manner. This 
highlights the critical importance of using fully homologous experimental systems when 





of previous reports where heterologous systems were used, and suggest that homologous GM-
CSF systems should be used to reach meaningful conclusions. 
 
Reported GMR stoichiometry studies using full-length surface receptors produced conflicting 
ratios for receptors within the activated GMR. Here we produced and purified soluble GMR 
components, sGMRα and sβc, and formed soluble GMR complexes in solution and determined 
the stoichiometric ratio of these complexes in the absence of membranes. Analysis of the 
individual soluble receptor components revealed that sGMRα exists as a monomer, whereas sβc 
exists as a dimer. Soluble GMRα was found to bind GM-CSF with a stoichiometry of 1:1. 
Importantly GM-CSF, but not a GM-CSF analogue (E21R), formed a ternary complex composed 
of one sβc dimer with a single molecule of each sGMRα and GM-CSF. These studies revealed a 
functionally relevant, direct interaction between GM-CSF and hβc extracellular domain that had 
been anticipated but never observed. A similar receptor assembly is likely to be conserved in the 
related IL-3 and IL-5 receptors. Interestingly the soluble GMR studies revealed both an inducible 
complex and a preformed complex, where the extracellular regions of sGMRα and sβc could 
interact in the absence of ligand. 
 
In summary, my research characterised how the individual GMR components assemble into an 
active receptor complex and determined a stoichiometry of 1:1:2 for GM-CSF:sGMRα:sβc. 
Importantly, this functionally relevant soluble GMR ternary complex led to X-ray 





I certify that this work contains no material which has been accepted for the award of any other 
degree or diploma in my name in any university or other tertiary institution and, to the best of my 
knowledge and belief, contains no material previously published or written by another person, 
except where due reference has been made in the text. In addition, I certify that no part of this 
work will, in the future, be used in a submission in my name for any other degree or diploma in 
any university or other tertiary institution without the prior approval of the University of 
Adelaide and where applicable, any partner institution responsible for joint-awards of this 
degree. 
 
I give consent to this copy of my thesis, when deposited in the University Library, being made 
available for loan and photocopying, subject to the provisions of the Copyright Act 1968. 
 
The author acknowledges that copyright of published works contained within this thesis resides 
with the copyright holder(s) of those works. 
 
I also give permission for the digital version of my thesis to be made available on the web, via 
the University’s digital research repository, the Library Search and also through web search 










I am immensely grateful to Professor Angel Lopez, initially for employing me as a member of 
such a highly regarded laboratory, and for the privilege of his supervision and guidance 
throughout the completion of my PhD studies. His support, extensive knowledge, guidance and 
patience throughout the past years have been truly appreciated. Thankyou Angel. 
 
Within the Lopez Lab, the Cytokine Receptor Laboratory, there have been many past and present 
members who I would like to thank for their immense help and friendship throughout the course 
of my studies. Dr Jo Woodcock for initially inspiring my interest in the cytokine-receptor field 
and for reminding me to regularly step back and observe the bigger picture. Thankyou for your 
constant positivity and mentoring. Dr Tim Hercus, a fabulous colleague whose help, enthusiasm, 
knowledge and attention to detail inspired me throughout this work, thankyou. I also appreciate 
the help of Bron Cambareri, my tissue culture mentor, an inspiration for persistence and 
thoroughness in all aspects of lab work. Thanks also to Mara Dottore, not only for teaching me 
your binding expertise, but also for the many enjoyable years of sharing our lab bay together.  
 
Thanks to Dr Richard D’Andrea for his collaboration towards the chimeric receptor work and 
appreciate his guidance in the preparation of my first published paper. My thanks are also 
extended to Dr Geoff Howlett of the Department of Biochemistry and Molecular Biology, 
University of Melbourne, Parkville, Victoria for performing the analytical ultracentrifugation 
experiment and for being such an enthusiastic collaborator. 
 
There have been many members of the Cytokine Receptor Laboratory over the years that I have 
been fortunate enough to work with throughout my studies: Hayley Ramshaw, Emma Barry, 




Gaunt, Emily Wilson, Wendy Winnall, Melissa Lee and Jane Murphy. Thanks for you all for 
your friendship and for surrounding me in an enjoyable and supportive working environment. I 
appreciate all I have learnt from you, and for your help and support. 
 
An enormous and heartfelt thanks goes to my parents. Their continuous support throughout all 
my studies gave me the foundation to achieve this goal. Especially Mum, for instilling me with a 
love of science. Not once as I grew up did I feel that a girl loving science was anything but the 
norm, thankyou. Looking back I can also appreciate how much my Grandpa Lew’s support of 
my creativity, followed then by his encouragement to make plans to ensure achieve I achieved 
my goal. This built the groundwork for what I do everyday. For all the daily rainfall data we 
collected together, then graphed just for the interest, undoubtedly encouraged my passion of my 
chosen career path. And my lifelong friend Sherrill, for as long as I can remember you have 
inspired me achieve, while staying true to myself, and motivated me to reach that little bit further 
than I imagined I could go, thankyou. 
 
I could not have finished this thesis without the love and support of my wonderful husband 
Lyall. There are not enough words to thankyou for your support and all that you do for me, 
thankyou. And lastly, to my two children Jenna and Ewan, I hope that in the years to come that 
you do not find this thesis a standard to attain, but that it inspires you to follow your passions and 
that it instils you with the belief that you can do anything you set your mind and your heart to. 
 





Akt  protein kinase B 
AML  acute myeloid leukemia 
Ba/F3  pro-B murine cell line 
BION-1 anti-hβc neutralising monoclonal antibody 
CML  chronic myeloid leukemia 
COS  African green monkey fibroblast cell line 
CRM  cytokine receptor module 
CTLL-2 cytotoxic T lymphocyte murine cell line 
E21R GM-CSF containing point mutation where glutamic acid at position 21 is 
substitute with an arginine  
ELISA enzyme-linked immunosorbent assay 
EPO  erythropoietin 
EPO-R erythropoietin receptor 
FCDP-1 murine bone marrow cell line 
G-CSF granulocyte-colony stimulating factor 
GH  growth hormone 
GHR  growth hormone receptor 
GM-CSF granulocyte-macrophage colony-stimulating factor 
GMR  granulocyte-macrophage colony-stimulating factor receptor 
GMRα  granulocyte-macrophage colony-stimulating factor receptor 
alpha chain 
gp130  glycoprotein 130 
Grb-2  growth factor receptor-bound protein 2 
hβc  human common beta chain 
8
 
IL-3  interleukin 3 
IL-5  interleukin 5 
IL-3Rα  interleukin 3 receptor alpha chain 
IL-5Rα  interleukin 5 receptor alpha chain 
IL-6  interleukin 6 
JAK  janus kinase 
JMML Juvenile myelomonocytic leukemia 
Kd  dissociation constant 
MAP-K mitogen-activated protein kinase 
mGM-CSF murine granulocyte-macrophage colony-stimulating factor 
mIL-3Rα  murine interleukin 3 receptor alpha chain 
mIL-5Rα  murine interleukin 5 receptor alpha chain 
mβc  murine common beta chain 
mβcIL-3 murine beta chain specific for IL-3 
Mpl  thrombopoietin receptor  
PAP   pulmonary alveolar proteinosis 
PTB  phosphotyrosine binding domain 
sGMRα  soluble granulocyte-macrophage colony-stimulating factor receptor alpha chain  
sβc  soluble human granulocyte-macrophage colony-stimulating factor      
receptor beta chain 
SCF  stem cell factor  
TPO  thrombopoietin 
SH2  src-homology domain 





1. Broughton SE, Hercus TR, Nero TL, Dottore M, McClure BJ, Dhagat U, Taing H, 
Gorman MA, King-Scott J, Lopez AF, Parker M. 2016 Conformational changes in the 
GM-CSF receptor structure suggest a molecular mechanism for affinity conversion and 
receptor signalling. Structure 24(8):1271-81 
 
2. Panousis C, Dhagat U, Edwards KM, Rayzman V, Hardy MP, Braley H, Gauvreau GM, 
Hercus TR, Smith S, Sehmi R, McMillan L, Dottore M, McClure BJ, Fabri LJ, Vairo G, 
Lopez AF, Parker MW, Nash AD, Wilson NJ, Wilson MJ, Owczarek CM. 2016 CSL311, 
a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated 
by the common β chain of the IL-3, GM-CSF and IL-5 receptors. MAbs 8(3):436-53. 
 
3. Broughton SE, Hercus TR, Hardy MP, McClure BJ, Nero TL Dottore M, Huynh H, 
Braley H, Barry EF, Kan WL, Dhagat U, Scotney P, Hartman D, Busfield SJ, Owczarek 
CM, Nash AD, Wilson NJ, Parker MW Lopez AF. 2014 Dual mechanism of interleukin-
3 receptor blockade by an anti-cancer antibody. Cell Reports  8(2):410-19. 
 
4. Ramshaw H, Xu X, Jaehne EJ, McCarthy P, Greenberg Z, Saleh E, McClure BJ, 
Woodcock J, Kabbara S, Wiszniak S, Wang TY, Parish C, van den Buuse M, Baune BT, 
Lopez A, Schwarz Q. 2013 Locomotor hyperactivity in14-3-3ζ KO mice is associated 
with dopamine transporter dysfunction. Transl Psychiatry #:3:e327 
 
5. Hercus TR, Barry EF, Dottore M, McClure BJ, Webb AI, Lopez AF, Young IG, Murphy 
JM. 2013 High yield production of a soluble human interleukin-3 variant from E.coli 
10
 
with wild-type bioactivity and improved radiolabelling properties. PLOS One 
8(8):e74376. 
 
6. Powell JA, Thomas D, Barry EF, Kok CH, McClure BJ, Tsykin A, To LB, Brown A, 
Lewis ID, Herbert K, Goodall GJ, Speed TP, Asou N, Jacob B, Osato M, Haylock DN, 
Nilsson SK, D’Andrea RJ, Lopez AF, Guthridge MA. 2009 Expression profiling of a 
hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic 
factor in AML. Blood 114(23):4859-70. 
 
7. Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J, Ramshaw H, 
Woodcock JM, Xu Y, Guthridge M, McKinstry WJ, Lopez AF, Parker MW. 2008 The 




8. Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer 
FA, Thomas DT, To B, Begley CG and Lopez AF. 2006 Growth factor pleiotrophy is 
controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J. 25(3):479-
89. 
 
9. Guthridge MA, Barry EF, Felquer FA, McClure BJ, Stomski FC, Ramshaw H and 
Lopez A.F. 2004 The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 
receptors mediates hematopoietic cell survival through activation of NF-(kappa)B and 




10. McClure BJ, Hercus TR, Cambareri BA, Woodcock JM, Bagley CJ, Howlett GJ and 
Lopez AF. 2003 Molecular assembly of the ternary granulocyte-macrophage colony-
stimulating factor receptor complex. Blood. 101(4):1308-15. 
 
11. McClure BJ, Stomski FC, Lopez AF and Woodcock J.M. 2001 Perverted responses of 
the human granulocyte-macrophage colony-stimulating factor receptor in mouse cell 
lines due to cross-species beta-subunit association. Blood. 98(10):3165-8. 
 
12. Ramshaw HR, Woodcock JM, Bagley CJ, McClure BJ, Hercus TR and Lopez AF. 2001 
New approaches in the treatment of asthma. Immunol. Cell. Biol. 79(2):154-9. Review. 
 
13. McClure BJ, Woodcock JM, Harrison-Findik D, Lopez AF and D’Andrea RJ. 2001 
GM-CSF binding to its receptor induces oligomerisation of the common beta-subunit. 
Cytokine. 13(4):240-3. 
 
14. Rossjohn J, McKinstry WJ, Woodcock JM, McClure BJ, Hercus TR, Parker MW, Lopez 
AF and Bagley CJ. 2000 Structure of the activation domain of the GM-CSF/IL-3/IL-5 
receptor common beta-chain bound to an antagonist. Blood. 95(8):2491-8. 
 
15. Guthridge MA, Stomski FC, Barry EF, Winnall W, Woodcock JM, McClure BJ, Dottore 
M, Berndt MC and Lopez AF. 2000 Site-specific serine phosphorylation of the IL-3 
receptor is required for hemopoietic cell survival. Mol Cell. 6(1):99-108. 
 
16. Sun Q, Jones K, McClure BJ, Cambareri B, Zacharakis B, Iverson PO, Stomski FC, 
Woodcock JM, Bagley CJ, D’Andrea R and Lopez AF. 1999 Simultaneous antagonism 
12
 
of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 
stimulation of human eosinophils by targeting the common cytokine binding site of their 
receptors. Blood. 94(6):1943-51. 
 
17. Woodcock JM, McClure BJ, Stomski FC, Elliott MJ, Bagley CJ and Lopez AF. 1997 
The human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor exists 
as a preformed receptor complex that can be activated by GM-CSF, interleukin-3, or 
interleukin-5. Blood. 90(8):3005-17. 
 
18. Dyson PG, Jackson KA, McClure BJ, Rawlings TP and To LB. 1996 Increased levels of 
megakaryocyte progenitors in peripheral blood mobilised by chemotherapy and/or 






It is nearly 30 years since the initial identification of the hematopoietic cytokine receptor GMRα. 
Less than a decade later in 1996, when the work described here was initiated, there were many 
unknowns about how the GMR subunits assembled in response to GM-CSF binding and initiated 
receptor activation. 
 
At this time the GM-CSF receptor subunits GMRα and hβc had been identified, and together 
shown to provide high affinity GM-CSF binding and signal transduction. The interaction of GM-
CSF with GMRα and hβc, and the ligand contacts required had been modelled on the well-
characterised structure of Growth Hormone bound to its homodimeric receptor. While this was 
crucial in revealing individual residues required for GM-CSF binding and receptor activation, the 
stoichiometry of the active GMR complex was unclear. The nature of the individual subunits 
GMRα and hβc had not been characterised, and conflicting reports proposed the minimum 
assembly required for GMR signal transduction to be either simple receptor heterodimers or 
higher order receptor complexes, but the exact stoichiometry remained unresolved. 
 
Using both cell surface expressed receptors and soluble extracellular domains of the GMR, the 
receptor assembly required for the activation of the GMR is shown here. The work presented in 
this thesis provided the path forward from structural homology modelling, and provided the 
initial studies that ultimately led to the resolution of the GMR atomic structure. Defining the 
molecular mechanisms of GMR receptor assembly will ultimately provide targets for therapeutic 



















1.1 The regulatory roles of hematopoietic cytokines. 
The communication between cells within the body is an exquisitely regulated process that allows 
complex coordinated events such as maintenance of hematopoiesis, and the control of growth 
and development of the growing body. Hematopoiesis is the dynamic process that regulates 
steady state blood cell numbers, increases of blood cell numbers following blood loss and 
regulates the immune response to clear infections. These processes are achieved by precise 
regulation of required blood cell numbers and their maturation and activation when necessary. 
 
Important regulatory molecules called cytokines facilitate communication between cells within 
the body [1]. These small, secreted glycoproteins regulate hematopoiesis by promoting the 
lineage commitment of stem cells, stimulating their expansion and differentiation and ultimately 
inducing the effector functions of mature blood cells (see Figure 1). Multiple cell types produce 
cytokines, including fibroblasts, myeloid cells, endothelial cells, T cells and bone marrow 
stroma. Cytokines may exert their functions locally in a paracrine manner on cells within close 
proximity, or influence cell populations at sites distant from the point of cytokine production.  
 
In addition to the regulatory role cytokines play in hematopoiesis they are also instrumental in 
the co-ordination of the inflammatory response. Inflammation involves various immune cells and 
many mediators that act to clear sites of infection within the body. Cytokines, in addition to other 
mediators including chemokines, act as messengers to promote leukocyte numbers and their 








The process of hematopoiesis derives the eight major blood lineages from self-renewing multipotent stem cells. 
CMP (common myeloid progenitor), CLP (common lymphoid progenitor), CFC (colony forming cell). (From 
Bloodlines by Don Metcalf Alpha Med Press 2007 www.bloodlines.stemcells.com/chapters.html). 
 
Cytokines mediate their functions by binding to specific surface glycoproteins, cytokine 
receptors, that are expressed on responsive cells at low levels (100-1000 per cell) [2]. When 
cytokines engage their receptors, signals are transduced within the cell resulting in activation of a 
biochemical cascade that results in a biological response. These cytokine stimulated signalling 
processes are vital to ensure the appropriate growth, survival and functional activity of 
responsive cells. 
 
Through understanding how different cytokines control the process of hematopoiesis, light has 
been shed on how a stem cell is directed to follow a particular commitment pathway and how 




influence cell survival or function, or may act in conjunction with other cytokines. Examples of 
hematopoietic cytokines include thrombopoietin (TPO), erythropoietin (EPO) and granulocyte-
colony stimulating-factor (G-CSF) which stimulate the production of platelet and 
megakaryocytes, red blood cells and neutrophils, respectively, while stem cell factor (SCF), an 
essential growth factor in normal hematopoiesis, exerts potent synergistic effects when combined 
with other cytokines [3]. 
 
1.2 Myeloid cell production and function 
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF), Interleukin-3 (IL-3) and 
Interleukin-5 (IL-5) are a distinct family of cytokines that regulate myeloid cells, including 
neutrophils, macrophages and eosinophils. The GM-CSF, IL-3 and IL-5 cytokine subfamily act 
specifically to promote survival, proliferation, differentiation and effector functions of myeloid 
cells (see Figure 1). These three cytokines are closely related as seen by their close proximity of 
chromosomal location, the structure of their genes and how they transduce a signal in responsive 
cells. In addition, these cytokines show some degree of overlapping biological activities on 
certain hematopoietic lineages, whilst maintaining distinct biological actions. GM-CSF, IL-3 and 
IL-5 are principally produced by activated T cells and act to modulate survival and effector 
functions of cells that express receptors for these cytokines [4]. GM-CSF exerts its effector 
functions on myeloid progenitors and mature myeloid cells including neutrophils, monocytes, 
eosinophils, basophils and dendritic cells [5]. IL-3 influences early hematopoietic progenitors 
and myeloid progenitors, eosinophils and basophils, while the role of IL-5 is restricted to 
regulation of eosinophils [6] and B cells [7]. 
 
The presence of the GM-CSF, IL-3 or IL-5 receptor (GMR, IL-3R or IL-5R) on the surface of a 




receptors that are composed of two subunits, a ligand specific α chain and a shared β chain 
(hβc). The α chains GM-CSFRα [8], IL3Rα [9], and IL5Rα [10] bind their cognate ligand with 
low affinity (1-10nM[8], 10-100nM[11] and 100-500nM[12], respectively) but this interaction is 
insufficient for signalling. The subsequent recruitment of the common signalling receptor 
subunit hβc, shared by all three cytokines, leads to high affinity binding and signal transduction 
[13].  
 
1.3 Granulocyte-Macrophage Colony-Stimulating Factor 
GM-CSF is a heterologous glycoprotein, approximately 28000Da that is principally produced by 
activated T-cells, macrophages and endothelial cells. Macrophages and granulocytes rise in 
numbers and exhibit a prolonged life-span and enhanced effector function in response to GM-
CSF [14-17], properties that have encouraged its use initially in infectious diseases such as those 
associated with AIDS [18, 19] and clinically as an adjunct in cancer therapy to correct anaemia, 
particularly neutropenia which results from ablative chemotherapy [20]. GM-CSF has also been 
used to mobilise stem cells from the bone marrow into the peripheral blood such that these cells 
can be easily harvested and used for autologous transplantation following chemotherapy 
treatment [21]. GM-CSF also controls dendritic cell production, differentiation and function and 
potentiates responses of CD4+ T cells in vivo [22, 23]. 
 
Interestingly, mice that are null for GM-CSF show no perturbations in steady state hematopoiesis 
suggesting GM-CSF is redundant in basal hematopoiesis. GM-CSF knockout mice have a 
distinct pathology where surfactant and lipids accumulate in the alveolar space of the lung, a 
condition similar to a human condition known as pulmonary alveolar proteinosis (PAP) [24]. 
This suggested GM-CSF is critical for pulmonary homeostasis and resistance to local infection 




IL-5 leads to other disease conditions where pathology arises as the result of inappropriate 
chronic inflammatory responses. These include asthma [26, 27], multiple sclerosis [28, 29] and 
rheumatoid arthritis [30]. The production of GM-CSF by chondrocytes has been implicated in 
the inflammatory pathology associated with arthritis as GM-CSF knockout mice are protected 
from collagen induced arthritis [31]. Persistent cytokine production, including GM-CSF, has 
been directly measured from synovial fibroblasts and its production may play an important role 
in the recruitment and activation of inflammatory cells in arthritic joints [32]. GM-SF is also 
drives arthritic and inflammatory pain [33]. The development of a human monoclonal antibody 
that neutralises GM-CSF signalling, mavrilimumab, has shown good efficiency treating 
rheumatoid arthritis in clinical trials [34] suggesting targeting GMR can provide a therapeutic 
benefit. 
 
In addition to the pathological role GM-CSF can play in inflammatory diseases it has also been 
implicated in myeloid leukaemia’s including acute myeloid leukemia (AML), juvenile 
myelomonocytic leukemia (JMML) and chronic myeloid leukemia (CML) where it is believed to 
enhance the growth and survival of leukemic blasts [35, 36]. JMML, a lethal childhood disease, 
is a prime example of this as malignant cells produce GM-CSF in an autocrine fashion to 
promote the spontaneous proliferation of malignant cells and in vitro progenitors show 
hypersensitivity to GM-CSF [37, 38].  
 
Understanding how GM-CSF promotes cell signalling through its specific receptor interactions 
will aid the development of molecules that can prevent inappropriate GM-CSF signals [4]. Such 
molecules that target the GMR have shown potential for treatment in both inflammatory and 
leukemic diseases [39, 40]. To aid in the design of specific inhibitors a clear insight into how the 





The crystal structure of GM-CSF has been solved [41]. It comprises a core structure of four 
alpha-helical bundles with a double overhanded topology, a fold which is common to other 
hematopoietic cytokines including IL-5 [42] and growth hormone (GH) [43]. This highlights the 
structural conservation between cytokines despite displaying a low level of sequence similarity. 
While the atomic structure of GM-CSF is known, the molecular interactions required to interact 
with its receptor components are still being determined. 
 
1.4 The GM-CSF Receptor 
GM-CSF receptors are expressed on cells of the myeloid lineage including progenitor and 
mature neutrophils, eosinophils, macrophages monocytes and mast cells [44-46]. As with other 
hematopoietic cytokines, activation of the GM-CSF receptor in response to GM-CSF is followed 
by oligomeric receptor formation and receptor phosphorylation. Unlike homodimeric receptor 
systems (eg.GH and EPO-R) the human GM-CSF receptor is a heterodimer composed of 2 
distinct subunits, a receptor α chain (GMRα) [8] that provides ligand specificity and hβc [13], 
and is communal to the IL-3 and IL-5 receptors. Both GMRα and hβc are transmembrane 
proteins of apparent molecular weight of 84 and 130kDa respectively and are glycosylated on 
their extracellular domains. The presence of asparagine-linked glycosylation on the extracellular 
domains of GMRα (11 potential sites) and hβc (3 potential sites) is crucial for both low and high 
affinity binding [47]. 
 
Both GMRα and hβc are members of the type I cytokine receptor family, identified by the 
presence of conserved cytokine receptor modules (CRM) in their extracellular domain. The 
common structural motif within the CRM is the presence of at least 2 fibronectin like folds, a 




contains seven β-strands (A-G and A’-G’ respectively) interspersed by loop regions. In addition, 
each CRM contains 4 spatially conserved cysteine residues required for correct protein folding 
and a transmembrane proximal tryptophan-serine motif (WSXWS) [48] which is essential for 
receptor surface expression [49]. EPO-R, G-CSFR, IL-4R, IL-6R, IL-7R and IL-2β also belong 
to the type I cytokine receptor family. The hβc extracellular domain contains two CRM modules, 
whereas the GMRα contains a single CRM (as do IL3Rα and IL5Rα). The GMRα chain has a 
unique N-terminal domain that only shares homology with IL3Rα and IL5Rα, characterising 
these three alpha chains as a distinct receptor family. 
 
GMRα binds GM-CSF with low affinity (equilibrium dissociation constant, Kd = 1-10nmol/L) 
and is unable to mediate signalling alone, although some reports have suggested a role for 
GMRα alone in glucose transport [50]. The hβc has not been shown to detectably bind GM-CSF 
alone, but forms a high affinity receptor (Kd = 20-100pmol/L) with the GMRα subunit. 
 
Given the importance of GMR in signals that regulate immune responses, hematologic recovery, 
and in some cases, leukemia, a significant amount of work has been devoted to structure-
function analysis of the cytokine-receptor systems. Characterisation of this family of receptors 
sought to identify functional epitopes responsible for receptor activation and identified regions in 
the cytoplasmic domain of hβc that couple to specific signalling molecules such as janus kinases 
(JAKs), STATs and the ras/MAP Kinase pathway [51-53]. However results from these studies 
have in some cases been ambiguous or even conflicting. 
 
Structural and dimerization requirements exist for the GMR to assemble upon ligand binding and 
for subsequent signalling to occur, some of which have been defined. While the stoichiometry of 




residues involved in GM-CSF, GMRα and hβc protein interaction and biological activity. For 
example, the binding of GM-CSF to GMRα appears to involve an electrostatic interaction 
between Asp112 in the fourth alpha helix of GM-CSF and Arg280 in the F-G loop of GMRα [54, 
55]. The biological activities and high-affinity binding of GM-CSF are exquisitely dependent on 
Glu21 in the first alpha helix of GM-CSF implying an interaction with hβc, although direct 
contact has not been demonstrated. Substitution of this amino acid with arginine generates a 
GM-CSF analogue, E21R, which exhibits only low-affinity binding and is unable to stimulate 
cellular proliferation and mature cell functions [56]. Importantly E21R generated as recombinant 
protein in E. coli is able to antagonise GM-CSF binding and function [57], however, the 
molecular basis of this antagonism is not fully understood. In hβc, residues in the B-C loop 
(Tyr365, His 367, Ile368) and F-G loop (Tyr421) of domain 4 are crucial for GM-CSF high-affinity 
binding and function [58-61]. Furthermore, the monoclonal antibodies directed against the hβc 
epitope encompassing these loops blocks GM-CSF binding and biological activities [62, 63]. 
 
The regions of GMR targeted by site-directed mutagenesis were based on the structural 
homology with the GH homodimeric receptor:ligand complex, a homodimeric type 1 cytokine 
receptor whose structure had been solved by crystallography. While the GHR structure is a 
useful tool to guide the selection of potential ligand:receptor and receptor:receptor interactions 
within the GMR, it is important to remember that GHR is a simple homodimeric receptor and 
may not completely reflect the heterodimeric nature of the GMR. 
 
Heterodimerization of GMRα and hβc is recognised as a crucial step for the activation of the 
GM-CSF receptor complex, however, the exact composition of the ternary complex remains 




is usually a pre-requisite for receptor activation. For example, IL-6 induces oligomerization of 
IL-6Rα and gp130 [64] that results in the assembly of a hexameric complex containing two IL-6 
molecules, two IL-6Rα subunits and a gp130 homodimer [65]. Formation of this higher order 
complex is required for receptor phosphorylation and cell signalling in response to IL-6 [66]. 
Similarly, erythropoietin induces receptor dimerization and subsequent receptor phosphorylation 
[67, 68]. The IL-3 receptor, which is closely related to the GMR [69], binds IL-3 and induces 
receptor heterodimerization between IL-3Rα and hβc, followed by intermolecular covalent 
disulphide bridging between their N-terminal domains [70]. The structural similarities and 
functional overlap between the GM-CSF and IL-3 receptor systems have suggested that the 
activation of the GMR may follow a similar pattern of events. Indeed, GM-CSF has been shown 
to induce co-association of the GMRα and hβc [71], and a general mechanism has been noted 
that involves disulphide bridging between receptor α chain and a cysteine motif in the hβc that is 
essential for activation of GM-CSF, IL-3 and IL-5 receptors [72] (and unpublished 
observations). Despite exhibiting some common features of activation with other receptors, the 
GMR also appears to exhibit some distinct features. For example, mutant forms of the GMR that 
are deficient in GM-CSF binding when expressed alone on cells are able to support binding 
when co-expressed with hβc [49, 55], suggesting the hβc can compensate for losses in binding 
affinity. 
 
Receptor chimera studies suggest that simple heterodimerization of GMRα and hβc is sufficient 
to activate the GM-CSF receptor (Figure 2) [71]. However, both crosslinking and dominant 
negative studies using surface expressed receptors suggest the formation of higher order GM-
CSF receptor complexes are required for receptor activation (Figure 2) [70, 73]. Dimerization of 




receptor activation [74] which this work confirmed. This may reflect the need to bring into close 
proximity the cytoplasmic domains of two hβc molecules associated with JAK-2, resulting in 
JAK transphosphorylation and receptor phosphorylation. Interestingly, hβc has been shown to 
exist as a preformed homodimer on the cell surface [70, 74] and the crystal structure of the 
complete extracellular domain of hβc has recently also shown it to be a dimer [75]. However, the 
exact stoichiometry of the active GM-CSF receptor complex had not been resolved until the 




Schematic presentation of possible GM-CSF receptor complexes. (A) GMRα and hβc in absence of GM-CSF and 
(B) potential reversible βc homodimerization. Following GM-CSF binding GMR subunits may assemble to form a 
heterodimer composed of GM-CSF:GMRα:hβc with stoichiometry of 1:1:1(C) or (D) a higher order complex with 
GM-CSF:GMRα:hβc stoichiometry of 2:2:2 [72]. 
 
1.5 GM-CSF receptor signal transduction 
The biological actions of GM-CSF, include proliferation, differentiation and functional 




regulated intracellular signalling cascade influencing gene expression. Receptor signalling in 
response to GM-CSF emanates from the intracellular domain of the hβc subunit through 
protein/protein interactions resulting in the activation of the JAK/STAT pathway, the mitogen-
activated protein (MAP) kinase pathway, and the PI-3 kinase pathway. The hβc achieves this 
despite a lack of intrinsic tyrosine kinase activity within the receptor [76, 77]. 
 
The critical first step in GM-CSF signalling, following receptor oligomerization, is the activation 
of the tyrosine kinase JAK-2. The requirement for two molecules of JAK-2 to be brought into 
close proximity for activation suggests the requirement that at least two hβc be present in the 
activated receptor. Following JAK-2 activation, a rapid and reversible phosphorylation of many 
cellular proteins occurs including the hβc receptor, but not GMRα. JAK-2 activation is essential 
for c-myc induction (supporting a proliferative cellular response) and the activation, dimerization 
and nuclear translocation of STAT-5 that regulates several GM-CSF inducible genes including 
pim-1, oncostatin M and Id-1 [78]. JAK-2 constitutively associates with a proline-rich membrane 
proximal region of βc, termed box 1, and disruption of this region leads to lack of binding and 
activation of JAK-2 [53, 74]. 
 
The tyrosine residues within the intracellular region of hβc (at positions 450, 452, 577, 612, 695, 
750, 806 and 866) are targets for phosphorylation by JAK-2 and these phosphorylated residues 
then act as docking sites allowing signalling complexes to assemble through src-homology 
(SH2) and phosphotyrosine binding (PTB) domains. A mutation of these tyrosine residues has 
enabled distinct pathways emanating from each residue to be discerned. Residues Tyr577, 
Tyr612 and Tyr695 of hβc are implicated in the activation of the ras/MAP kinase pathway [79]. 
Tyr577 recruits SHC through its PTB domain [52, 80, 81] domain whilst Tyr577 and Tyr612 are 




the ras/MAP kinase pathway. The PI 3-kinase pathway is also activated by GM-CSF [79, 82, 83] 
despite the lack of direct interaction between PI3-kinase and the hβc. A 14-3-3 binding motif 
surrounding the serine at position 585 of hβc has been identified [84]. This has been shown to 
recruit PI 3-kinase allowing activation of effector molecules of this pathway including Akt, 
resulting cell survival through the activation of survival genes including bcl-2 [85, 86]. 
Interestingly, when all eight tyrosine residues in the hβc intracellular domain are conservatively 
mutated to phenylalanine, preventing tyrosine phosphorylation, the hβc is still capable of 
transmitting a survival signal in response to ligand [52]. This suggests the signalling through 
regulation of the motif surrounding Ser585 is sufficient to elicit a survival response in the 
absence of JAK/STAT and ras/MAP kinase pathway activation. Constitutive phosphorylation of 
Ser585 is seen in CML and AML blasts [87, 88] potentially contributing to leukemic blast 
survival. 
 
Despite the large number of cellular proteins that are modified following GM-CSF receptor 
activation, the GMRα chain is not a target of phosphorylation nor has it been shown to directly 
recruit signalling molecules. Despite this, the presence of the short intracellular domain is 
absolutely required to support GM-CSF induced signalling through hβc [53]. Whilst the 
pathways that emanate from the GM-CSF receptor (and IL-3R and IL-5R) have been extensively 
mapped the stoichiometry of the receptor components remained unclear until this body of work. 
Resolution of the GMR stoichiometry and the identification of interfaces through which it 
assembles will provide novel targetable regions. 
 
1.6 Inhibitors of GM-CSF/IL-3/IL-5 signalling 
The involvement of GM-CSF (and IL-3 and IL-5) in chronic inflammatory diseases has driven 




molecules can be potential therapeutic agents and also useful tools for mapping epitopes 
important for receptor activation and assembly. Both anti-ligand neutralising antibodies [89] and 
antagonists that sequester ligand, such as soluble GMRα (sGMRα) [90], have been shown to 
prevent ligand-binding the receptor and subsequent receptor activation. An alternate approach to 
prevent activation of ligand specific receptors has been to prevent ligand from interacting with 
the α chain. This has been achieved by generating anti-IL-3Rα chain blocking antibodies [70] or 
by engineering specific ligand mutants such as the GM-CSF mutant E21R that behaves as a 
specific GM-CSF antagonist [57]. More recently the generation of an antibody that binds an 
epitope that encompasses the ligand-binding site of hβc can, not only inactivate the GMR, but 
also simultaneously inactivate signal transduction through the IL-3R and IL-5R [63]. Similarly 
the signalling of these three cytokines can be inhibited by oligodeoxynucleotides targeting the 
hβc [91]. Increasingly, synthesised compounds and mimetic peptides are being generated and 
screened to prevent receptor activation and have the potential for therapeutic use [92, 93]. 
 
In addition to specific engineered antagonists of GM-CSF, other surface receptors can interact 
with and modulate GM-CSF signal transduction. The laminin receptor (LR) has also been 
reported to interact with the intracellular portion of GMRα and hβc and this acts to inhibit GMR 
complex formation and subsequent signalling [94]. However, when laminin or fibronectin bind 
the LR this prevents the association of LR with hβc and allows GMR to complex and signal. 
This may enhance cell responsiveness at transendothelial migration sites to GM-CSF. 
 
1.7 Experimental systems for analysis of GM-CSF receptor assembly and activation. 
Central to the analysis of cytokine and receptor mutants is the choice of experimental system 
used. To date this has relied on mouse myeloid and lymphoid cell lines (Ba/F3, CTLL and 




of endogenous receptors for the murine cytokines can potentially pose a problem as the human 
and mouse receptors show high structural homology. In the murine system there are two βc 
subunits, mβc that are analogous to hβc, transducing signals by mGM-CSF, mIL-3 or mIL-5, 
and mβcIL-3, that is specific for mIL-3 [95, 96]. Analysis of hGMR introduced into cell lines 
expressing endogenous mouse GMR components have led to misleading interpretations of 
receptor functions. For example, transfection of hGMRα alone in murine FDCP-1 cells was 
initially reported to be sufficient to mediate a proliferative signal despite only displaying low 
affinity hGM-CSF binding [97]. However, it was later shown that functional reconstitution of 
hGMR required both hGMRα and hβc subunits [13], and that the initial observation with 
hGMRα alone was confounded by the recruitment of endogenous mβc [98]. Likewise, 
interaction of an extracellular point mutant of hβc with an endogenous mGMRα in FDCP-1 cells 
has been shown to lead to factor-independent proliferation [99] and chimeras between a 
constitutively active erythropoietin receptor with the cytoplasmic domain of GMRα promoted 
proliferation but only in presence of mβc [100]. 
 
The homology between the human and mouse GM-CSF receptors, which allow cross-species 
interactions, have led to the misinterpretation of the role of receptor subunits and their functional 
regions. While a cellular system is required for investigation of the cellular signalling and 
functional responses of cytokines, a cell free system using soluble forms of receptor components 
is emerging as a powerful tool for investigating the assembly, stoichiometry and ultimately 
atomic structure of hematopoietic cytokines bound to their receptors. 
 
1.8 GM-CSF Soluble receptors 
Soluble GMRα components occur naturally and have been exploited to probe receptor 




and the process of ligand-complex formation were investigated on surface expressed receptors 
and in solution where solubilised membranes were isolated. GM-CSF binding in solution to 
solubilised membranes that contained GMR lacked high affinity binding (Kd= 500pM), but GM-
CSF could be cross-linked within a 110- and 200kDa receptor ligand-complex [101], presumably 
to GMRα and hβc respectively [56]. This technique not only allowed the isolation and 
characterisation of GMR from a variety of cell types in a cell free environment, but also 
suggested that stable GM-CSF:GMR complexes could be formed in solution. Analysis of the 
GMR in solution had the potential to be further exploited not only to investigate binding 
characteristics of the GMR, but also for the investigation of the receptor complexes that were 
formed upon ligand binding. 
 
While full length soluble GMR could be generated by solubilising membrane in vitro, it was also 
becoming apparent that the GMRα could be produced not only in a full length transmembrane 
form, but also as a secreted soluble form in vivo [90, 102]. Expression of the sGMRα isoform 
occurs through an alternative mRNA splicing of the GMRα gene product [47] and ectodomain 
shedding [103]. This soluble receptor binds GM-CSF with low affinity (Kd = 3.8nmol/L) akin to 
cell surface expressed GMRα and can act as an antagonist to both surface expressed low and 
high affinity binding GMR in vitro and to biological activity [90]. The naturally occurring 
sGMRα isoform is not only present in the supernatant of cell lines that express GMR but is also 
secreted from monocytes [103] and is a normal constituent of human plasma [104]. Interestingly, 
GM-CSF and inflammatory mediators up regulate the naturally occurring sGMRα secretion, 
which may act to down modulate inflammatory responses [103]. In addition to their innate 
biological activity, soluble receptors can be used as building blocks in vitro to investigate how 
receptor complexes come together. Such studies can reveal important information such as the 




soluble receptor complexes can be used to reveal the atomic structure through x-ray 
crystallography. 
 
Crystal structures of ligands alone or in complex with soluble receptors have been elucidated, 
such as GH, only the atomic structure of GM-CSF from this sub-family has been determined 
[41]. The heterodimeric complex GM-CSF forms with GMRα and βc was initially modelled 
based on homology to the homodimeric GH receptor. Insights into the stoichiometry of another 
hematopoietin receptor family member, the IL-6 receptor, were achieved using soluble receptor 
components of IL-6R and the shared signalling subunit gp-130. These studies reveal that IL-6 
binds with low affinity to the IL-6R with a stoichiometry of 1:1, whereas the high affinity 
complex is hexameric containing two molecules of each IL-6, IL-6R and gp-130 [105]. The use 
of an analogous approach assembling complexes of the soluble receptor extracellular domains of 
both GMRα and βc could therefore give insight into the progression of assembly and 
stoichiometry of the GMR. 
 
1.9 Thesis Aims: 
GM-CSF plays an important role in the proliferation, differentiation and survival of myeloid 
precursors and mature effector cell functions, and has been implicated in the pathology of 
myeloid leukemias and chronic inflammatory diseases. Recent advances in the signalling 
pathways that emanate from the activated GMR have revealed the regulatory pathways that are 
utilised to mediate GM-CSF signalling through defined regions of the hβc. Despite these 
findings it was unclear how this receptor family assemble upon ligand engagement, if functional 
intermediate complexes were formed or how receptor assembly may be selectively modulated to 
prevent signal transduction. It also remained unclear if the GMR is composed of a simple 




was addressed by characterising the assembly of the GMR subunits in the presence and absence 
of ligand, in both a soluble form and when expressed on the cell surface. Cell systems were 
developed and critically analysed to investigate the assembly of full length GMRα, hβc and 
functionally dimeric receptor chimeras with GM-CSF. The development of these systems aimed 
to enable the determination of the GMR stoichiometry to reveal insights into the molecular 
mechanism of GMR assembly. These studies are critical preliminary steps required for 
crystallisation studies of the GMR complex to solve its atomic structure and understand how 
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The Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF )
Receptor Exists as a Preformed Receptor Complex That Can Be Activated
by GM-CSF, Interleukin-3, or Interleukin-5
By Joanna M. Woodcock, Barbara J. McClure, Frank C. Stomski, Michael J. Elliott, Christopher J. Bagley,
and Angel F. Lopez
The granulocyte-macrophage colony-stimulating factor GM-CSF. The preformed complex required only the extracel-
lular regions of GMRa and bc , as shown by the ability of(GM-CSF) receptor is expressed on normal and malignant
hematopoietic cells as well as on cells from other organs soluble bc to associate with membrane-anchored GMRa or
soluble GMRa. Kinetic experiments on eosinophils andin which it transduces a variety of functions. Despite the
widespread expression and pleiotropic nature of the GM- monocytes with radiolabeled GM-CSF, IL-3, and IL-5 showed
association characteristics unique to GM-CSF. Significantly,CSF receptor, little is known about its assembly and activa-
tion mechanism. Using a combination of biochemical and receptor phosphorylation experiments showed that not only
GM-CSF but also IL-3 and IL-5 stimulated the phosphoryla-functional approaches, we have found that the human GM-
CSF receptor exists as an inducible complex, analogous to tion of GMRa-associated bc . These results indicate a pattern
of assembly of the heterodimeric GM-CSF receptor that isthe interleukin-3 (IL-3) receptor, and also as a preformed
complex, unlike the IL-3 receptor or indeed other members unique among receptors of the cytokine receptor superfam-
ily. These results also suggest that the preformed GM-CSFof the cytokine receptor superfamily. We found that mono-
clonal antibodies to the GM-CSF receptor a chain (GMRa) receptor complex mediates the instantaneous binding of
GM-CSF and is a target of phosphorylation by IL-3 and IL-5,and to the common b chain of the GM-CSF, IL-3, and IL-5
receptors (bc ) immunoprecipitated both GMRa and bc from raising the possibility that some of the biologic activities of
IL-3 and IL-5 are mediated through the GM-CSF receptorthe surface of primary myeloid cells, myeloid cell lines, and
transfected cells in the absence of GM-CSF. Further associa- complex.
q 1997 by The American Society of Hematology.tion of the two chains could be induced by the addition of
receptor a:bc heterodimerization followed by covalent disul-G phide bridging between receptor a chain and bc .16 The struc-RANULOCYTE-MACROPHAGE colony-stimulatingfactor (GM-CSF) is a pleiotropic cytokine that exhib-
tural similarities and functional overlap between theits effects on most cell types in the hematopoietic compart-
GM-CSF and IL-3 receptor systems have suggested that acti-ment.1,2 GM-CSF exhibits overlapping biologic activities
vation of the GM-CSF receptor may follow a similar patternwith interleukin-3 (IL-3) on several hematopoietic cells ow-
of events. Indeed, GM-CSF has been shown to induce coas-ing to a similar pattern of receptor expression and to the
sociation of GMRa with bc ,17 and a general mechanismsharing of a communal signal transducing receptor subunit
has been noted that involves disulphide bridging betweenthat is also shared with IL-5.3 Indeed, on eosinophils that
receptor a chain and a cysteine motif in bc that is essentialexpress GM-CSF, IL-3, and IL-5 receptors, these three cyto-
for activation of GM-CSF, IL-3, and IL-5 receptors (Bagleykines stimulate the same functions with very similar po-
et al18 and unpublished observation). Despite exhibitingtency.4 The functional receptors for GM-CSF, IL-3, and IL-
some common features of activation with other receptors,5 are closely related and are composed of two subunits: a
the GM-CSF receptors also appear to exhibit some unusualligand-specific a chain and the communal b chain (bc ).5-7
features. For example, mutant forms of GMRa that are defi-The receptor a chains bind their cognate cytokine ligands
cient in GM-CSF binding when expressed alone on cellswith low affinity but are largely unable to mediate signalling
are able to support binding when coexpressed with bc ,19,20alone, although some reports have suggested a role for GM-
suggesting that bc can compensate for losses in binding af-CSF receptor a chain (GMRa) in glucose transport.8 The
communal b chain, bc , is unable to bind any cytokine alone,
but confers high-affinity binding on a ligand: a chain com-
From the Division of Human Immunology, Hanson Centre forplex (kd Ç100 pmol/L) and is required for receptor signal-
Cancer Research, Institute of Medical and Veterinary Science, Ade-ling.5-7 Functional high-affinity receptors for GM-CSF, IL-
laide, South Australia; and the Inflammation and Tissue Repair Ther-3, or IL-5 can be reconstituted on cells that do not normally
apeutic Team, SmithKline Beecham Pharmaceuticals, Essex, UK.express these receptors by coexpressing cytokine-specific a
Submitted March 24, 1997; accepted June 9, 1997.chains and b9-11c ; however, the relationship and assembly of Supported by grants from the National Health and Research
these subunits on the cell surface are unknown. Council of Australia. C.J.B. is a Rotary Peter Nelson Leukaemia
The mechanism of activation of the GM-CSF receptor is Research Fellow of the Anti-Cancer Foundation of the Universities
likely to involve receptor dimerization, although the molecu- of South Australia.
Address reprint requests to Angel F. Lopez, MD, PhD, Divisionlar basis of this phenomenon is poorly understood. Ligand-
of Human Immunology, Hanson Centre for Cancer Research, Insti-induced receptor dimerization is a common theme among
tute of Medical and Veterinary Science, Box 14 Rundle Mall Postthe cytokine receptor superfamily and is usually a prerequi-
Office, Adelaide, South Australia 5000.site for receptor activation. For example, IL-6 induces IL-
The publication costs of this article were defrayed in part by page6Ra and gp130 dimerization12 with homodimerization of charge payment. This article must therefore be hereby marked
gp130 causing receptor phosphorylation.13 Similarly, ciliary ‘‘advertisement’’ in accordance with 18 U.S.C. section 1734 solely to
neurotrophic factor induces receptor dimerization and subse- indicate this fact.
quent receptor activation.14 In the case of the IL-3 receptor q 1997 by The American Society of Hematology.
0006-4971/97/9008-0007$3.00/0that is closely related to the GM-CSF receptor,15 IL-3 induces
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The PCR product obtained from this set of primers was subclonedfinity. Conversely, a mutation in GM-CSF abolishes the abil-
into pRc/CMV to produce sGMRapRc/CMV.ity of the molecule to compete for low-affinity binding but
To allow for dual stable transfection of two receptors, pRc/CMVretains the ability to compete for high-affinity binding.21
was engineered such that the neomycin resistance gene (NeoR) wasLastly, a recent report showed that a naturally occurring
replaced with the puromycin resistance gene (pac) from pRuf puro.24soluble form of GMRa is retained at the cell surface when Briefly, the 1.5-kb Kpn I-BamHI fragment from pRc/CMV con-coexpressed with bc , although coimmunoprecipitation of the taining NeoR and its flanking SV40 early promoter and poly-adenyla-
two subunits could only be demonstrated in the presence of tion region was subcloned into pUC19. The NeoR gene was removed
GM-CSF.22 by EcoRV-Nae I digestion and pac introduced as a Sal I-Cla I
We report here that the human GM-CSF receptor exists fragment from pRuf puro. The puromycin resistance gene plus
flanking SV40 early promoter and poly-adenylation region was ex-as both an inducible complex and, unlike other cytokine
cised from pUC19 as a Kpn I-BamHI fragment and subcloned intoreceptors, as a preformed receptor complex. Using mono-
Kpn I-partial BamHI digested sbcpRc/CMV, resulting in sbcpRc/clonal antibodies (MoAbs) specific for the GM-CSF receptor
CMVpuro. Subsequently, full-length bc cDNA was introduced in ona and bc , we found that both subunits could be coimmuno-
an EcoRI-Xba I fragment thereby generating bcpRc/CMVpuro.precipitated in the absence of GM-CSF regardless of whether
Construction of stable CHO cell lines. The CHO cell lines,they were surface expressed or expressed as soluble forms sbcCHO and sGMRa CHO, were developed as described previouslyby the same cells. Consistent with there being two types of for the GMRa CHO cell line, A9/C7.21 CHO lines expressing
GM-CSF receptor complex, we show in kinetic experiments sGMRa or GMRa were subsequently cotransfected with either
on eosinophils that GM-CSF exhibits unique association ki- bcpRc/CMVpuro or sbcpRc/CMVpuro by the same method and se-
netics with two types of binding site; one type exhibits asso- lected in 2.5 mg/mL Puromycin (Calbiochem, La Jolla, CA). Cell
surface expression of transfected receptors was confirmed by flowciation kinetics very similar to those of IL-3 and IL-5,
cytometry as described previously16 and analyzed on an EPICS Pro-whereas the other type shows virtually instantaneous associa-
file II Flow Cytometer (Coulter Electronics, Hialeah, FL).tion. Significantly, stimulation of cells not only with GM-
Purification of human eosinophils and monocytes. EosinophilsCSF but also with IL-3 and IL-5 induces the phosphorylation
were purified from the peripheral blood of eosinophilic individualsof bc associated with GMRa. A model is proposed in which by centrifugation on a hypertonic gradient of metrizamide as de-IL-3 and IL-5 recruit the performed GM-CSF receptor into scribed previously.25 Monocytes were purified from the peripherala high order complex, raising the possibility that some of the blood of normal donors obtained from the Adelaide Red Cross Trans-
biologic activities of IL-3 and IL-5 are mediated indirectly fusion Service as described previously.26
through activation of the preformed GM-CSF receptor com- Antibodies. MoAbs directed against GMRa, IL-3Ra, or bc were
plex. generated as previously described27 and purified and characterized
as detailed elsewhere.16,27,28 The MoAbs 8E4 and 4F3 were selected
for their ability to specifically immunoprecipitate bc , 8G6 for
MATERIALS AND METHODS GMRa, and 9F5 for IL-3Ra. The MoAb 1C1 and an antipeptide
polyclonal rabbit antibody (against residues 131-241 of bc ) wereCell lines. Chronic myelogenous leukemia (CML) cells were
used for immunoblotting bc and an MoAb 8D10 for immunoblottingobtained as described previously16 and cultured in RPMI supple-
GMRa. Phosphotyrosine residues were detected by immunoblot us-mented with 10% fetal calf serum (FCS). Mo7e cells and Ba/F-3
ing directly horseradish peroxidase-conjugated PY20 antibody (Sap-cells expressing GMRa/bc were maintained in DMEM (GIBCO,
phire Bioscience, Alexandria, New South Wales, Australia). MoAbsMelbourne, Australia) supplemented with 20 mmol/L HEPES sup-
4F3, 8G6, and 6H6 were used for cell surface expression stainingplemented with 10% FCS and 5 or 2 ng/mL GM-CSF, respectively.
for bc , GMRa, and IL-3Ra, respectively. The anti-bc antibody,TF-1.8 cells were maintained in RPMI supplemented with 10% FCS
3D7,28 was used for affinity purification of sbc protein. The MoAbsand 2 ng/mL GM-CSF. Factor dependent cells were routinely starved
were purified from ascites as described.27 A rabbit polyclonal anti–of growth factor overnight before cytokine treatment. Chinese ham-
GM-CSF antibody was used for immunoprecipitating GM-CSF.21ster ovary (CHO) cells were maintained in F12 medium supple-
Purification of recombinant soluble human bc receptor. Solublemented with 10% FCS and transfected as described previously.21
bc protein was purified from conditioned medium from CHO cellsPlasmid construction. The cDNA for the human bc was cloned
stably expressing the protein using a 3D7 anti-bc MoAb affinityby polymerase chain reaction (PCR) from cDNA prepared from the
column. Bound soluble bc was eluted with a linear gradient from 3KMT-2 cell line.23 A soluble form of the bc (sbc ) was created by
to 1 mol/L KSCN in 10 mmol/L Tris-HCl, pH 8.0, and subsequentlyPCR using the following synthetic oligonucleotides: (1) 5*-TGA-
buffer exchanged into phosphate-buffered saline (PBS) containingATTCGCCTGTCCAGAGCTGACCAGGG-3* that starts 25 nucleo-
0.02% (vol/vol) Tween 20 [polyoxyethylene (20)-sorbitan monolau-tides 5* of the ATG and contains an engineered HindIII site and (2)
rate].5*- ATACACTCTATATCACGACTCGGTGTCCCAGGAGCG -3*
125I-surface labeling and immunoprecipitation conditions. Cellsthat contains an inframe termination codon immediately 5* of the
were cell-surface labeled with 125I by the lactoperoxidase method astransmembrane region followed by an engineered Xba I site. The
described previously.29 Approximately 108 cells were labeled withPCR product obtained from these primers was subcloned into the
Neomycin resistance conferring expression vector pRc/CMV (In- 1 mCi 125I (NEN, Boston, MA) in PBS. Cells were lysed in lysis
buffer consisting of 137 mmol/L NaCl, 10 mmol/L Tris-HCl (pHvitrogen Corp, San Diego, CA) giving rise to sbcpRc/CMV. A solu-
ble form of the human GMRa (sGMRa) was made in a similar 7.4), 10% glycerol, and 1% nonidet P-40 (NP40) with protease and
phosphatase inhibitors (10 mg/mL leupeptin, 2 mmol/L phenylmethl-fashion using the following synthetic oligonucleotides: (1) 5*-ATA-
CACAAGCTTAGCACCATGCTTCTCCTGGTG-3* that starts 18 sulphonyl fluoride, 10 mg/mL aprotonin, and 2 mmol/L sodium vana-
date) for 30 minutes at 47C followed by centrifugation of the lysatenucleotides 5* of the ATG and contains an engineered HindIII site
and (2) 5*-ATACACTCTAGATCACCCGTCGTCAGAACCAAA- for 15 minutes at 47C. After 1 hour of preclearance with protein A-
sepharose (Pierce, Rockford, IL) at 47C, the supernatant was incu-TTC-3* that contains an inframe termination codon immediately 5*
of the transmembrane region followed by an engineered Xba I site. bated for 18 hours with 10 mg/mL antibody. Protein-Ig complexes
AID Blood 0007 / 5h3f$$$121 09-11-97 19:11:13 blda WBS: Blood
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were captured by incubation for 1 hour with protein A-sepharose in a similar fashion to soluble receptor assays described previously.34
Aliquots of soluble receptor (100 mL) were incubated with 125I-followed by 6 subsequent washes in lysis buffer and then subjected
to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- labeled GM-CSF (10 mL) over a concentration range of 0.5 to 20
nmol/L. An excess of unlabeled GM-CSF was added to assays toPAGE). Immunoprecipitation of proteins from conditioned medium
was performed similarly. determine nonspecific binding. Assays were incubated at room tem-
perature for 1 hour, and then Con A-sepharose (10 mL of 50% slurryDeglycosylation conditions. Deglycosylation of proteins was
performed after immunoprecipitation with the protein still attached in PBS) was added to each tube and allowed to bind over 1 hour.
Sepharose (100 mL of 50% slurry in PBS) was then added to eachto the protein A-sepharose beads. The immunoprecipitated protein
was first incubated in 200 mmol/L sodium cacodylate, pH 7.0, 0.1% assay to increase the amount of precipitable material, and the tubes
were centrifuged to pellet the beads. Pelleted beads were washedSDS and then in 0.75% NP40 with neuraminidase, O-glycanase
(Genzyme, Castle Hill, New South Wales, Australia), and N-glyca- once in PBS and then the radioactivity was determined by counting
on a g-counter.nase (New England Biolabs, Arundel, Australia) for 18 hours at
377C before separation by SDS-PAGE. Kinetic binding assays. Association kinetics were determined at
47C with eosinophils and monocytes using radio-iodinated cytokinesSDS-PAGE and silver staining. Immunoprecipitated proteins
were analyzed by SDS-PAGE on 7.5% or 10% polyacrylamide gels at 200 pmol/L. Cells (2 to 4 1 106 per tube) were incubated in 0.15
mL of binding medium containing radioligand with or without 100-as stated. Samples were boiled for 10 minutes in either the presence
or absence of 2-mercaptoethanol (ie, reducing or nonreducing) be- fold excess unlabeled cytokine in borosilicate tubes on a rotating
table. Assays were harvested at time points after addition of radio-fore separating immunoprecipitated proteins by SDS-PAGE. Molec-
ular weights (MW) were estimated using SeeBlue Pre-Stained Stan- iodinated cytokine by overlaying onto 0.2 mL FCS and spinning for
30 seconds at maximum speed in a Beckman microfuge (Beckman,dards (Novex, San Diego, CA). Radiolabeled proteins were
visualized using an ImageQuant Phosphorimager (Molecular Dy- Gladesville, New South Wales, Australia). The visible cell pellet
was removed by cutting and the radioactivity in the pellet determinednamics, Sunnyvale, CA). Silver staining of gels was performed as
described previously.30 on the g-counter. The apparent association rate (Kobs ) was calculated
using the KINETIC program (Elsevier Biosoft) from the specificImmunoblotting and enhanced chemiluminescence (ECL) detec-
tion. Immunoprecipitated proteins separated by SDS-PAGE were binding data. Kobs is a composite function encompassing both on
and off rates (Kon and Koff , respectively) from the receptor: Kobs Åtransferred to nitrocellulose membrane by electroblotting. Nitrocel-
lulose membranes were routinely blocked in a solution of PBS, Kon[L] / Koff .
0.05% Tween 20 (vol/vol) (PBT) containing 5% skim milk (wt/vol)
or in 10 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.05% Tween RESULTS20 (vol/vol) (TNT) containing 5% bovine serum albumin (wt/vol)
and probed with antibody, followed where appropriate by either GMRa andbc are preassociated on the cell surface. Dur-
rabbit antimouse horseradish peroxidase (Dako, Carpenteria, CA) ing the course of our studies on IL-3 receptor complex for-
or goat antirabbit horseradish peroxidase (Dako). Immunoreactive mation, we previously observed coimmunoprecipitation of
proteins were detected by chemiluminescence using the ECL kit an 80,000 MW protein with bc from 125I-surface–labeled
(Amersham, Little Chalfont, UK) following the manufacturer’s in- primary CML cells in the absence of exogenous stimuli.16
structions. Stripping of membranes was performed by incubating The size of this protein suggested it could be the GMRa.nitrocellulose membrane for 30 minutes at 507C in 100 mmol/L 2- To examine this possibility, we conducted immunoprecipita-mercaptoethanol, 2% SDS, 62.5 mmol/L Tris-HCl, pH 6.7, followed
tion of 125I-surface–labeled CML cells either in the presenceby two sequential washes in PBT or TNT. Membranes were re-
or absence of GM-CSF or IL-3 with anti-GMRa, anti–IL-blocked for 1 hour before reprobing.
3Ra, or anti-bc antibodies. Immunoprecipitation of unstimu-Production and radio-iodination of GM-CSF, IL-3, and IL-5. Re-
combinant GM-CSF was produced in Escherichia coli as described lated cells with anti-GMRa antibody 8G6 immunoprecipi-
previously.21 For the kinetic experiments, recombinant GM-CSF, IL- tated a protein of 80,000 MW, consistent with the size of
3, and IL-5 were produced in yeast as described previously.31 Radio- GMRa (Fig 1A). A second protein of 120,000 MW, corre-
iodination of cytokines was performed by the iodine monochloride sponding in size to bc , coimmunoprecipitated with GMRa
method32 and the iodinated proteins separated from iodide ions on in the absence of GM-CSF and its level did not increase
a Sephadex G-25 PD-10 column (Pharmacia, Uppsala, Sweden) and with the addition of GM-CSF (Fig 1A). Reciprocally, immu-eluted with PBS containing 0.02% Tween 20 and stored at 47C for noprecipitation with anti-bc antibody 4F3 immunoprecipi-up to 4 weeks. The yeast derived radio-iodinated cytokines were
tated both the 120,000 MW bc protein and the 80,000 MWpurified before use as described previously.31
GMRa protein in the presence or absence of GM-CSF (FigSaturation binding assays. Binding assays were performed on
1A). Coimmunoprecipitation of GMRa with bc with eitherCHO cells grown to confluency in 96-well plates over a concentra-
tion range of 10 pmol/L to 10 nmol/L 125I-labeled GM-CSF in bind- anti-GMRa or anti-bc antibodies could be the result of these
ing medium (RPMI containing 0.5% [wt/vol] bovine serum albumin antibodies recognizing similar epitopes on both receptor
and 0.1% [wt/vol] sodium azide) with nonspecific binding deter- chains. However, in previous studies, we have shown that
mined at each concentration with excess unlabeled GM-CSF. After these antibodies are absolutely specific for their respective
incubation at room temperature for 2 hours, radioligand was removed receptor chains and show no cross-reactivity.16, 28
and the wells were washed briefly twice in binding medium. Where In contrast to the coimmunoprecipitation seen with GMRastated, low-affinity binding was then removed with five sequential and bc , coimmunoprecipitation of IL-3Ra and bc by either15-minute washes in binding medium. Specific counts were deter-
anti–IL-3Ra or anti-bc antibodies was only seen in the pres-mined after lysis of the cell monolayer with subsequent transfer and
ence of IL-3 (Fig 1B), as shown previously.16 The phos-counting on a g-counter (Cobra Auto Gamma; Packard Instruments
phorimage signal for the IL-3 receptor (Fig 1B) is strongCo, Meridien, CT). Dissociation constants were calculated using the
relative to the signal obtained for GM-CSF receptor (FigEBDA and LIGAND programs33 (Elsevier Biosoft, Cambridge, UK).
Binding assays were performed on soluble receptors in solution 1A) owing to the high level of IL-3 receptor expression
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Fig 1. Coimmunoprecipitation
of GMRa and bc from primary
CML cells. (A and B) CML cells
were 125I–surface-labeled, treated
with (") or without (Ï) GM-CSF
or IL-3 (6 nmol/L) for 5 minutes
at 47C and immunoprecipitation
was performed either with anti-
GMRa (8G6), anti–IL-3Ra (9F5),
or anti-bc (4F3) MoAb. Immuno-
precipitated proteins were sepa-
rated on 7.5% SDS-PAGE and
visualized by phosphorimager
and are presented at exposure
levels appropriate for the spe-
cific signal obtained. (C) Proteins
immunoprecipitated from CML
cells with different antireceptor
antibodies either in the presence
(") or absence (Ï) of GM-CSF
were subjected to Western
transfer and immunoblotted us-
ing a polyclonal anti-bc antibody.
relative to GM-CSF receptor on these cells.35 As stated pre- Mo7e cells maintained in IL-3 and murine Ba/F-3 cells ex-
pressing human GMRa and bc maintained in GM-CSF wereviously, a protein of 80,000 MW, consistent in size with
GMRa, coimmunoprecipitated with bc in either the presence starved overnight before GM-CSF stimulation. Cells were
125I-surface labeled and proteins were immunoprecipitatedor absence of IL-3, although at much weaker intensity than
either bc or IL-3Ra16 and is hence not visible at the exposure with anti-GMRa (8G6) or anti-bc (8E4) before and after
treatment with GM-CSF. We observed coimmunoprecipita-shown (Fig 1B).
To confirm the identity of the 120,000 MW protein coim- tion of the 120,000 MW bc protein and the 80,000 MW
GMRa protein with either antibody in the presence or ab-munoprecipitated by anti-GMRa antibody 8G6, we per-
formed immunoprecipitations with unlabeled cells before sence of GM-CSF (Fig 2A and B), although the signal ob-
served on Mo7e cells was weak relative to the CML andand after treatment with GM-CSF using anti-GMRa (8G6),
anti-bc (4F3), and anti–IL-3Ra (9F5) antibodies. After Ba/F-3 cells, presumably due to low receptor expression.
However, the relative intensity of the two proteins immuno-Western transfer, an immunoblot with anti-bc antibody was
performed. An 120,000 MW protein was clearly detected in precipitated from Mo7e cells was similar regardless of
whether GM-CSF was present or not, whereas with the GM-the presence or absence of GM-CSF in both GMRa and bc
immunoprecipitates but not in the IL-3Ra immunoprecipi- CSF receptor expressing Ba/F-3 cells, GM-CSF stimulation
enhanced the association of bc with GMRa (Fig 2A and B),tate (Fig 1C). This indicates that bc is associated with GMRa
but not with IL-3Ra in the absence of added cytokine on indicating that only a proportion of GM-CSF receptors are
preformed in these cells. To confirm that the 120,000 MWthese primary CML cells.
One possible explanation for the preassociation of GMRa protein coimmunoprecipitated from Ba/F-3 cells with
GMRa was human bc and not a mouse b chain protein, anwith bc was the autocrine production of GM-CSF by the
CML cells. However, we were unable to detect either GM- immunoblot was performed on the immunoprecipitates with
anti-bc antibody. The anti-bc antibody was highly immunore-CSF protein by enzyme-linked immunosorbent assay or
GM-CSF mRNA by Northern analysis or reverse transcrip- active against the 120,000 MW protein immunoprecipitated
by anti-GMRa antibody in either the presence or absencetion-PCR (data not shown). Nevertheless, to confirm the
GM-CSF–independent association between GMRa and bc of GM-CSF, confirming the 120,000 MW protein as human
bc (Fig 2C). Reprobing the immunoblot with antiphosphoty-and to determine the generality of this observation, we per-
formed immunoprecipitation experiments on a human GM- rosine antibody PY20 showed that the bc was phosphorylated
only after treatment of the Ba/F-3 cells with GM-CSF (FigCSF–dependent cell line (Mo7e) and on a mouse cell line
(Ba/F-3) transfected with the human GM-CSF receptor. 2C), indicating that the preformed GMRa:bc complex is not
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Fig 2. Coimmunoprecipitation of GMRa and bc from Mo7e and hGMRa/hbc -expressing Ba/F-3 cells. (A) Mo7e cells were starved overnight
and 125I–surface-labeled and treated with (") or without (Ï) GM-CSF (6 nmol/L) for 5 minutes and immunoprecipitation was performed either
with anti-GMRa MoAb (8G6) or anti-bc MoAb (4F3). Immunoprecipitated proteins were separated on 7.5% SDS-PAGE under reducing conditions
and the gel was exposed to phosphorimager. (B) hGMRa/hbc -expressing Ba/F-3 cells were starved overnight and 125I–surface-labeled and
treated with (") or without (Ï) GM-CSF (6 nmol/L) for 5 minutes and immunoprecipitation was performed with anti-GMRa MoAb (8G6).
Immunoprecipitated proteins were separated on 7.5% SDS-PAGE under reducing conditions and the gel was exposed to phosphorimager. (C)
Proteins immunoprecipitated from hGMRa/hbc -expressing Ba/F-3 cells with anti-GMRa MoAb (8G6) either in the presence (") or absence (Ï)
of GM-CSF were subjected to Western transfer and immunoblotted using anti-bc antibody 1C1 (upper panel) or antiphosphotyrosine antibody
PY20 (lower panel).
activated and that this complex was not the result of residual may relate to the ability of bc to spontaneously form dimers,
as previously noted.16,18,37cytokine on the cells after overnight factor depletion. These
findings strongly suggest that GMRa and bc are associated The association of sbc with GMRa was studied by
transfecting the sbc construct into CHO cells expressingat the cell surface in the absence of GM-CSF as a preformed
complex. GMRa and monitoring sbc retention at the cell surface with
anti-bc MoAb. Initial flow cytometric analysis showed spe-A soluble form of bc interacts with cell surface expressed
GMRa. To determine whether the extracellular portions of cific binding of anti-bc MoAb on the surface of CHO cells
coexpressing sbc and GMRa but not on CHO cells express-GMRa and bc are sufficient for ligand-independent
GMRa:bc interaction, we made a construct encoding a solu- ing sbc alone (data not shown). Importantly, the specific
association of sbc with GMRa on the surface of CHO cellsble form of bc (sbc ) comprising the entire extracellular do-
main but lacking the transmembrane and cytoplasmic regions could be also demonstrated by coimmunoprecipitation ex-
periments. In these experiments we also sought to establishand examined its ability to associate with GMRa. Initial
characterization of sbc was performed by transfection into that the retained bc reactivity detected on the GMRa-ex-
pressing CHO cells was indeed sbc and not another proteinCHO cells and affinity purification of conditioned medium
on an anti-bc antibody 3D7 coupled to CNBr-activated seph- with a common epitope or a fusion protein produced by an
anomalous transfection event. To examine surface expressedarose column. Two proteins of 55,000 and 65,000 MW were
specifically eluted from the affinity column and visualized bc specifically and avoid involvement of bc from intracellular
compartments, CHO cells expressing either full-length oron a reducing SDS-PAGE gel by silver staining (Fig 3A).
These two proteins were also detected after Western transfer soluble bc with or without GMRa were surface labeled with
125I and bc protein immunoprecipitated using an anti-bc anti-by immunoblotting with anti-bc antibody (1C1; Fig 3B),
implying that they represent two forms of sbc protein. In- body (8E4). A single 125I-labeled protein of 120,000 MW
was immunoprecipitated from CHO cells expressing full-triguingly, when the eluted sbc fractions were run on SDS-
PAGE under nonreducing conditions, proteins of 120,000 length bc (Fig 4A). Two 125I-labeled proteins of 55,000 and
65,000 MW were immunoprecipitated from CHO cells ex-MW and higher were seen by silver staining (Fig 3A) and
also by anti-bc immunoblotting (Fig 3B), suggesting that the pressing GMRa and sbc (Fig 4A) that corresponded in size
to the sbc proteins detected in cell supernatants (Fig 3).sbc forms disulphide-linked dimers and higher order com-
plexes. A similar phenomenon was observed with a soluble No labeled protein was immunoprecipitated from CHO cells
expressing sbc alone (data not shown), indicating that theform of the mouse IL-3–specific b chain, sAIC2A,36 and
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Fig 3. Soluble bc protein was
purified from conditioned me-
dium from CHO transfectants.
Soluble purified bc protein was
run under reducing (R) or nonre-
ducing (NR) conditions on 10%
SDS-PAGE and either (A) silver
stained or (B) subjected to West-
ern transfer and immunoblotted
with anti-bc antibody (1C1).
Fig 4. Soluble bc is retained on the surface of GMRa-expressing CHO cells. (A) CHO cells expressing GMRa and either full-length bc (bc ) or
soluble bc (sbc ) were 125I–surface-labeled and immunoprecipitation was performed with anti-bc MoAb (8E4). The immunoprecipitated proteins
were then either incubated with (2) or without (1) deglycosylating enzymes and subsequently separated on 7.5% SDS-PAGE under reducing
conditions and visualized by phosphorimager. (B) Soluble bc was immunoprecipitated from the medium of CHO cells coexpressing GMRa and
soluble bc (sbc ) and the immunoprecipitated proteins were either subjected to enzymatic deglycosylation (2) or not (1) and subsequently
separated on 7.5% SDS-PAGE. Western transfer was then performed and immunoblotting with anti-bc antibody 1C1.
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Fig 5. Scatchard transformation of saturation
binding studies performed on CHO cells coexpress-
ing (A) GMRa and full-length bc or (B) GMRa and
soluble bc (sbc ). Binding assays were performed with
125I-labeled GM-CSF over a concentration range of
10 pmol/L to 10 nmol/L. After binding had reached
equilibrium, the cells were washed briefly and either
lysed directly (s) or subjected to five 15-minute
washes to remove ligand bound with low affinity
(●). The dashed line indicates the best fit for nondis-
sociated binding and the solid line indicates the best
fit for dissociated binding.
sbc retained on the surface of GMRa-expressing cells does of a soluble form of GMRa and sbc in solution. To test this
idea, we constructed a soluble carboxy-truncated form ofnot represent sbc protein in the process of secretion but is
specifically retained by GMRa. GMRa that comprised only the extracellular portion of the
receptor, termed sGMRa. By immunoprecipitation and im-To investigate the nature of the sbc protein doublet de-
tected on GMRa-expressing CHO cells, in vitro deglycosyl- munoblotting using a GMRa chain specific antibody (8G6),
we detected a 65,000 MW protein in the medium of CHOation was performed on the immunoprecipitated protein be-
fore SDS-PAGE. The two 125I-labeled sbc proteins were both cells transfected with this construct, indicating that the solu-
ble GMRa protein was expressed and was able to bind GM-rendered to a 50,000 MW protein (Fig 4A). Similarly, the
two 55,000 and 65,000 MW forms of sbc immunoprecipi- CSF specifically with low affinity (kd 13.7 nmol/L; data not
shown).tated from conditioned medium were converted to a 50,000
MW protein after in vitro deglycosylation as seen by immu- We then cotransfected the sGMRa construct together with
the sbc encoding cDNA into CHO cells. Both soluble pro-noblot using anti-bc antibody (1C1; Fig 4B). This shows that
the 55,000 and 65,000 MW proteins represent differentially teins were detectable by immunoprecipitation and Western
blotting with appropriate antibodies in the cell medium ofglycosylated forms of sbc , as has previously been observed
with the full-length bc ,36 and that both forms are retained cotransfected cells (data not shown). Significantly, sbc pro-
tein was detected by immunoblot when immunoprecipitatedon GMRa-expressing cells.
To determine whether the GMRa:sbc complex is able to not only with anti-bc (4F3) but also anti-GMRa antibody
(8G6) but not an irrelevant antibody (9F5) (Fig 6A). Thisbind GM-CSF with high affinity, saturation binding assays
were performed on GMRa CHO cells coexpressing a similar suggests that some but not all sGMRa is associated with sbc
in solution. Immunoprecipitation of a mixture of conditionedamount of either sbc or full-length bc . Because of the very
high level of GMRa chain expression on these transfectants medium from cells expressing sGMRa and sbc separately
did not result in coimmunoprecipitation of the two chains(5 1 105 sites per cell, as determined by Scatchard analysis)
no high-affinity sites could be detected directly from either (data not shown). This is consistent with the retention of
sbc on GMRa-expressing CHO cells in that it appears thattransfectant (Fig 5A and B). To reduce this interference,
dissociation of weakly bound radioligand was performed coexpression of the two soluble receptor chains is required
for the association to occur.after binding, thereby removing ligand interacting with low-
affinity receptors. Using this approach, high-affinity binding To determine whether the sGMRa:sbc complex is capable
of binding ligand, conditioned medium from cells expressingsites (kd 236 pmol/L) were detectable on GMRa cells coex-
pressing full-length bc (Fig 5A) but not on those coexpress- sGMRa and sbc was incubated with GM-CSF and subse-
quently immunoprecipitation was performed with anti–GM-ing sbc (kd 5.3 nmol/L; Fig 5B). This finding implies that
the sbc protein is unable to confer full high-affinity binding CSF antibody. Immunoblotting of the precipitated material
showed that sbc was associated with the anti–GM-CSF im-on the GM-CSF:GMRa complex, a function that may require
a conformational change facilitated by the transmembrane munoprecipitated complex when conditioned medium from
cells coexpressing the two receptor proteins was used, butand cytoplasmic regions of bc .
Soluble GMRa and bc can exist as a complex and bind not when conditioned medium from cells expressing the two
chains separately was mixed (Fig 6B). This implies thatGM-CSF. Based on our demonstration of a preformed
complex between GMRa and bc on the cell surface and also the association of sbc with GM-CSF is dependent on its
interaction with sGMRa in conditioned medium from cellsthe retention of sbc by cells expressing GMRa chain, we
suspected that it may be possible to observe coassociation coexpressing sGMRa and sbc .
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Fig 6. Soluble forms of GMRa and bc spontaneously associate when coexpressed and bind GM-CSF. (A) Conditioned medium from CHO
cells coexpressing soluble GMRa and soluble bc was immunoprecipitated using either anti-bc (4F3), anti-GMRa (8G6), or a control antibody
(9F5); and the proteins were separated on 10% SDS-PAGE, Western transferred, and immunoblotted with anti-bc antibody 1C1. (B) Conditioned
medium from CHO cells either coexpressing soluble GMRa and soluble bc (sGMRa/sbc ) or a mixture of conditioned medium from CHO cells
expressing the soluble proteins separately (sGMRa " bc ) were incubated with GM-CSF and immunoprecipitation was performed with anti–
GM-CSF antibody. Proteins were separated on 10% SDS-PAGE, Western transferred, and then immunoblotted with anti-bc antibody 1C1.
GM-CSF exhibits rapid receptor association compared into two classes of binding site (Table 1): one site exhibiting
a rapid approach to equilibrium about 1,000-fold faster thanwith IL-3 and IL-5. To examine whether a preformed GM-
CSF receptor complex may influence the kinetics of GM- IL-3 or IL-5 and the other exhibiting similar apparent associ-
ation kinetics to IL-3 and IL-5 (Table 1). Only a small pro-CSF binding, we examined the kinetics of association of
125I–GM-CSF to primary human eosinophils and monocytes. portion of the GM-CSF binding sites exhibit rapid binding
kinetics, with the majority behaving like IL-3 and IL-5 recep-We used these cells because they express IL-3 receptors and,
in the case of eosinophils, IL-5 receptors as well as GM- tors with a slower apparent association (Table 1). In previous
studies, we have shown that eosinophils exhibit only high-CSF receptors, thus allowing a comparison between different
receptor systems. The association of GM-CSF was compared affinity binding sites for GM-CSF, IL-3,38 and IL-5.31 From
these studies it appears that the GM-CSF receptors exists inwith IL-3 and IL-5 on human eosinophils in binding studies
performed at 47C with 200 pmol/L 125I-labeled cytokine in two pools that exhibit different kinetic properties.
On monocytes, as on eosinophils, the kinetics of GM-CSFwhich specific binding was determined over a 24-hour time
course (Fig 7A). We found that GM-CSF binding ap- binding were rapid and approached equilibrium faster than
IL-3 binding (Fig 7B). We have previously shown that theproached equilibrium faster than IL-3 and IL-5 and that bind-
ing was detected at very early time points. Curve fitting approach to equilibrium by GM-CSF is approximately 10
times faster than IL-3.39 The rate of approach to equilibriumanalysis showed that a significantly improved fit was ob-
tained for GM-CSF association when binding was resolved of IL-3 on monocytes is comparable to that seen for IL-3 and
Fig 7. Association kinetics of 125I-labeled cyto-
kines binding to (A) eosinophils and (B and C) mono-
cytes at 47C with 200 pmol/L 125I-CSF: (●) GM-CSF,
(j) IL-3, and (m) IL-5.
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Table 1. Kinetic Parameters for 125I-CSF Interaction also resulted in bc phosphorylation that was immunoprecipi-
With Eosinophils table by either anti-bc (8E4) or anti–IL-3Ra antibody (9F5)
(Fig 8A). However, strikingly, we found that anti-GMRa125I-CSF K*obs (min01) No. of Sites†
antibody also immunoprecipitated phosphorylated bc in cellsGM-CSF‡ 2.5 { 1.2 15
treated with IL-3, indicating that GMRa is associated with0.0061 { 0.0015 105
the IL-3–induced receptor complex (Fig 8A). Similar resultsIL-3 0.0071 { 0.0024 90
were obtained in TF-1.8 cells, with the addition that anti-IL-5 0.005 { 0.002 160
GMRa antibody also immunoprecipitated bc phosphorylatedKinetic parameters determined as described in the Materials and
in response to IL-5 (Fig 8B). However, treatment of TF-1.8Methods.
cells with erythropoietin did not result in bc phosphorylation* Apparent association rate.
(data not shown), indicating that bc phosphorylation is spe-† Number of binding sites exhibiting Kobs .
‡ Statistical fit of 1 versus 2 sites (P Å .005). cific to GM-CSF, IL-3, and IL-5 and not a general activation
event. The involvement of GMRa in the IL-3– and IL-5–
induced receptor complexes is specific to GMRa and may
IL-5 and the slower binding site for GM-CSF on eosinophils, be mediated by the preformed GMRa:bc complex. Thus,
suggesting that association at these sites may involve similar these findings raise the possibility that the preformed
mechanisms, whereas GM-CSF binding to the rapidly asso- GMRa:bc complex can be recruited into an active receptor
ciating sites on eosinophils and monocytes is different. complex induced not only by GM-CSF but also by IL-3 or
The preformed GMRa:bc can be phosphorylated in re- IL-5.
sponse to IL-3 and IL-5. The functional significance of the
preformed GMRa:bc complex was examined by means of
DISCUSSIONreceptor activation studies. It is known that, in the course
of activation of the GM-CSF, IL-3, and IL-5 receptors, bc We show here the existence of a GMRa:bc complex that
is formed in the absence of GM-CSF. We have observedbecomes phosphorylated in response to ligand binding,10,40
a process that requires the ligand-specific a chain. We have this ligand-independent association between GMRa and bc
with both cell surface expressed receptors in several cellexamined the phosphorylation of bc induced by cytokines in
Mo7e and TF-1.8 cells and have found that phosphorylated lines and also with carboxy-truncated soluble forms of the
receptor subunits. The number of preformed GMRa:bc com-bc can be detected by antiphosphotyrosine (PY20) immu-
noblot after treatment with GM-CSF and immunoprecipita- plexes observed on cells varied from cell to cell. In some
cases, all of the GMRa and bc chains were apparently coas-tion with either anti-bc (8E4) or anti-GMRa (8G6) antibody
(Fig 8A and B). Similarly, treating Mo7e cells with IL-3 sociated and no further association was induced by GM-
Fig 8. bc phosphorylated in
response to GM-CSF, IL-3, or IL-
5 is immunoprecipitable by anti-
GMRa antibody. (A) Mo7e cells
were starved overnight and then
treated with either 6 nmol/L
GM-CSF, IL-3, or medium for 5
minutes at 47C and then immu-
noprecipitated with either anti–
IL-3Ra (9F5), anti-GMRa (8G6),
or anti-bc (8E4) antibody. (B) TF-
1.8 cells were starved overnight
and then treated with either 6
nmol/L GM-CSF, IL-3, or IL-5 or
medium for 5 minutes at 47C and
then immunoprecipitated with
either anti-GMRa (8G6) or
anti-bc (8E4) antibody. Immuno-
precipitated proteins were sepa-
rated on 7.5% SDS-PAGE, West-
ern transferred, and then
immunoblotted with antiphos-
photyrosine antibody (PY20).
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CSF treatment, whereas on other cells only a component of activation.42 It is possible that various perturbations of an
already preformed complex may result in receptor activation.GMRas and bcs were preassociated and further association
was induced by GM-CSF treatment. This suggests that two In our hands we did not observe receptor activation, as mea-
sured by antiphosphotyrosine reactivity of the performedpools of GM-CSF receptors exist: preformed complexes and
ligand induced complexes. complex (Fig 2C). However, it would be interesting to exam-
ine this possibility with bc mutants and indeed in humanThe notion of two GM-CSF receptor pools is consistent
with previous experiments showing that GM-CSF induces leukemias.
In seeking to determine the functional significance of theGMRa and bc association17 and reconciles this observation
with that of Ronco et al,19 who suggested that the GM-CSF preformed GMRa:bc complex, we performed kinetic analy-
sis for GM-CSF association. Using normal cells expressingreceptor may exist as a preformed complex. This possibility
was raised by the inability of a mutant GMRa to bind GM- GM-CSF receptor, we found that the association of GM-CSF
to both eosinophils and monocytes is more rapid relative toCSF unless it was coexpressed with bc . This was interpreted
as bc preassociated with GMRa compensating for the loss IL-3 and IL-5 and, in the case of eosinophils, is bimodal. In
previous studies we have shown that eosinophils exhibit onlyof GM-CSF binding on the mutant GMRa. In an analogous
manner, a GM-CSF helix D mutant showed no detectable high-affinity binding sites for GM-CSF, IL-3,38 and IL-5.31
This suggests that there are sufficient bcs to support full-binding to GMRa alone, yet could bind to cells expressing
both GMRa and bc ,21 possibly reflecting the effect of a affinity conversion of GM-CSF receptors and that the recep-
tors exist in two forms: one form approaches equilibriumGMRa:bc preformed complex.
By using soluble receptor constructs, we were able to very rapidly and a second form binds with similar kinetics
to IL-3 and IL-5. This is consistent with the presence of twodemonstrate the formation of sGMRa:sbc complexes in solu-
tion, indicating that the extracellular domains of the two pools of receptor for GM-CSF: a small number of receptors
that bind GM-CSF rapidly, possibly representing preformedproteins are sufficient to mediate the interaction. This in
turn is dependent on the two soluble receptor chains being complexes as described here, and a larger pool, possibly
composed of free GMRas and bcs that exhibit slower associ-expressed by the same cell, because neither the addition
of sbc to GMRa expressing cells nor combining separately ation on GM-CSF binding akin to IL-3 and IL-5 binding. We
have previously reported that GM-CSF binds more rapidly toexpressed sGMRa and sbc resulted in complex formation.
This suggests that the association between the two proteins monocytes39 and induces their adhesion faster than IL-3.43
The presence of preformed GMRa:bc complexes may alsooccurs as the proteins reach the cell surface, possibly before
or during transport to the cell surface. However, interest- account for these kinetic differences on monocytes by pro-
viding a pool of preformed receptors that rapidly associateingly, the retention of sbc by cells expressing GMRa did
not result in a detectable increase in affinity for GM-CSF, with GM-CSF.
The binding cross-competition exhibited between GM-in contrast to full-length bc that confers high-affinity binding
on the GM-CSF:GMRa complex. Under the dissociation CSF, IL-3, and IL-5 has previously been described on nor-
mal26,38,44 and leukemia cells.45,46 The molecular basis of thisconditions used it is possible that binding of intermediate
affinity was lost and so we can only conclude that sbc is phenomenon is the competition between GM-CSF:GMRa,
IL-3:IL-3Ra, and IL-5:IL-5Ra for bc interaction. The pro-unable to confer full high-affinity binding on GMRa-ex-
pressing cells. This deficiency in binding with sbc may be posed preformed GMRa:bc complex might be expected to
have an effect on this phenomenon, sequestering bc for thedue to the bc lacking transmembrane and extracellular por-
tions. Our findings are consistent with recent studies in which exclusive binding of GM-CSF. However, cross-competition
experiments performed previously on eosinophils38 anda naturally occurring soluble form of GMRa was found to
be retained on the cell surface when coexpressed with full- CML cells35 show that IL-3 is able to compete for 125I–GM-
CSF binding effectively, with up to 90% competition. Thislength bc on BHK cells.22 The soluble GMRa conferred GM-
CSF binding on the cells albeit with intermediate affinity, suggests that the bc associated with GMRa in the preformed
complex is in equilibrium with free bc and is therefore com-indicating some deficit in the interaction with bc . These
observations suggest that the transmembrane and cyto- petable by IL-3. This may also explain the relative numbers
of preformed complexes observed on cells in that the levelplasmic regions of these receptor subunits may be required
for conformational changes and optimal high-affinity bind- of preformed complex would be dependent on the relative
level of expression of bc . Thus, cells that express excess bcing. Alternatively, these associations observed with soluble
forms of the receptor may not represent normal receptor and thus exhibit high-affinity binding sites only may have
relatively more preformed sites compared with cells thatinteractions.
The precise regions in the extracellular domains of GMRa express limiting amounts of bc .
The stoichiometry of the active GM-CSF receptor is notand bc that mediate their spontaneous association in the cell
membrane and in solution are not known. From modelling known and may involve a GMRa:bc ratio of 1:1 or a 2:2
complex. Because of the disulphide-linked GMRa:bc hetero-studies and comparison with the growth hormone crystal
structure,41 the A-B loop and the E strand in the fourth do- dimer and molecular modelling of the extracellular region
of bc , we favor the second possibility.18 This is also consis-main of bc appear to be good candidates for interaction
with the second domain of the cytokine receptor module of tent with the observations that at least two molecules of
GMRa are required for receptor activation47 and that phos-GMRa. It is worth noting that insertions, deletions, and point
mutations in this domain of bc lead to factor-independent phorylation of bc dimers36 and disulphide-linked bc con-
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Fig 9. Proposed models for assembly of (A) GM-CSF–, IL-3–, and IL-5–induced receptor complexes and (B) preformed GM-CSF receptor
complexes into activated receptors. In (A), GMRa, IL-3Ra, or IL-5Ra are in close proximity to (although not associated with) bc on the cell
surface. Ligand binding to the appropriate a chain induces a:bc heterodimerization and a conformational change in a chain that allows its
disulphide linkage to bc . Modelling of bc suggests that this bridging would only be possible if the unpaired cysteines in the a chain of receptor
1 formed a disulphide bridging with cysteine of bc in receptor 2.18 The bringing together of two bc with their associated JAK-2 molecules
would then lead to receptor activation. In (B), it is postulated that the binding of IL-3 or IL-5 to their specific a chain and bc triggers a
conformational change in the a subunit analogous to model (A). However, in this case, a disulphide bridge can be formed between the free
cysteine in the IL-3Ra or IL-5Ra and a cysteine in bc that is already noncovalently associated with GMRa chain in a preformed complex. This
interaction may be sufficient to bring together two bc and two JAK-2 kinases leading to receptor activation. This model raises the possibility
that some of the functions mediated by IL-3 and IL-5 are mediated inducibly through the activation of a preformed GMRa:bc complex.
taining complexes18 occurs in response to GM-CSF. In this The unidirectional activation of the GM-CSF receptor by
IL-3 is reminiscent of trans-downmodulation experiments inmodel, binding of ligand may render cysteine residues in
GMRa and bc reactive, leading to disulphide bond formation the mouse in which IL-3 was found to trans-downmodulate
GM-CSF, macrophage colony-stimulating factor (M-CSF),across two receptors in a hexameric configuration, thus
bringing together two bc -associated JAK-2 molecules, and granulocyte colony-stimulating factor (G-CSF) recep-
tors, but GM-CSF or G-CSF were unable to trans-downmod-thereby inducing receptor activation (Fig 9A). Given the
observation of the preformed GMRa:bc , we speculate that ulate the mouse IL-3 receptor.48,49 The transphosphorylation
of GMRa-associated bc we observe appears to be limited toit could be recruited into an IL-3 or IL-5 receptor complex
(Fig 9B). Consistent with this possibility, we found that anti- the GM-CSF/IL-3/IL-5 receptor system in that erythropoie-
tin is ineffective and is probably a reflection of the uniqueGMRa antibodies immunoprecipitated phosphorylated bc
when cells were stimulated not only with GM-CSF but also mode of assembly of this heterodimeric receptor family.
GM-CSF receptors are expressed by many cells of the hema-with IL-3 and IL-5. In contrast, GM-CSF did not induce
phosphorylation of bc associated with IL-3Ra (Fig 8A), con- topoietic lineage and, intriguingly, most cells that express
either IL-3 or IL-5 receptors also express GM-CSF receptors.sistent with IL-3 receptor existing only as a fully inducible
receptor. The data presented here suggest that IL-3 and IL-5 are able
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13. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasakawato activate preformed GM-CSF receptors, thus raising the
K, Yamanishi K, Taga T, Kishimoto T: IL-6 induced homodimerisa-possibility that the biologic functions of IL-3 and IL-5 are
tion of gp130 and associated activation of a tyrosine kinase. Sciencemediated in part by signalling through the GM-CSF receptor.
260:1808, 1993A further possibility is that the GM-CSF preformed complex
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SHORT COMMUNICATION
GM-CSF BINDING TO ITS RECEPTOR INDUCES
OLIGOMERISATION OF THE COMMON
BETA-SUBUNIT
Barbara J. McClure,1 Joanna M. Woodcock,1 Duygu Harrison-Findik,1
Angel F. Lopez,1 Richard J. D’Andrea1,2
The stoichiometry of the granulocyte-macrophage colony-stimulating factor (GM-CSF) recep-
tor complex is still unresolved. We have utilised a sensitive, functional assay for receptor
homodimerisation to show that GM-CSF induces dimerisation of the common signalling subunit,
h!c. We generated a chimeric cytokine receptor in which the extracellular and transmembrane
domains of h!c are fused to the cytoplasmic domain of erythropoietin receptor (EPO-R). Given
that to induce EPO-R activation and mitogenic signalling there is a requirement for formation
of a specific homodimeric complex, we reasoned that the cytoplasmic domain of EPO-R could
be utilised as a highly sensitive reporter for functional homodimer formation. We show that, in
the presence of a cytoplasmically truncated GM-CSF "-subunit, the h!c–EPO receptor chimera
transduces a mitogenic signal in BaF-B03 in response to GM-CSF. This is consistent with
formation of a h!c homodimer following GM-CSF binding and implies that ligand stimulation
induces formation of a higher order complex that contains the h!c homodimer.
! 2001 Academic Press
The granulocyte-macrophage colony-stimulating
factor (GM-CSF) receptor complex is comprised of a
ligand-specific !-subunit (GMR!) and a signalling "
subunit (h"c) that is shared with the IL-3 and IL-5
receptors.1 Both subunits belong to the cytokine
receptor (CR) superfamily. Triggering of cytoplasmic
janus-activated kinases (JAKs) associated with the
intracellular portions of cytokine receptors (CRs)
is the critical first step in signalling.2 A major un-
resolved issue, due to contradictory reports, regards
the stoichiometry of the active GMR complex.
While there are significant questions relating to
the role of h"c dimerisation in GM-CSF activation
other CRs are well characterised as homodimeric com-
plexes. One of the best-characterised of this class of
receptors is erythropoietin receptor (EPO-R), in which
case multiple studies have demonstrated that homo-
dimerisation is critical for signalling.3–5 The most com-
pelling evidence that activation results in formation of
an EPO-R homodimer with a specific conformation is
provided by recent studies using a protein-fragment
complementation system. This demonstrated that for-
mation of the active homodimer follows a ligand-
induced conformational change, involving a switch
from a unique unliganded, homodimeric structure, to
the ligand-bound, activated, homodimeric complex.6,7
Given that to induce EPO-R activation and
mitogenic signalling there is a requirement for for-
mation of a specific homodimeric complex, we
reasoned that the cytoplasmic domain of EPO-R could
be utilised as a reporter for functional homodimer
formation. Specifically, we wished to determine
whether stimulation with GM-CSF leads to formation
of a complex containing a h"c homodimer. We gener-
ated a chimeric CR in which the extracellular and
transmembrane domains of h"c are fused to the cyto-
plasmic domain of EPO-R. We show that in the
presence of the chimeric receptor and GMR!,
GM-CSF-induces mitogenic signalling in BaF-B03
cells that is independent of the cytoplasmic domain of
GMR!. This implies that ligand stimulation induces
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formation of a higher order complex that contains at
least an h"c homodimer.
RESULTS AND DISCUSSION
To address the question of whether homodimeris-
ation of h"c occurs during GMR signal transduction a
receptor chimera was generated that will only function
in response to GM-CSF upon homodimerisation. This
chimeric receptor comprises extracellular and trans-
membrane domains of h"c fused to the intracellular
domain of EPO-R. We determined the ability of this
receptor to mediate proliferation, when co-expressed
with GMR! on BaF-B03 cells and stimulated with
GM-CSF. BaF-B03 cells were infected with GMR! in
combination with h"c or h"c/EPO-R. Receptor expres-
sion in the resulting cell pools was determined by flow
cytometry. Figure 1 shows that pools expressing
GMR! and h"c (A); and GMR! and h"c/EPO-R (B)
display similar levels of receptors. A control popu-
lation infected with GMR! alone also expressed
similar levels of receptor (data not shown). The prolif-
erative potential of each population in response to
GM-CSF was determined. As expected BaF-B03 cells
expressing GMR! or h"c/EPO-R alone cannot respond
to GM-CSF (Fig. 2A and data not shown). EPO-R
signalling is normal in BaF-B03 cells, as a population
infected with a full-length EPO-R retrovirus construct
is capable of responding to EPO with an ED50 of
0.3 U/ml (data not shown). Cells expressing both
subunits of the GM-CSF receptor can respond to
GM-CSF with an ED50 of 0.03 ng/ml (Fig. 2B). Impor-
tantly, cells expressing both h"c/EPO-R and GMR!
were able to respond to GM-CSF (Fig. 2C).
Signalling through the chimeric receptor in
response to GM-CSF is consistent with the induction
of dimerisation of h"c/EPO-R. However, we wished to
rule out the possibility that the GMR! and EPO-R
cytoplasmic domains were interacting leading to acti-
vation in the absence of dimerisation of the EPO-R
cytoplasmic domain. This was important as the GMR!
cytoplasmic domain contributes to signalling in the
context of normal GMR.8 For this we employed a
truncated GMR! that lacked cytoplasmic sequences
(GMR!#COOH). BaF-B03 cells were infected with
GMR!#COOH together with h"c or h"c/EPO-R.
Figure 1 shows that the receptor expression of
pools expressing GMR!#COOH and h"c (C); or
GMR!#COOH and h"c/EPO-R (D) were similar. A
control population infected with GMR!#COOH alone
expressed similar receptor levels (data not shown) and
did not respond to GM-CSF (Fig. 2D). Scatchard
analysis revealed that GMR!#COOH could bind
GM-CSF with high affinity when expressed with h"c
(data not shown). When h"c is co-expressed with
GMR!#COOH, BaF-B03 cells no longer exhibit a
proliferative response to GM-CSF (Fig. 2E) consistent
with the importance of the GMR! cytoplasmic domain
for GM-CSF mediated signalling. Importantly, how-
ever cells expressing the GMR! cytoplasmic truncation
(GMR!#COOH) and h"c/EPO-R chimera responded
to GM-CSF (Fig. 2F) consistent with GM-CSF
induced homodimerisation of h"c. Thus it is likely that
in response to GM-CSF a complex is formed that
contains h"c dimers.
9,10 This may occur via an inter-
mediate !" complex with some signalling capacity, as
chimeric molecules, which permit forced heterodimer-
isation of ! and " subunits, are sufficient to generate a
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Figure 1. Flow cytometric analysis of transfected BaF-B03 cell lines.
Expression of cells transfected with GMR!+h"c (A); GMR!+h"c/
EPO-R (B); GMR!#COOH+h"c (C); or GMR!#COOH+h"c/
EPO-R (D) was determined as described in Materials and Methods.
Thin line indicates reactivity with an isotype-matched control (A14).
Thick line represents receptor expression of h"c or h"c/EPO-R with
1C1 monoclonal antibody (right panels) and GMR! with 4H1
monoclonal antibody (left panels).
h"c oligomerisation in response to GM-CSF / 241
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have proposed previously that formation of an !"
heterodimer may be an intermediate step in formation
of the higher order complex comprising at least an h"c
dimer.9,10 Activation of the GM-CSF-induced h"c
homodimer requires the cytoplasmic domain of the
GMR! subunit for mitogenic signalling. This is an
interesting observation as it suggests that the h"c and
EPO-R cytoplasmic domains are functionally different
with respect to activation. The differential requirement
for the GMR! cytoplasmic domain may reflect subtle
differences in the structural requirements for formation
of functional h"c and EPO-R homodimers. Alterna-
tively, the GM-CSF-induced h"c dimer requires
additional GMR!-mediated events for activation of
proximal signalling molecules. The system outlined
here will be potentially useful for studying critical
differences in activation of the signalling subunits in
response to GM-CSF and EPO-R.
In summary we have described a highly sensitive
functional assay for receptor dimerisation to show
induced oligomerisation of h"c in response to
GM-CSF. In this respect activation of the GM-CSF
signalling subunit is reminiscent of many other recep-
tors that utilise JAK2 (EPO, thrombopoietin, growth
hormone and prolactin receptors). We are currently
using chimeric h"c/EPO-R constructs containing acti-
vating mutations10,13 to establish further the role of
homodimerisation in h"c activation.
MATERIALS AND METHODS
Generation of chimeric h!c and truncated GMR"
cDNAs
The extracellular and transmembrane regions of h"c and
the cytoplasmic domain of EPO-R (kindly provided by Dr L.
Jolliffe, J&J Research, Ratitan, New Jersey, USA) were
generated by PCR and then cloned into the retroviral vector
pRufNeo. An AvrII site was introduced to facilitate cloning
and the resulting h"c/EPO-R chimeric cDNA encoded
VLLALRPRRRALK at the junction between the h"c
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Figure 2. Dimerisation of h!c is required for signalling in response to GM-CSF.
Following an overnight starvation, BaF-B03 cells expressing either GMR! alone (A); GMR!+h"c (B); GMR!+h"c/EPO-R (C); GMR!#
COOH alone (D); GMR!#DCOOH+h"c (E); or GMR!#COOH+h"c/EPO-R (F), were cultured with increasing concentrations of hGM-CSF
for 48 h and proliferation measured by the incorporation of 3H-thymidine. The results are expressed as a percentage of maximal proliferation of
that seen with murine IL-3 and each point represents the mean of triplicate determination with error bars representing one standard deviation.
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cytoplasmic deletion of GMR! (GMR!#COOH) was gener-
ated by PCR to introduce an inframe termination codon 4
residues after the transmembrane domain. Both wild-type
GMR! and GMR!#COOH cDNA were cloned into the
retroviral expression vector pLXSN.
Generation of cell lines, flow cytometry and
proliferation assays
Purified plasmid DNA was used to transfect the eco-
tropic packaging cell line, $2 and virus from the G418-
resistant $2 cells was used to infect the murine IL-3
dependant pro-B cell line BaF-B03 by co-cultivation. Recep-
tor expression was confirmed by flow cytometry using an XL
flow cytometer (Coulter Electronics, Hialaeh, FL, USA).
Monoclonal antibodies 1C1,14 for detection of wild-type
and chimeric h"c, and 4H1 and A14 (GMR!-specific and
isotype control) were produced as described.14 Following
cytokine starvation overnight, the proliferation of BaF-B03
populations in response to GM-CSF was determined as
previously described.15
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Brief report
Perverted responses of the human granulocyte-macrophage colony-stimulating
factor receptor in mouse cell lines due to cross-species b-subunit association
Barbara McClure, Frank Stomski, Angel Lopez, and Joanna Woodcock
Transfected murine cell lines are com-
monly used to study the function of many
human cytokine or receptormutants. This
study reports the inappropriate activation
of the human granulocyte-macrophage
colony-stimulating factor (hGM-CSF) re-
ceptor by the human GM-CSF antagonist,
E21R, when the human receptor is intro-
duced into the murine cell line BaF-B03.
E21R-induced proliferation of the BaF-
B03 cells is dependent on transfection
with both hGM-CSF receptor a and bc
subunits. Studies on the underlying
mechanism revealed constitutive associa-
tion between human and mouse bc and
GM-CSF receptor-a, tyrosine phosphory-
lation of mouse and human bc, and asso-
ciation of phosphorylated mouse bc into
an activated human GM-CSF receptor
complex in response to E21R and GM-
CSF. This interspecies receptor cross-
talk of receptor signaling subunits may
produce misleading results and empha-
sizes the need to use cell lines devoid of
the cognate endogenous receptors for
functional analysis of ligand and receptor
mutants. (Blood. 2001;98:3165-3168)
© 2001 by TheAmerican Society of Hematology
Introduction
Human granulocyte-macrophage colony-stimulating factor (hGM-CSF)
is a pleiotropic cytokine that stimulates the proliferation, differentiation,
and survival of myeloid precursors and induces the effector functions of
mature myeloid cells.1,2 These multiple functions are mediated by
binding to high-affinity receptors that comprise a GM-CSF–specific a
chain (hGMR-a) and an affinity-converting, signal-transducing b
subunit (hbc), which is shared with the interleukin-3 (IL-3) and IL-5
receptors.3,4 In the murine system there are 2 b subunits, mbc, which is
analogous to hbc, transducing signals induced by mGM-CSF, mIL-3 or
mIL-5, and mbIL-3, which is specific for mIL-3.5,6 Mouse myeloid cell
lines, for instanceFDCP-1 andBaF-B03, express bothmouseb subunits.
Given the importance of hbc in transducing signals that regulate
immune responses, hematologic recovery, and, in some cases, leukemia,
a significant amount of work has been devoted to structure-function
analysis of these cytokine-receptor systems. Studies have led to the
engineering of cytokine analogs with unique properties such as the
hGM-CSF mutant E21R that behaves as a specific hGM-CSF antago-
nist.7 Characterization of the receptors has sought to identify functional
regions involved in receptor activation and has identified regions in the
cytoplasmic domain of hbc that couple to specific signaling molecules
such as JAKs, STATs, and the ras/MAP kinase pathway.8-10 However
results from these studies have in some cases been ambiguous or even
conflicting.
Central to the analysis of cytokine and receptormutants is the choice
of experimental system. Predominantly, mouse myeloid cell lines,
which are readily transfected with human receptor subunits, have been
used. A major problem is the expression of endogenous receptors for
these cytokines in these cell lines. For example, transfection of hGMR-a
alone in murine FDCP-1 cells was initially reported to be sufficient to
mediate a proliferative signal despite only displaying low-affinity
hGM-CSF binding.11 However, it was later shown that functional
reconstitution of hGMR required both hGMR-a and hbc subunits,12 and
that the initial observation with hGMR-a alone was confounded by the
recruitment of endogenousmbc.13 Likewise, interaction of an extracellu-
lar point mutant of hbc with an endogenous mGMR-a has been shown
to lead to factor-independent proliferation14 and chimeras between a
constitutively active erythropoietin receptor with the cytoplasmic do-
main of GMR-a promoted proliferation but only in presence of mbc.15
Here we show an abnormal response of the human GM-CSF antagonist
E21R in transfected mouse cell lines and the molecular basis for
human-mouse GM-CSF receptor cross-talk. These results emphasize
the need for caution when interpreting data from experiments using
transfectants and the desirability of using homologous systems.
Study design
Cell lines and proliferation assays
The human erythroleukemic cell line TF1.8, the megakaryocytic leukemia
human cell line, UT7, and the murine pro-B-cell line, BaF-B03 (transfected with
human GMR-a and hbc), were grown as previously described.16,17 Following
cytokine starvation overnight, the proliferation of cell lines in response to
hGM-CSF or E21R was determined as previously described.18 E21R, a single
point mutant of hGM-CSF (Gln21Arg) was donated by Bresagen
(Adelaide, Australia).
Antibodies
Murine monoclonal antibodies 1C1 and 8E4, for detection of hbc, and 4H1
for immunoprecipitating hGMR-a were produced as previously de-
scribed.16 1C1 was biotinylated using a cellular labeling and immunoprecipi-
tation kit (BoehringerMannheim, Rose Park, SA,Australia) and streptavidin–
horseradish peroxidase (HRP) was purchased fromAmersham Life Science
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(Little Chalfont, United Kingdom). Anti-mbc rabbit polyclonal K-17 was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). HRP-
conjugated antibodies specific for mouse or rabbit immunoglobulins were
purchased from Pierce (Rockford, IL) and Dako (Botany, NSW, Australia),
respectively. The HRP-conjugated antiphosphotyrosine monoclonal antibod-
ies, PY20 and 4G10, were obtained from Transduction Laboratories
(Lexington, KY) and Upstate Biotechnology (Lake Placid, NY), respectively.
Immunoprecipitation, sodium dodecylsulfate–polyacrylamide
gel electrophoresis, and immunoblotting
Analysis of ligand-induced receptor complexes and their phosphotyrosine
status was determined using starved cells that were stimulated with factors
for 5 minutes at room temperature at indicated concentrations. Cells were
lysed and immunoprecipitated proteins were run on reducing sodium
dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and sub-
jected to immunoblotting as previously described.19
Results and discussion
Human GM-CSF supports the proliferation of human cells by
activating endogenous hGMR.7 The antagonistic hGM-CSF mu-
tant, E21R, however, cannot mediate a proliferative response in
human cells and is unable to bind hGMR with high affinity.7 We
observed that the biologic activity of E21R is strikingly different
when analyzed in hGMR-transfected murine cell lines. First, the
biologic activity of E21R was determined in comparison to
wild-type hGM-CSF on the human cell line, TF1.8, and the murine
cell line BaF-B03 transfected with both hGMR-a and hbc (hGMR
BaF-B03). Human GM-CSF induces proliferation of TF1.8 cells
with an effective dose (ED50) of 0.03 ng/mL, whereas E21R is
unable to elicit a proliferative response and antagonizes the activity
of wild-type GM-CSF (Figure 1A).7 Surprisingly, however, E21R
induced a proliferative response in the hGMR BaF-B03 cell line at
concentrations of E21R above 10 ng/mL (Figure 1B).
It has been previously described that hGMR-a can interact with
either hbc or mbc to transmit a growth signal in response to
hGM-CSF in BaF-B03 cells.13 However, the interaction of hGMR-a
with mbc, unlike hbc, does not form a high-affinity receptor. The
proliferation induced by E21R in hGMR BaF-B03 cells is also the
result of a low-affinity interaction with a dissociation constant of
approximately 4 nM (data not shown) as determined by Scatchard
analysis of saturation binding,18 identical to the affinity of E21R
measured on human neutrophils.7
The abnormal proliferative response of hGMR BaF-B03 cells to
E21R differs from the previously described cross-talk phenomenon
between hGMR-a and mbc because it is dependent on the
coexpression of both hGMR-a and hbc. This is highlighted by the
inability of BaF-B03 cells expressing hGMR-a alone to respond to
E21R, even at concentrations of 100 mg/mL (data not shown).
Because the abnormal agonism was only observed in cell lines
where mbc is endogenously expressed, it suggested that the
unexpected activity demonstrated by E21R may be the result of a
novel cross-species interaction, involving both hbc and mbc.
Together with the inability of E21R to mediate a proliferative
response in human cells, it cannot stimulate tyrosine phosphoryla-
tion of hbc. The tyrosine phosphorylation status of hbc was
investigated to determine if E21R can activate hbc in this murine
system. Tyrosine phosphorylation of hbc was readily detected in
the murine cell line hGMR BaF-B03 after stimulation with E21R
(Figure 2B), but not the human cell line expressing endogenous
hbc, UT7 (Figure 2A), and TF1.8 (data not shown). In comparison,
tyrosine phosphorylation of hbc was detected following stimulation
Figure 2. Transfected hbc spontaneously associates with endogenousmbc and
the bc complex is phosphorylated inappropriately in response to E21R.
Factor-deprived human UT7 cells (A) or mouse hGMR BaF-B03 cells (B-D) were
stimulated as indicated for 5 minutes at 25°C. Cells were lysed and hbc was
immunoprecipitated with 8E4 anti-hbc antibody (A-C). The presence of tyrosine
phosphorylated hbc was detected using an antiphosphotyrosine antibody, PY20 (A)
or 4G10 (B,C). Filters were then stripped and reprobed for the presence of hbc with
1C1 anti-hbc antibody (A,B). The presence of mbc following hbc immunoprecipitation
was determined on a duplicate filter using anti-mbc antibody, K-17 (C). Tyrosine
phosphorylated proteins were immunoprecipitated with the 4G10 antiphosphoty-
rosine antibody (D) and the presence of hbc detected using 1C1 antibody. The filter
was then stripped and reprobed for the presence of mbc with K-17.
Figure 1. The human GM-CSF antagonist E21R behaves as an agonist on
mouse cell lines. Factor-deprived human TF1.8 (A) and mouse hGMR BaF-B03
cells (B) were stimulated with hGM-CSF (F) or E21R (E). Functional antagonism of
0.03 ng/mLGM-CSF with increasing concentrations of E21R on human TF1.8 cells is
also shown (Œ). Cells were cultured with cytokine for 48 hours and the resulting
proliferation was measured by the incorporation of 3H-thymidine. The results are
expressed in disintegrations per minute (dpm) and each point represents the mean of
triplicate determination with error bars representing 1 SD.
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with hGM-CSF in both human UT7 cells and murine hGMR
BaF-B03 cells (Figure 2A,B). The dose response of E21R-induced
tyrosine phosphorylation of hbc is consistent with the proliferation
data where responsiveness occurs at a concentration of E21R above
10 ng/mL, with no response at 1 ng/mL (Figure 1B).
Because mbc functions when recruited to a hGM-CSF–
hGMR-a complex, we investigated if this molecule plays a role in
facilitating the tyrosine phosphorylation of hbc in response to
hGM-CSF or E21R in hGMR BaF-B03 cells. Stimulation of
hGMR BaF-B03 cells with either GM-CSF or E21R resulted in
tyrosine phosphorylation of hbc (Figure 2C). Significantly, mbc
was associated with hbc and this interaction appears to occur
regardless of stimulation (Figure 2C). It is interesting to note that
dimerization of a least 2 hbc subunits is required for hGMR
activation.19,20 The interaction between mouse and human bc may
provide the molecular basis to support the agonistic activity of
E21R and mediate this perverted receptor response observed in this
murine cell line.
Phosphotyrosine immunoprecipitations were performed to ad-
dress if preassociation between the human and murine bc subunits
allows mbc to be associated with an activated hGMR complex.
Human bc was immunoprecipitated by an antiphosphotyrosine
antibody following stimulation of hGMR BaF-B03 cells with
hGM-CSF but not when left unstimulated or with an isotype-
matched control antibody (Figure 2D). Mouse bc appears to be
weakly phosphorylated in the absence of stimulation, but interest-
ingly was strongly coimmunoprecipitated with antiphosphoty-
rosine antibody after stimulation with hGM-CSF (Figure 2D),
suggesting an increase in phosphorylation of mbc on stimulation
with the human ligand.
The hGMR subunits GMR-a and hbc have previously been
shown to exist as a preformed complex on human cells,20,21 and we
have now shown that mbc and hbc are also associated prior to
ligand stimulation on hGMR BaF-B03 cells. To determine whether
mbc is also a component of a preformed complex on hGMR
BaF-B03 cells, hGMR-a was immunopreciptated from nonstimu-
lated and GM-CSF–stimulated cells. Immunoblotting revealed that
both hbc and mbc were associated with hGMR-a regardless of
stimulation (data not shown) suggesting that mbc chain may be a
component of a preformed hGMR receptor on hGMR BaF-B03
cells. Therefore activation of the receptor by GM-CSF and E21R
may be mediated by a preformed hGMR-a–hbc–mbc complex in
these cells.
The ability of human and mouse bc subunits to interact and
influence responses of a hGM-CSF variant introduces a new level
of complexity in the analysis of ligand-receptor interaction and
subsequent signaling capabilities. It also raises the question of the
influence this interaction has had on previous hGMR studies that
have been performed in murine cell lines. Clearly mbc can become
associated within an active hGMR complex, and it is important to
consider its contribution to the receptor’s biologic response. This is
of concern especially when investigating the activation of down-
stream signaling molecules.22 In light of the interaction between
hbc and mbc it will be difficult to discriminate which signaling
molecules have emanated from the hbc alone.23 In addition, the
associated mbc subunit may facilitate signaling by an otherwise
inactive hbc mutant. This may explain the surprising result seen
where hbc deficient in intracellular tyrosines is still capable of
responding to hGM-CSF.10 In addition, the observation that a
cytoplasmically truncated hbc can still respond to hGM-CSF when
expressed in BaF-B03 cells may be potentiated via signaling
through mbc.24 The contribution this interspecies subunit interac-
tion plays when distinguishing regions in hGMR responsible for
differentiation or proliferation in murine myeloid cell lines remains
unclear. It has been demonstrated previously that hbc can form
homodimers that are activated in response to hGM-CSF.20,21 The
association between mbc and hbc must result in a complex that has
different properties to hbc homodimers because E21R is unable to
activate the latter.
A number of receptors belonging to the cytokine receptor
family show cross-species specificity between human and murine
components. Because receptor dimerization is a common theme in
receptor activation, it cannot be ruled out that interaction of
interspecies signaling components may obscure results when
studying a wide range of human receptors in murine cells and
similar precautions may need to be taken. In addition to our
findings that the use of transfected murine cell lines may not be the
best approach when studying hGM-CSF ligand variants, other
cytokines show similar discrepancies. An analogous situation has
been reported for a human IL-4 mutant that can mediate either
agonistic or antagonistic responses when studied in either a murine
or human cell line, respectively.25 Similarly, mutational analysis of
thrombopoietin shows conflicting data in the identification of
residues functionally important in interaction with its receptor
when screened on Mpl-transfected BaF-B03 cells compared to
enzyme-linked immunosorbent assay or Biacore analysis.26,27
The demonstration of an inherent association between mouse
and human bc shown here highlights the need for a careful selection
of appropriate systems. In the case of the hGMR the availability of
bc knockout mice permits the use of cells from these animals for
receptor reconstitution experiments as a better background to
analyze structural and functional outcomes with the hGMR.
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HEMATOPOIESIS
Molecular assembly of the ternary granulocyte-macrophage colony-stimulating
factor receptor complex
Barbara J. McClure, Timothy R. Hercus, Bronwyn A. Cambareri, Joanna M. Woodcock, Christopher J. Bagley,
Geoff J. Howlett, and Angel F. Lopez
Granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) is a hematopoietic
cytokine that stimulates the production
and functional activity of granulocytes
and macrophages, properties that have
encouraged its clinical use in bone mar-
row transplantation and in certain infec-
tious diseases. Despite the importance of
GM-CSF in regulating myeloid cell num-
bers and function, little is known about
the exact composition and mechanism of
assembly of the GM-CSF receptor com-
plex. We have now produced soluble
forms of the GM-CSF receptor ! chain
(sGMR!) and " chain (s"c) and utilized
GM-CSF, the GM-CSF antagonist E21R
(Glu21Arg), and the"c-blockingmonoclo-
nal antibody BION-1 to define themolecu-
lar assembly of theGM-CSF receptor com-
plex. We found that GM-CSF and E21R
were able to form low-affinity, binary com-
plexeswith sGMR!, each having a stoichi-
ometry of 1:1. Importantly, GM-CSF but
not E21R formed a ternary complex with
sGMR! and s"c, and this complex could
be disrupted by E21R. Significantly, size-
exclusion chromatography, analytical ul-
tracentrifugation, and radioactive tracer
experiments indicated that the ternary
complex is composed of one s"c dimer
with a single molecule each of sGMR! and
of GM-CSF. In addition, a hitherto unrecog-
nized direct interaction between"c andGM-
CSF was detected that was absent with
E21R and was abolished by BION-1. These
results demonstrate a novel mechanism of
cytokine receptor assembly likely to apply
also to interleukin-3 (IL-3) and IL-5 and have
implications for our molecular understand-
ing and potential manipulation of GM-CSF
activation of its receptor. (Blood. 2003;101:
1308-1315)
© 2003 by TheAmerican Society of Hematology
Introduction
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a
cytokine produced by many cells in the body that regulates the
production, effector cell function, and survival of myeloid cells.1-4
Macrophages and granulocytes rise in numbers and exhibit a
prolonged life span and enhanced effector function in response to
GM-CSF,5,6 properties that have encouraged its use in bone marrow
transplantation7 and infectious diseases such as those associated
with AIDS.8 In addition, GM-CSF controls dendritic cell produc-
tion, differentiation, and function and potentiates responses of
CD4! T cells in vivo.9,10 This dual action of GM-CSF has
encouraged its utilization in different vaccination strategies.11 On
the other hand, these same properties have implicated GM-CSF in
myeloid leukemia and several inflammatory conditions such as
asthma12 and rheumatoid arthritis.13
The actions of GM-CSF are mediated by specific receptors
composed of 2 different subunits, a receptor " chain (GMR"),14
which provides specificity and the major binding contact, and a #
chain (#c),15 which is common with the interleukin-3 (IL-3) and
IL-5 receptors, promotes affinity conversion, and acts as the major
signal transducer. For this complex to be assembled and to signal,
there exist structural and dimerization requirements, some of which
have been defined. Extensive structure-function analysis has identi-
fied several residues involved in GM-CSF, GMR", and #c protein
interaction and biologic activity. For example, the binding of
GM-CSF to GMR" involves an electrostatic interaction between
Asp112 in the fourth " helix of GM-CSF and Arg280 in the F-G
loop of GMR".16,17 The biologic activities and high-affinity
binding of GM-CSF are exquisitely dependent on Glu21 in the first
" helix of GM-CSF, although direct contact with #c has not been
demonstrated. Substitution of this amino acid with arginine gener-
ates a GM-CSF analog, E21R (Glu21Arg), which exhibits only
low-affinity binding and is unable to stimulate cellular proliferation
and mature cell functions.18 Importantly, E21R is able to antago-
nize GM-CSF binding and function19; however, the molecular basis
of this antagonism is not fully understood. In #c, residues in the
B-C loop (Tyr365, His367, Ile368) and F-G loop (Tyr421) of
domain 4 are involved in GM-CSF high-affinity binding and
function.20-23 The monoclonal antibody (mAb) BION-1, which
binds an area in #c encompassing these loops, blocks GM-CSF
binding and biologic activities.24
Dimerization of the " and #c subunits of this family of cytokine
receptors is recognized as a crucial step for their activation;
however, the exact composition of the assembled complex remains
unclear. A number of studies suggest that simple heterodimeriza-
tion is sufficient to activate the GM-CSF receptor,25 whereas both
cross-linking and dominant-negative studies using surface-expressed
receptors suggest that the formation of higher-order GM-CSF receptor
complexes is required for receptor activation.26,27 Dimerization of #c in
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particular has also been shown to be an important and necessary step for
receptor activation,28,29 probably reflecting the need to bring into close
proximity the cytoplasmic domains of 2 #c molecules associated with
Janus kinase-2 (JAK-2), resulting in JAK transphosphorylation and
receptor phosphorylation. Interestingly,#c has been shown to crystallize
as a dimer30 and to exist as a preformed homodimer on the cell
surface.26,28 Despite these findings, little is known about the full
assembly of this family of receptors, the intermediate steps in their
formation, and how receptor assemblymay be selectively modulated.
In this paper we show for the first time the full assembly of the
human GM-CSF receptor in solution. This shows a novel mode of
cytokine receptor assembly in which 1 molecule of GM-CSF
associates with 1 molecule of GMR" and 2 molecules of #c. In
addition, these studies reveal an essential, direct interaction be-
tween GM-CSF and #c and provide a molecular understanding of
GM-CSF antagonism by E21R or BION-1. This novel mode of
receptor assembly may also apply to the IL-5 and IL-3 receptors.
Materials and methods
Human GM-CSF and GM-CSF analogs
Soluble wild-type human GM-CSF was produced in Escherichia coli and
recovered from the periplasmic space by osmotic shock as described
previously.19 Crude periplasmic extracts were adjusted to 25 mM N-
ethylmorpholine HCl (NEM), pH 7.0, loaded onto Q Sepharose Fast Flow
(Amersham Biosciences, Sydney, Australia) equilibrated in 25 mM NEM,
pH 7.0, and a linear gradient of 0 to 600 mM NaCl in 25 mM NEM, pH 7.0,
used to elute the bound proteins. GM-CSF purified by anion exchange was
further purified by reversed phase high-performance liquid chromatography
(HPLC), lyophilized, dissolved in phosphate-buffered saline (PBS) as
previously described,19 and sterile-filtered (0.45 $m). The E21R analog of
GM-CSF (BresaGen, Adelaide, South Australia) contains a glutamate to
arginine substitution at residue 21 and a modified 12–amino acid leader
peptide, MFATSSSTGNDG, to facilitate expression in E coli.31
Radiolabeling of human GM-CSF
To enable phosphorylation of GM-CSF under mild conditions, we made the
GM-CSF analog, SGMKIN, in which the amino acids from alanine at
position 3 to proline at position 6 were replaced by the peptide sequence
RRASV, which is recognized by the catalytic subunit of cyclic adenosine
monophosphate (cAMP)–dependent protein kinase from heart muscle.32
Complementary oligonucleotides were used to create a HindIII/NcoI
fragment encoding the N-terminal 12 amino acids of SGMKIN. This
fragment was ligated with an NcoI/BamHI fragment encoding the C-
terminal 116 amino acids of human GM-CSF (hGM-CSF) into HindIII/
BamHI–digested pIN-III-OmpH3 expression vector19 to create the plasmid,
pSGMKIN. Soluble SGMKIN was expressed in E coli and purified as
described for wild-type GM-CSF. The final product was at more than 95%
purity by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS-PAGE), and the SGMKIN analog displayed biologic activity indistin-
guishable from the wild-type GM-CSF (data not shown). Labeling of
SGMKIN with 32P used a protocol adapted from Kaelin et al.32 Fifty
micrograms of purified SGMKIN was incubated in a 200-$L reaction mix
containing 20 mM Tris (tris(hydroxymethyl)aminomethane) HCl, pH 7.5;
100 mM NaCl; 12 mM MgCl2; 10 mM #-mercaptoethanol; 1 $Ci/$L
(0.037 MBq/$L) [%-32P]adenosine triphosphate ([%-32P]ATP) (3000 Ci/
mmol [111 000 GBq/mmol]; Geneworks, Adelaide, South Australia), and 1
U/$L of the protein kinase catalytic subunit (Sigma, Castle Hill, Australia).
The reaction proceeded at 4°C for 30 minutes, was terminated by the
addition of 200 $L of 100 mM EDTA (ethylenediaminetetraacetic acid),
adjusted to 0.1% (vol/vol) trifluoroacetic acid (TFA; Auspep, Parkville,
Australia), 1% (vol/vol) acetic acid, and loaded onto a Sep-Pak C18
reversed phase cartridge (Waters, Rydalmere, Australia) equilibrated in
0.01% TFA. The cartridge was washed with 0.01% TFA and bound
SGMKIN eluted using 10 mL of 50% (vol/vol) acetonitrile in the presence
of 0.01% TFA. Ten equal fractions were collected, and those containing the
peak of eluted radioactivity were pooled and concentrated using a
Speed-vac (Savant Instruments, Farmingdale, NY) to a final volume of
approximately 100 $L.
Production of recombinant soluble GM-CSF receptor subunits
DNA fragments encoding the soluble extracellular domains of GMR"





GCG-3& for s#c, with EcoRI and BamHI restriction sites underlined. Stop
codons were inserted immediately prior to the transmembrane domain for
each receptor molecule, following Gly at position 320 for GMR" and Ser at
position 438 for #c. The PCR products were digested with BamHI and
EcoRI and cloned into the baculovirus transfer vector BacPAK9 (Clontech,
PaloAlto, CA) and the sequence of the cloned inserts were verified by cycle
sequencing with BigDye chemistry (Applied Biosystems, Foster City, CA).
The cDNA encoding sGMR" and s#c was introduced into the genome of
Bsu36I-digested BacPAK6 viral DNA (Clontech) by homologous recombi-
nation following the manufacturer’s instructions. Expression of recombi-
nant protein is under the control of the strong polyhedrin promoter.
Large-scale expression of sGMR" or s#c was performed by infection of
Sf21 cells, grown in serum-free Ex-Cell 420 medium (JRH Biosciences,
Brooklyn, Australia), with recombinant baculovirus at a multiplicity of
infection of 0.3. Supernatant containing soluble receptor was harvested
following incubation at 27°C for 5 to 7 days.
Purification of soluble GMR! and s"c
Conditioned media containing sGMR" (20 L) or s#c (9 L) were concen-
trated to less than 1 L using tangential flow filtration cartridges (10 000
molecular weight cutoff, 0.23 m2) (Millipore, Northryde, Australia) oper-
ated at 80 kPa and 4°C. Insoluble material in the concentrate was pelleted at
3000g for 30 minutes and the resulting supernatant filtered (3 $m) prior to
affinity chromatography.Affinity matrices were prepared by coupling E21R
or the anti-#c mAb, BION-1,24 to cyanogen bromide (CNBr)–activated
Sepharose 4B (Amersham Biosciences) following the manufacturer’s
instructions. Recombinant soluble receptor was bound to the affinity
matrix, washed extensively in PBS containing 0.01% (vol/vol) polyoxyeth-
ylene 20 sorbitan monolaurate (Tween 20), and bound proteins eluted with
100 mM NaCl, 100 mM sodium acetate (pH 4.0). The eluate fractions were
immediately neutralized using 2 M Tris and analyzed for the presence of
soluble receptor by SDS-PAGE. Fractions containing purified soluble
receptor were pooled and concentrated using a stirred-cell device with a
10 000 molecular weight cutoff, low protein-binding membrane (YM10;
Millipore) operated at 300 kPa and 4°C. Concentrated soluble receptor was
dialyzed extensively into PBS, sterile-filtered (0.2 $m), and stored at 4°C.
SDS-PAGE
Samples were analyzed on 10% or 12.5% polyacrylamide gels containing
38:1 acrylamide/bisacrylamide under reducing or nonreducing conditions
as specified. Bands were visualized by staining with either Coomassie
brilliant blue R-250 or silver.33
Mass spectrometry
Electrospray ionization mass spectrometry was performed using a PE/Sciex
API100 mass spectrometer (Perkin-Elmer Sciex Instruments, Ontario,
Canada). Protein samples were desalted in-line using a 1' 10 mm reversed
phase column eluted with 60% (vol/vol) acetonitrile in the presence of
0.04% (vol/vol) TFA and the primary mass spectrum transformed to give a
true-mass profile using instrument software.
Protein analyses by size-exclusion chromatography
Size-exclusion chromatography was initially used to quantify purified
soluble receptors and their ligands. Samples were chromatographed on a
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SMART system with a Superdex 200PC 3.2/30 (3.2 mm ' 300 mm)
column (Amersham Biosciences) operated at 40 $L/min at 25°C using 150
mM NaCl, 50 mM sodium phosphate, pH 7.0, as running buffer. The area
under the protein peak was integrated using the extinction coefficient
(absorbance units' mL(1 ' mg(1) calculated for each protein: GM-CSF,
0.95; E21R, 0.88; sGMR", 1.17; s#c, 1.95.
To analyze protein-protein interactions, individual proteins and protein
complexes were prepared in a final volume of 50 $L, adjusted with PBS as
required, and incubated at 25°C for at least 1 hour. Samples were analyzed
by size-exclusion chromatography using the SMART system as described
above with data presented from representative experiments (n ) 5). The
dependence of elution time on the log10 (MW) of protein standards was
used to calibrate the column and to generate a trend line for each set of
standards. External standards included myoglobin, MW 17 kDa; ovalbu-
min, MW 44 kDa; %-globulin, MW 158 kDa; and thyroglobulin, MW 670
kDa (Biorad Laboratories, Hercules, CA). Internal standards were GM-
CSF, MW 14.5 kDa; E21R, MW 15.7 kDa; sGMR", MW 43 kDa; and s#c,
MW101 kDa as determined by mass spectrometry and SDS-PAGE. Soluble
#c was found to be a dimer by size-exclusion chromatography consistent
with previous reports.30 Calibration curves constructed from the external
and internal standards were essentially parallel (see Figure 2A). The
calibration curve for the internal standards was extrapolated to higher
mass (670 kDa) because this was found to be the limit of the linear range
for the external standards.
Analytical ultracentrifugation
The molecular weights of GM-CSF, E21R, sGMR", s#c, and the binary and
ternary complexes were determined by sedimentation equilibrium. Indi-
vidual proteins and protein complexes were isolated by size-exclusion
chromatography using a fast protein liquid chromatography (FPLC) system
with a Superdex 200 10/30 (10 mm ' 300 mm) column (Amersham
Biosciences) operated at 0.5 mL/min at 25°C using 150 mM NaCl, 50 mM
sodium phosphate, pH 7.0, as running buffer. Pooled fractions were
concentrated using Centricon 10 microconcentrators (Amicon, Beverly,
MA). Sedimentation equilibrium experiments were performed using a
Beckman XL-A analytical ultracentrifuge equipped with a Ti60 rotor
(Beckman, Palo Alto, CA) and filled epon centerpieces (12-mm path
length). Sedimentation equilibrium profiles were obtained at 20°C using the
rotor speeds indicated. Equilibrium distributions were fitted by nonlinear
regression analysis to obtain best-fit values for the M (1-*+), where M is the
molecular weight and * the partial specific volume of the sedimenting
species and + the solution density. The compositional molecular weights of
the proteins and the partial specific volumes of GM-CSF and E21R were
calculated from their amino acid sequences. Partial specific volumes for the
glycosylated forms of sGMR" and s#c were calculated assuming these
proteins were monomer and dimmer, respectively. A value of 0.622 mL/g
was assumed for the partial specific volume of carbohydrate. The experimen-
tal value of M (1-*+) and the molecular weight (Mp) and partial specific
volume of the protein component were then used to solve for the weight
fraction of bound carbohydrate and hence the partial specific volume of the
carbohydrate-bound protein. Values for the partial specific volumes of the
GM-CSF/sGMR" and E21R/sGMR" complexes were calculated assuming
a 1:1 complex and no volume change on association. A value of 0.72 mL/g
was assumed for the GM-CSF/sGMR"/s#c complex.
Cross-linking experiments
Stable cross-linking of s#c or soluble complexes of ligand with s#c was
performed by incubation of 2.6 $g s#c with either 2.4 $g GM-CSF or E21R
for 1 hour at 25°C followed by addition of BS3 cross-linker (Pierce,
Rockford, IL) at a final concentration of 0.1 mg/mL for 10 minutes. The
reaction was then stopped by addition of ethanolamine HCl, pH 8.0, to a
final concentration of 100 mM. Cross-linked proteins were subjected to
reducing SDS-PAGE and compared with non–cross-linked material. Anti-
body Fab fragments of BION-1 (anti-#c fourth domain blocking mAb) and
2H1 (anti-#c fourth domain control mAb) used in cross-linking experi-
ments were generated by digestion with ficin using the Immunopure IgG1
Fab Preparation Kit (Pierce) following the manufacturer’s instructions. Fab
fragment (18 $g) was preincubated with 2.6 $g s#c for 30 minutes at 25°C
prior to the addition of 2.4 $g GM-CSF in a final volume of 20 $L for a
further hour. Cross-linking was then performed as above followed by
SDS-PAGE analysis.
Results
Production, purification, and analysis of GM-CSF
soluble receptor components
Complementary DNA fragments encoding the extracellular do-
mains of GMR" and #c (sGMR" and s#c) were generated by PCR
and cloned into a baculovirus transfer vector. Following introduc-
tion into a baculovirus expression system by homologous recombi-
nation, the soluble receptor components were generated by infec-
tion of Sf21 cells. Purification of the soluble receptors was
achieved by affinity chromatography using immobilized ligand for
sGMR" and immobilized mAb BION-124 for s#c. Purified soluble
receptors were recovered at more than 95% purity as assessed by
silver-stained SDS-PAGE under reducing conditions (Figure 1A)
with an apparent molecular weight (MW) of approximately 43 kDa
for sGMR" and 55 kDa for s#c. Importantly, these MWs deter-
mined for sGMR" and for s#c did not alter when analyzed under
nonreducing conditions (Figure 1B), indicating the absence of
disulfide-linked dimers. A small amount of disulfide-aggregated
s#c was visible by nonreducing SDS-PAGE (Figure 1B) and as an
early, minor peak during size-exclusion chromatography (Figure
2C). The absence of detectable disulfide-linked dimers in s#c was
confirmed by ion-spray mass spectrometry, which demonstrated
that the protein preparation had a major species of 50.623 kDa with
several minor species representing glycosylation variants.
The physical properties of sGMR" and s#c were further
characterized by size-exclusion chromatography.We initially deter-
mined the retention times of sGMR" (Figure 2B), s#c (Figure 2C),
GM-CSF (Figure 2D), and E21R (Figure 2G). The individual
proteins eluted at 39.17 minutes for sGMR", 34.75 minutes for
s#c, 44.56 minutes for GM-CSF, and 44.11 minutes for E21R.
External MW standards for calibration of the size-exclusion
chromatography (Figure 2A) indicated that sGMR", GM-CSF, and
E21R were monomeric but that s#c was dimeric. The dimeric
nature of s#c was confirmed by cross-linking experiments with
purified s#c, which produced a covalent dimer with a MW of 100
kDa as determined by SDS-PAGE (see Figure 8B). The observation
that s#c exists as a dimer is consistent with a recent report
describing the structure of the extracellular domain of #c expressed
in insect cells.30,34 We observed that both the ligands and the
receptor components eluted from size-exclusion chromatography
Figure 1. SDS-PAGE analysis of purified sGMR! and s"c.Soluble GMR" and s#c
were produced by Sf21 cells infected with recombinant baculovirus encoding
appropriate cDNAand affinity purified from the supernatant as described in “Materials
and methods.” Soluble GMR" (1 $g) and s#c (0.5 $g) were fractionated by 10%
SDS-PAGE under reducing (A) and nonreducing (B) conditions and silver stained.
The positions of molecular weight markers are shown in kilodaltons.
1310 McCLURE et al BLOOD, 15 FEBRUARY 2003 ! VOLUME 101, NUMBER 4
70
Chapter 5: Molecular assembly of the granulocyte- macrophage colony-stimulating factor receptor complex
earlier than expected from the elution times of the external MW
standards (Figure 2A). We chose to use the proteins of interest as
internal MW standards and constructed a calibration curve for the
internal MW standards that is parallel to that constructed from the
external MW standards (Figure 2A). This is expected to provide a
superior estimate of the masses of the receptor complexes.
Soluble GMR! interactions with GM-CSF and E21R
Purified sGMR" (6 $M) was incubated with GM-CSF (12 $M)
and fractionated on a Superdex 200 column, producing a modest
shift (from 39.17 minutes to 38.51 minutes) in the elution time of
sGMR" (Figure 2E). The shifted peak, with an apparent MW of 48
kDa, contained both GM-CSF and sGMR" as determined by
SDS-PAGE analysis of fractions (data not shown). The MW of the
GM-CSF/sGMR" binary complex is consistent with a stoichiome-
try of 1:1 as has previously been described.35 The complete peak
shifts observed when sGMR" binds GM-CSF suggest that all of
this soluble receptor is competent to bind ligand. Saturation
binding experiments revealed that GM-CSF bound to sGMR" with
a dissociation constant (Kd) of 1.5 to 9 nM, similar to that seen with
cell surface–expressed GMR" (data not shown).
Purified sGMR" (6 $M) was incubated with E21R (12 $M) and
fractionated on a Superdex 200 column, producing a modest shift
(from 39.17 minutes to 38.40 minutes) in the elution time of sGMR"
(Figure 2H). The shifted peak, with an apparent MW of 49 kDa,
contained both E21R and sGMR" as determined by SDS-PAGE
analysis of fractions (data not shown). The MW of the E21R:sGMR"
binary complex is consistent with a stoichiometry of 1:1.
The s"c induces the formation of a GM-CSF ternary complex
Purified s#c (3 $M) was incubated with sGMR" (6 $M) plus
GM-CSF (12 $M) and fractionated on a Superdex 200 column,
producing a complete shift in the elution time of s#c (from 34.75
minutes to 32.67 minutes) as well as peaks corresponding to the
binary complex at 38.40 minutes and free ligand at 44.61 minutes
(Figure 2F). The peak eluting at 32.67 minutes had an apparent
MW of 155 kDa and contained GM-CSF, sGMR", and s#c as
determined by SDS-PAGE analysis of fractions (Figure 3A). The
MW of this ternary GM-CSF receptor complex is consistent with a
stoichiometry of 1 GM-CSF:1 sGMR":2 s#c.
In contrast, no ternary complex was observed when purified s#c
(3 $M) was incubated with sGMR" (6 $M) plus E21R (12 $M)
and fractionated on a Superdex 200 column (Figure 2I). Whereas the
binary complex eluting at 38.32 minutes contained E21R and sGMR",
the peak at 34.80 minutes contained s#c but no sGMR" or E21R as
determined by SDS-PAGE analysis of fractions (Figure 3B).
E21R disrupts the formation of the ternary
GM-CSF receptor complex
To investigate whether the formation of a binary complex was an
intermediate step in the formation of the ternary GM-CSF receptor
complex, we tested the effect of E21R in this process. Purified s#c
(3 $M) was incubated with sGMR" (6 $M) and GM-CSF (12 $M)
for 1 hour. A 100-fold molar excess of E21R was then added, and
after a further 1-hour incubation the mixture was fractionated on a
Superdex 200 column. In the absence of E21R the ternary GM-CSF
receptor complex eluted at 33.12 minutes (Figure 4). Significantly,
in the presence of a 100-fold molar excess of E21R (Figure 4) there
was a reduction in the amount of ternary GM-CSF receptor
complex and an increase in its elution time (34.10 minutes), more
comparable with the elution time of free s#c (34.75 minutes). The
Figure 3. SDS-PAGE analysis of the ternary GM-CSF receptor complex.Mixtures
of s#c, sGMR", and either GM-CSF (A) or E21R (B) were analyzed by size-exclusion
chromatography as described for Figure 2F and I. Fractions were collected at
1-minute intervals, fractionated by 12.5% SDS-PAGE under reducing conditions, and
silver stained.33 The positions of individual components are indicated.
Figure 4. E21R prevents formation of the ternary GM-CSF receptor complex.
Following formation of the GM-CSF/sGMR"/s#c ternary complex using a 1:2:4 molar
ratio, a 100-fold molar excess of E21R over GM-CSF was added for a further hour at
25°C before size-exclusion chromatography. The chromatogram shows the A280
profile of a GM-CSF/sGMR"/s#c mixture in the absence (thick line) or presence of
E21R (thin line) or in s#c alone (dashed line).
Figure 2. GM-CSF but not the GM-CSF analog E21R induces the assembly of
the ternary GM-CSF receptor complex in solution. The presence and molecular
weight of individual proteins and protein complexes were determined using size-
exclusion chromatography as described in “Materials and methods.” (A) Linear
regression of log10 (MW ' 10(3) versus elution times using external (E) and internal (F)
standards for calibration of the column. (B-I) Individual proteins sGMR" (B), s#c (C),
GM-CSF (D), and E21R (G) were applied separately. Mixtures of sGMR" (6 $M) and
GM-CSF (12 $M) (E); s#c (3 $M), sGMR" (6 $M), and GM-CSF (12 $M) (F); sGMR"
(6 $M) and E21R (12 $M) (H); s#c (3 $M), sGMR" (6 $M), and E21R (12 $M) (I)
were incubated for 1 hour before being applied to the column. The number above
each peak represents elution time. Peaks containing binary (BC) or ternary (TC)
complexes are indicated.
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reduction in the amount of ternary complex along with an increased
amount of binary complex (38.40 minutes) and free ligand (44.00
minutes) is consistent with sGMR" preferentially forming a binary
complex with E21R, which is unable to recruit s#c into a
ternary complex.
Stoichiometry of the ternary GM-CSF receptor complex
To confirm the 1 GM-CSF:1 sGMR":2 s#c stoichiometry of the
ternary GM-CSF receptor complex obtained by size-exclusion
chromatography, we utilized 2 other complementary and indepen-
dent methods. In one of these the molecular weights of the
individual proteins and of the binary and ternary complexes were
determined by sedimentation equilibrium. The results showed
(Figure 5; Table 1) values similar to those obtained by gel filtration.
The estimates of the molecular weight of the binary complexes
GM-CSF/sGMR", 52.7 kDa (Figure 5A; Table 1), and E21R/
sGMR", 54.8 kDa, (Figure 5B; Table 1), are consistent with a 1:1
stoichiometry. The molecular weight of the ternary GM-CSF/
sGMR"/s#c complex was determined to be 135 kDa (Figure 5C
and Table 1). This value is consistent with a model where one s#c
dimer (97.4 kDa) associates with one GM-CSF/sGMR" binary
complex (52.7 kDa) (Table 1) with a theoretical molecular weight
of 150.1 kDa.
In a separate approach, we used radiolabeled GM-CSF as a
tracer molecule. Purified s#c (0 to 7 $M) was titrated against a
mixture of sGMR" (3.2 $M) and cold GM-CSF (7.3 $M) spiked
with the GM-CSF analog 32P-SGMKIN and subjected to size-
exclusion chromatography as above. Addition of s#c to the
GM-CSF/sGMR" mixture led to the dose-dependent formation of
the ternary complex and depletion of the binary complex (Figure
6A). Once the concentration of s#c saturated the available binary
complex, a shoulder appeared on the trailing edge of the ternary
complex peak, presumably reflecting the presence of free s#c.
Formation of the ternary complex was associated with a dose-
dependent accumulation of radioactivity at the appropriate elution
time of the ternary complex and was accompanied by a reduction of
radioactivity at the elution time of the binary complex (Figure 6B).
Titration of s#c did not lead to a reduction of radioactivity at the
elution time of free ligand, although a modest shift at the leading
edge of the free ligand peak was observed. We then determined the
distribution of 32P-SGMKIN into the ternary complex and ex-
pressed it as a percentage of total label in the ternary and binary
complexes versus proportion of s#c present (Figure 6C). When
compared with the theoretical distribution predicted for a ternary
complex with a GM-CSF/sGMR"/s#c ratio of 1:1:2 or 2:2:2,
the observed distribution was consistent with a 1:1:2 stoichiom-
etry. The observed distribution only departed from the modeled
linear distribution as the concentration of binary complex
became limiting.
The use of radiolabeled GM-CSF also allowed us to investigate
whether the presence of s#c in the ternary complex led to affinity
conversion. GM-CSF spiked with the GM-CSF analog 32P-
SGMKIN was titrated against an equimolar mixture of sGMR" and
s#c, allowed to equilibrate, and fractionated by size-exclusion
chromatography. For each GM-CSF concentration point, radioactiv-
ity bound in the binary and ternary complexes was determined
and the proportion in each complex was expressed as a
percentage of total bound counts. We found (Figure 6D) a 4-fold
preferential distribution of 32P-SGMKIN into ternary complexes
at subsaturating concentrations of ligand, indicating that the
Table 1. Sedimentation equilibrium analysis of the molecular weights
of GM-CSF, E21R, sGMR!, s"c, and their complexes





GM-CSF 3 590 0.734 13 700 — —
E21R 4 050 0.734 14 300 — —
sGMR" 11 800 0.706 40 700 — —
s#c 26 600 0.723 97 400 — —
sGMR" plus GM-
CSF
14 600 0.718 52 700 54 400 1:1
sGMR" plus E21R 15 400 0.714 54 800 55 000 1:1
s#c plus sGMR" plus
GM-CSF
37 300 0.72 135 300 151 800 2:1:1
The buffer used was 150 mM NaCl/50 mM sodium phosphate, pH 7.0, and the
temperature was 20°C. The complexes formed between GM-CSF and E21R with
sGMR" and between GM-CSF, sGMR", and s#c were isolated by gel filtration. The
initial concentration used for all samples was between 0.40 and 0.47 mg/mL except
for E21R, where the starting concentration was 0.2 mg/mL. The reduced molecular
weights of the samples, M (1-v+), were determined by direct fitting of the sedimenta-
tion data presented in Figure 5. These values were used to calculate the molecular
weight (MW) of the sedimenting species using the partial specific volumes (v)
indicated.
Figure 5. Analyses of the ternary GM-CSF receptor complex by sedimentation
equilibrium. The individual proteins or protein complexes in 150 mM NaCl/50 mM
sodium phosphate, pH 7.0, were centrifuged at 20°C at angular velocity, W rpm, for
16 hours. The equilibrium profiles are presented as (W/W1)2 Ln(c/co) versus the
square of the radial distance, where c/co is the optical density at 280 nm divided by
the initial optical density and W1 is 20 000 rpm. For a single species, this plot is linear
with a slope proportional to the molecular weight of the sedimenting species. The
initial concentrations were in the range 0.40 to 0.47 mg/mL, and samples were
centrifuged at 20 000 rpm except for E21R, where the initial concentration was 0.2
mg/mL and the angular velocity 15 000 rpm. Panel A samples: GM-CSF (E), sGMR"
("), GM-CSF/sGMR" complex (F). Panel B samples: E21R (E), E21R/sGMR"
complex (F). Panel C samples: purified s#c (") was centrifuged at 15 000 rpm with
an initial concentration of 0.45 mg/mL, whereas the GM-CSF/sGMR"/s#c ternary
complex at an initial concentration of 0.47 mg/mL was centrifuged at either 8000 rpm
(Œ) or 15 000 rpm (F) for 16 hours at 20°C.
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presence of s#c in the ternary complex induces a measurable
degree of affinity conversion.
GM-CSF binds s"c in the absence of sGMR!
Initial chromatography experiments at approximately equimolar concen-
trations indicated that GM-CSFwas unable to form a complex with s#c
in the absence of sGMR". However, close inspection of the elution
profile of radiolabeled GM-CSF in the presence of free s#c (Figure 6B)
revealed amodest decrease in the elution time ofGM-CSF suggestive of
aweak interaction between s#c andGM-CSF.To investigate this further
and to determine the specificity of this interaction, we titrated s#c
against GM-CSF or the E21R analog (Figure 7). Titration of s#c against
GM-CSF had a dose-dependent effect on GM-CSF peak height with a
concomitant spreading of the GM-CSF profile to earlier elution times
(Figure 7A). Titration of s#c against E21R had no effect on E21R
elution time or profile (Figure 7B). These results show that GM-CSF
directly interacts with s#c through the functionally important Glu21
residue and that substitution of this residue makes a qualitative
difference to the GMR"-independent recognition of#c by GM-CSF.
Asecond approach confirmed the direct interaction ofGM-CSFwith
#c and extended these findings to the identification of the reciprocal
region in #c. We incubated purified s#c with a 3-fold molar excess of
GM-CSF or E21R, treated with the BS3 cross-linker and analyzed the
mixture by SDS-PAGE under reducing conditions (Figure 8). No
covalent interactions between s#c andGM-CSForE21Rwere observed
in the absence of cross-linker (Figure 8A). GM-CSF and E21Rwere not
dimerized by cross-linker under the conditions used, whereas the s#c
dimer was partially cross-linked, yielding a band of MW 100 kDa
(Figure 8B). Significantly, when GM-CSF was incubated with s#c and
cross-linked, a unique band of MW 70 kDa was observed (Figure 8B).
Western blotting with anti-#c or anti–GM-CSF antibodies showed that
this band contains both s#c andGM-CSF (data not shown). E21R could
not be cross-linked directly to s#c as seen by the absence of the 70 kDa
band (Figure 8B), thus confirming that Glu21 of GM-CSF is necessary
for direct contact with #c. Neither the structurally related cytokine
human growth hormone nor sGMR"was able to be cross-linked to s#c
under these conditions (data not shown).
To determine if the interaction between s#c and GM-CSF was
occurring through a functionally relevant region of #c, we used
BION-1, a mAb that blocks GM-CSF, IL-3, and IL-5 binding and
signaling through #c.24 BION-1 recognizes a discrete region in the
fourth domain of #c associated with high-affinity GM-CSF binding
and function.20,22,36 Preincubation of s#c with BION-1 Fab frag-
ment prevented GM-CSF from being cross-linked to s#c, as seen
by the absence of the 70-kDa band (Figure 8C). The Fab fragment
of a mAb that binds to the fourth domain of #c but does not block
cytokine binding was unable to perturb the cross-linking of s#c to
GM-CSF (Figure 8C).
Discussion
We report here the first demonstration of a fully assembled
GM-CSF/GM-CSF receptor ternary complex in solution and
describe the molecular interactions required for its formation. It is
shown that the ternary complex exhibits a novel mode of cytokine
receptor assembly that comprises 1 molecule of GM-CSF and 1
molecule of GM-CSF receptor " chain interacting monovalently
with a noncovalently linked dimer of #c. In addition, a direct
interaction between GM-CSF and #c in the absence of the receptor
Figure 6. Radiolabeled GM-CSF differentially partitions to the ternary GM-CSF
receptor complex. (A-C)A titration of purified s#c (0 to 7.03 $M) against a mixture of
3.2 $M sGMR" and 7.3 $M GM-CSF spiked with 32P-labeled SGMKIN. Reaction
mixes were set up with 0 (dashed gray), 0.88 $M (dashed black), 1.76 $M (thin gray),
3.52 $M (thin black), 5.27 $M (thick gray), or 7.03 $M (thick black) s#c and incubated
at 25°C for 1 hour before size-exclusion chromatography. Fractions were collected at
1-minute intervals. A control reaction was also prepared with 5.27 $M s#c and 3.2 $M
sGMR" but no GM-CSF (dashed black). (A) Chromatogram of A280 profiles for each
sample with the location of the ternary complex (TC), binary complex (BC), and free
ligand (GM) indicated. (B) Distribution of radioactivity among the ternary complex,
binary complex, and free ligand for the reactions described in panel A. (C) Radioac-
tive GM-CSF distributed into the ternary complex, expressed as a percentage of the
total radioactive GM-CSF in ternary and binary complexes; comparing experimentally
observed values for the reactions described in panel A (F) with a theoretical
distribution based on 1GM:1":2# (E) and 2GM:2":2# (") models. (D) Titration of
GM-CSF (0 to 7 $M) spiked with 32P-labeled SGMKIN against a mixture of 3.5 $M
sGMR" and 3.5 $M s#c. Reaction mixes were allowed to reach equilibrium at 25°C
for at least 2 hours before being fractionated by size-exclusion chromatography. The
distribution of radioactivity among ternary (F) and binary (E) complexes was
determined and the radioactivity in each complex was expressed as a percentage of
total bound counts where counts in TC plus counts in BC is 100%.
Figure 7. GM-CSF binds directly to "c. Purified s#c was titrated (0 to 20 $M)
against 5 $M GM-CSF (A) or 5 $M E21R (B). Reaction mixes were set up with 0
(dashed black), 1 $M (thin black), 2.5 $M (medium gray), 5 $M (medium black), 10
$M (thick gray), or 20 $M (thick black) s#c, incubated at 25°C for 2 hours, and
fractionated by size-exclusion chromatography.
Figure 8. Discrete regions in GM-CSF and "c mediate their direct interaction.
Purified s#c was incubated at 25°C for 1 hour alone or in the presence of either
GM-CSF or E21R. Samples were left untreated (A) or were treated for 10 minutes
with BS3 cross-linker (B). To determine if GM-CSF was interacting with the
cytokine-binding site in the fourth domain of #c, purified s#c was preincubated with a
Fab fragment of the neutralizing anti-#c mAb, BION-1, or the nonneutralizing control
anti-#c mAb, 2H1. GM-CSF was then allowed to bind and the mixture and individual
mAb treated with BS3 cross-linker (C). Samples were analyzed on 12.5% (A) or 10%
(B-C) SDS-PAGE gels and stained with Coomassie. The positions of molecular
weight markers are shown in kilodaltons, and the position of s#c cross-linked to
GM-CSF is indicated by Š.
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" chain could be demonstrated. The recruitment of #c as a preformed
dimer may facilitate receptor activation and may also represent a
mechanism utilized by the related IL-3 and IL-5 receptors. The
GM-CSF ternary complex was demonstrated by gel filtration and
sedimentation equilibrium analyses to have a molecular weight of
between 135 kDa and 156 kDa, consistentwith aGM-CSF/sGMR"/s#c
stoichiometry of 1:1:2. In addition, the relative distribution of radiola-
beled GM-CSF fitted a ternary complex with a 1:1:2 stoichiometry. The
preferential distribution of radiolabeled GM-CSF into the ternary
complex is indicative of s#c-mediated, affinity conversion. No disulfide
linkages between receptor subunits were observed; there were no
differences seenwhen the ternary complexwas analyzed bySDS-PAGE
under either reducing or nonreducing conditions or when the free
cysteine groups in s#c were blocked with iodoacetamide (data not
shown). These results are consistent with previous reports suggesting
that GM-CSF receptor heterodimerization is required to activate the
GM-CSF receptor,25 the dimeric nature of #c observed both on the cell
surface and in solution,26,28,30 the affinity conversion afforded by #c,15,20
and the requirement of at least a #c dimer for function and activation of
downstream signaling molecules.28,29 The intermediate binding affinity
for GM-CSF in the ternary complex is consistent with a report
describing the low-affinity binding of murine GM-CSF to detergent-
solubilized GM-CSF receptors extracted from a murine cell line.37 In
addition, these results do not rule out the formation of higher-order
complexes on the cell surface,27,38 which may lead to further affinity
conversion and disulfide linkage required for receptor stabilization,
activation, or internalization purposes. The assembly of the human
GM-CSF receptor shown here is different from that seen for the IL-639
and LIF40 receptors, which exhibit a stoichiometry of 2:2:2 and 1:1:1,
respectively. Interestingly, the dynamics of the GM-CSF receptor
assembly are analogous to the IL-6 receptor in that following the
binding of ligand to the major binding subunit (" chain) there is
recruitment of the signaling subunit (#c or gp130). However, although
dimerization of gp130 requires a second IL-6/IL-6R" chain binary
complex, this is not the case with #c, which is recruited to a single
GM-CSF/sGMR" binary complex as a preformed dimer. Despite the
dimeric nature of s#c and even in the presence of a 2-fold molar excess
of the GM-CSF/sGMR" binary complex, we saw no evidence for the
formation of a ternary complex with a stoichiometry of 2:2:2. The
functional monovalency of s#c may be due to conformational changes
within the s#c dimer, induced by the binding of one GM-CSF/sGMR"
binary complex that prevents the binding of a second binary complex.
The recruitment of s#c to the GM-CSF/sGMR" binary complex
occurs through functionally relevant sites inGM-CSF and#c itself. This
is demonstrated by the inability of the GM-CSF analog E21R to form
the ternary complex and by the inhibition of s#c cross-linking to
GM-CSF by the anti-#c mAb BION-1, which blocks the high-affinity
binding of GM-CSF.24 Given that there is an homologous glutamic acid
in IL-3 (position 22) and in IL-5 (position 13) and the fact that BION-1
also blocks high-affinity binding of IL-3 and IL-5, it is possible that this
mode of receptor assembly will also apply to the IL-3 and IL-5
receptors. The recruitment of dimerized #c and associated JAK-2
molecules may facilitate receptor phosphorylation and activation in this
subfamily of receptors. Using a soluble receptor systemwe could detect
for the first time a direct interaction between GM-CSF and #c in the
absence of the GM-CSF receptor " subunit. We observed this by gel
filtration (Figure 7) and cross-linking studies (Figure 8). The interaction
was sensitive to the E21R substitution and the mAb BION-1, indicating
that the direct interaction observed between GM-CSF and s#c is
chemically and spatially equivalent to the interaction that occurs with
the cell membrane–anchored receptor. Considering that all #c-
interacting cytokines do so through a chemically and structurally
conserved mechanism,36 it is likely that a direct interaction between #c
and IL-3 or IL-5 will also exist. The relative affinity of the direct #c
interaction for each cytokine may help to explain differences in
#c-mediated affinity conversion in the high-affinity binding of IL-3,
GM-CSF, or IL-5. Despite the direct interaction of #c with GM-CSF
seen in the soluble system, this may not be sufficient to activate the
receptor in vivo given the very high concentrations of both receptor and
ligand needed to detect this weak interaction (in the micromolar range)
and the fact that GMR" intracellular domain has been previously shown
to be crucial for GM-CSF signaling.41
In the IL-4 system, a high-affinity (Kd ) 0.15 nM) interaction
between IL-4 and the IL-4 receptor " chain42 utilizes a chemically and
structurally homologous mechanism, suggesting that the type of direct
interaction we observed between GM-CSF and #c may be conserved
among other cytokines. The direct interaction we detected between
GM-CSF and s#c also suggests that conformational changes in the
GM-CSF/sGMR" binary complex may not be necessary for the
recruitment of #c. However, the monovalent binding of the GM-CSF/
sGMR" binary complex to s#c suggests the possibility of an induced
conformational change within the extracellular domain of s#c. Confor-
mational changes in the cytoplasmic region of#cmay be induced by the
assembly of the ternary complex to promote #c/JAK-2 proximity and
receptor activation as shown for the erythropoietin receptor.43 The
assembly of the human GM-CSF receptor system in solution described
herein also provides a useful tool for investigating its dynamics and
structural requirements. The initial event in activation of the GM-CSF
receptor is the binding of ligand to the GMR"with low affinity prior to
recruitment of #c. The soluble system used here revealed a 1:1
stoichiometry of binding between the sGMR" chain and GM-CSFwith
a Kd equivalent to that seen with the full-length GMR" on the cell
surface. We were able to show that E21R, a GM-CSF analog defective
in high-affinity binding and a specific GM-CSF antagonist currently in
phase 2 clinical trials, also binds sGMR" with a 1:1 stoichiometry.
Importantly, E21R is incapable of forming a ternary receptor complex
andwhen present in excess is able to prevent the formation of the ternary
GM-CSF receptor complex, thus explaining its antagonistic activity.
This set of experiments also demonstrates that the assembly of the
GM-CSF receptor is a sequential process that involves first the
formation of a binary complex. In structural terms itwill be interesting to
use single point mutants of#c to examine the residues that participate in
direct contactwithGM-CSFor theGM-CSF receptor" chain.Thismay
be also a useful system for the identification of small molecules that
prevent the formation of the ternary complex. Finally, the assembly of
the human GM-CSF ternary complex in solution should aid in its
crystallization and ultimately in the solving of its structure.
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The papers presented here describe the nature of the GM-CSF receptor components and illustrate 
their stoichiometric progression upon GM-CSF binding from a low affinity interaction with 
GMRα, through to the recruitment of the signalling subunit hβc into a higher order complex 
[106-108]. This clarified the stoichiometry of the active GMR which had been unclear as the 
composition had only been inferred as higher order complexes or simple heterodimers through 
dominant negative receptor studies [73], and leucine zipper-mediated heterodimerization of 
GMRα and hβc intracellular domains, respectively [109].  
 
This was achieved by investigating the assembly of the GMR subunits in both a cell based 
system, where full length receptor components assemble and signal; and using soluble receptor 
system, where extracellular receptor domains assemble in solution and complex stoichiometry 
monitored directly in the absence of a cell membrane. The use of both a cell based and cell free 
system enabled investigation of different aspects of GMR assembly, and together revealed the 
formation of a higher order GMR complex upon receptor activation. This thesis also provided 
cautionary observations that can confound the identification of critical interactions between GM-
CSF and GMR components, which may be relevant to other type I cytokine receptors, by 
revealing potentially misleading interspecies interactions between homologous receptors [110]. 
 
A common feature of type I cytokine receptor activation is receptor oligomerization as 
prerequisite for the JAK2 homodimerization for initiation of signal transduction [72]. To 
determine if one or more hβc interact with GMRα for receptor activation we developed a 
chimeric receptor system that would only permit signal transduction if at least two hβc interacted 
within the active GMR. The chimeric receptor used comprised the extracellular and 




activated by receptor homodimerization [111]. When chimeric hβc/EPO-R receptor was 
expressed with GMRα on cells a GM-CSF response was demonstrated. This suggested the 
homodimerization of at least two hβc subunits was required for GMR activation and signal 
transduction. The GM-CSF responsiveness was attributed to hβc dimerization alone as hβc/EPO-
R responsiveness to GM-CSF was retained in the presence of a C-terminally truncated GMRα, 
excluding any contribution from the GMRα cytoplasmic domain in this system. This confirmed 
that an interaction between at least two molecules of signalling subunit hβc is required in the 
active GMR, akin to the signal transducing subunit of the IL-6 R, gp130 [66]. Dimerization of 
hβc is potentially required for IL-3 and IL-5 receptor as these cytokines also share hβc for signal 
transduction. This supported other lines of evidence that suggested that active GMR is more than 
just a simple heterodimeric complex of GMRα and βc [73, 74]. The formation of hβc 
homodimers within the active receptor may bring two JAK2 molecules, which are constitutively 
associated with hβc, into close proximity allowing them to transphosphorylate each other as the 
preliminary step for initiating receptor signal transduction. While these results indicated that the 
GMRα:hβc heterodimer alone does not signal, it did not indicate the number of GMRα subunits 
required for receptor activation or if multiple hβc dimers interact. 
 
While cell based systems are useful tools for the investigation of how receptors assemble and 
signal in response to cytokines our studies of the hGM-CSF antagonistic mutant, E21R, revealed 
the problematic influence that endogenous cytokine receptors can have [110]. We observed that 
the biological activity of E21R is strikingly different when analysed in hGMR transfected murine 
cell lines compared to its actions on human cells expressing endogenous GMR. In human cells 
E21R cannot mediate a proliferative response and is unable to bind hGMR with high affinity 




was promoted by the tyrosine phosphorylation of transfected hβc, an event that does not occur in 
an endogenous human system. In addition, we found a ligand independent pre-association 
between the mouse and human βc. The inappropriate signalling detected in this mixed species 
system may be the result of receptor activation following the recruitment of oligomers formed 
between the homologous mβc and hβc [110]. 
 
Receptor dimerization is a common theme in receptor activation, and the potential for inter-
species interaction of signalling components obscuring results when studying human receptors in 
murine cells must be controlled for. An analogous situation has been reported for a human 
interleukin-4 mutant that can mediate either agonistic or antagonistic responses when studied in 
either a murine or human cell line respectively [112]. Similarly, analysis of TPO mutants showed 
conflicting data in the identification of residues functionally important in interaction with its 
receptor when screened on Mpl transfected Ba/F3 cells compared to ELISA or Biacore analysis 
[113, 114]. These findings highlighted that the use of transfected murine cell lines expressing 
endogenous murine GMR may not be the best approach when studying hGM-CSF ligand 
variants. The use of lymphoid cell lines, such as CTLL-2, or cell lines made from mβc/mβIL-3 
knockout mice will avoid any potential contribution from endogenous murine GMR components 
[115]. Similarly receptor reconstitution experiments in mβc/mβIL-3 knockout mice may provide a 
better background to analyse functional outcomes of hGMR activation. The analysis of soluble 
GMR component assembly avoided potential interspecies interactions and facilitated the analysis 
of the receptor components in isolation. 
 
Receptor assembly studies using full-length receptors do not discern if the hβc homodimer 
assembles through interactions between the extracellular domains, intracellular domains or a 




interactions between IL-6 and soluble cytokine receptors revealing its composition [105, 116]. 
The production of soluble receptors provided an alternative system for elucidating ligand and 
receptor interactions in defined systems free of intracellular interactions. The stoichiometry of 
assembled soluble receptors can be determined directly by techniques such as size exclusion 
chromatography and analytical ultracentrifugation in the absence of heterologous receptor 
chains.  
 
Soluble forms of the GMR receptor were generated by over expression of secreted C-terminally 
truncated forms in COS cells [107]. This system allowed the initial characterisation of the 
soluble receptor components, sGMRα and sβc, and investigation of their interactions with each 
other or full-length receptors when co-expressed. Under certain circumstances, on the cell 
surface and as soluble receptors, the GMRα and βc could be found to co-associate in the absence 
of ligand. This indicated that these proteins directly interact through an as yet unidentified 
binding interface. Our soon to be published GMR structure (Appendix 1) reveals an interaction 
between the membrane proximal GMRα and βc from two adjacent ternary complexes. Although 
data showing the ligand independent association between GMRα and sβc was generated, the 
system used for these studies proved to be not optimal. Expression levels of the individual 
soluble receptors in the COS cell system were too low to enable purification of amounts required 
for receptor assembly studies. In addition, the majority of sβc produced in transiently transfected 
COS cells formed disulphide linked aggregates which could not be used in assembly studies. 
 
Production of cytokine receptor extracellular domains, such as IL-6R, in insect cells have been 
successfully used in receptor assembly studies [117]. Expression of human proteins in insect cell 
lines, such as Sf21, gives high yields of receptor protein with glycosylation that resembles the 




our yield dramatically and also overcame the problem of di-sulphide linked sβc aggregates, 
producing material suitable for receptor complex assembly. A high yield expression system 
subsequently established and enabled the large-scale production of receptor components for 
structural studies of GMR complexes. 
 
Both sGMRα and sβc were successfully produced in Sf21 insect cells using a baculovirus 
expression system. Characterisation of the purified soluble receptor components revealed 
sGMRα to be monomeric with low affinity GM-CSF binding characteristics that mimic the full-
length receptor. The sGMRα  was free of di-sulphide linked aggregates that have been 
previously described for a naturally occurring truncated form of sGMRα [118]. Soluble GMRα 
was found to bind GM-CSF in a 1:1 stoichiometric ratio, confirming previous studies [118]. 
Soluble βc was found to exist as a preformed homodimer as shown previously of full length cell 
surface approaches [74] and in the apo-crystal structure [75]. During our characterisation of the 
sβc we tried to revert sβc dimer into a monomer using a gentle caotropic agent, however a stable 
monomeric complex could not be formed (unpublished data). The homodimeric nature of sβc 
suggests the hβc is a non-functional dimer in the absence of ligand and GMRα chain, how hβc 
dimer then becomes activated following interaction with a ligand:GMRα is still unclear. The 
recruitment of hβc as a preformed dimer may facilitate receptor activation, and may also 
represent a mechanism utilised by the related IL-3 and IL-5 receptors. 
 
This work showed the first demonstration of a GMR soluble complex that contains the sGMRα, 
sβc and GM-CSF and the stoichiometry of this complex. The interaction of these three soluble 




are critical for GM-CSF binding and signalling. This was clearly demonstrated by the direct 
interaction revealed by crosslinking studies of GM-CSF, but not E21R, with the sβc. 
 
Interaction between GM-CSF and hβc has not been previously described on cell surface 
expressed receptors. In addition the blocking antibody that targets the ligand-binding site of hβc, 
BION-1 [63, 119], can prevent GM-CSF interacting with cell surface hβc, mimicking the 
neutralising antibody’s ability to prevent high affinity binding on the cell surface and subsequent 
signalling. This was the first description of a direct physical interaction between hβc and GM-
CSF that occurs through a functionally relevant epitope in the absence of GMRα. Unlike GM-
CSF, E21R in unable to interact with sβc demonstrating that E21 on GM-CSF can directly 
interact with βc. 
 
Previously our model, based on computer modelling, proposed the GMR contained a 
stoichiometry of 2GM-CSF:2hβc:2GMRα, based on the structural homology to the GH receptor 
and inclusion of the role of disulphide linkages between receptor component [72]. The ability of 
IL-3 to trans-phosphorylate GMRα associated hβc support the formation of a higher order 
complex that contains two alpha-receptors [107]. Our studies revealed that at least two hβc 
extracellular domains are for signalling and that the extracellular domains of hβc exist as a 
preformed dimer, both findings support the proposal of a higher order GMR complex. However, 
size exclusion chromatography revealed the stoichiometry of the sβc:GMRα:GM-CSF soluble 
receptor ternary complex was found to be 2:1:1. This may represent an assembly intermediate, as 
this complex did not bind GM-CSF with high affinity. Although improved affinity was seen 
following the addition of hβc to the GMRα:GM complex, we were unable to demonstrate high 




(unpublished observations). This suggests the cell membrane, transmembrane or intracellular 
interactions may be required for full affinity conversion, potentially through stabilising the 
complex or membrane anchoring required for conformational constraints. Our subsequent gel 
filtration studies using higher protein concentrations for complex formation suggest that the 
system can be pushed to produce a larger complex, possibly 2:2:2 (Appendix 1). 
 
The crystal structure of hβc extracellular domain revealed a stable interlocking dimer [75] that 
revealed a new binding epitope in domain 1, and functional activity confirmed by mutagenesis 
studies [120]. Domain 1 of hβc appears to contribute loop residues, in addition to those 
previously described in domain 4, to the ligand-binding site. This had not been predicted by our 
previous modelling based on the GHR structure. While the structural determination of hβc 
extracellular domain in isolation is an important step forward in understanding the nature of the 
GMR, it does not address how the GMR assembles. This structure described the membrane 
proximal domains to be 120 angstroms apart and this presumably reflects a similar separation of 
the cytoplasmic domains. It remains difficult to understand how the interlocking hβc dimer 
would allow the trans-phosphorylation of associated JAK2 to occur when a 120 angstrom space 
exists between the intracellular hβc domains. While it is useful to determine the structure of the 
individual components that comprise the GMR, alone they are unable to illustrate the assembly 
of receptor components that occurs upon ligand binding. 
 
The production of a soluble GMR ternary complex, as described in this thesis, was the initial 
requirement needed to resolve the molecular structure of this receptor complex. Structural 
analysis of the GMR is paramount to reveal critical molecular interactions required for complex 
formation upon GM-CSF high affinity binding. The identification of critical epitopes required 




activation, an important advance in for diseases including asthma, arthritis and some leukemias 
given GM-CSF’s pathogenic role [121]. These studies also highlight that any such drugs 
generated must be analysed on human cells, or in in vitro systems that are not confounded by 
non-human endogenous receptor chains, which can lead to inappropriate GMR activation by 
interaction with heterologous receptors. 
 
This work lead to the large-scale production of the individual extracellular GMR components in 
the Sf21 insect cell line expression system. These cell lines enabled the production of milligram 
quantities of the individual GMR receptor components. Individual components were then 
purified by affinity chromatography, ternary complexes were assembled and isolated using size 
exclusion chromatography, and analysed in crystallographic studies (Appendix 1).  
 
In summary, this thesis described the nature of the components of the GMR using both full-
length receptors in cell based systems and soluble extracellular domains, and describes the 
formation and stoichiometry of a soluble GMR ternary complex. This provided important 
preliminary data that lead to successful crystallographic studies and the subsequent resolution of 
the GMR ternary complex that and brought insight into how this multi-subunit type I cytokine 

















Chapter 7: Concluding Remarks
 
CONCLUDING REMARKS 
The work presented here were fundamental for the determination of the structure of the GM-CSF 
receptor complex (Appendix 1). The atomic structure of the GM-CSF ternary complex was 
subsequently determined and revealed a hexamer assembly of two hβc, two GMRα chains and 
two GM-CSF molecules (Figure 3). This stoichiometry differed from the observed 2:1:1 
described in Chapter 5. This is likely due to our consequent findings that GM-CSF ternary 
complex formation showed a protein concentration dependant shift in molecular weight 





The structure of the GM-CSF Receptor Ternary Complex as it would sit on the cell membrane. GM-CSF is 
highlighted in blue and GMRα in yellow. One monomer of hβc is shown in magenta (chain a) and the other in green 
(chain b). Labels correspond to domain names (Appendix 1).  
 
 
The hexameric GM-CSF ternary complex showed an arrangement similar to other type I 
cytokine receptors that use three sites of interaction, and the hβc formed an intertwined 
homodimer akin to the apo-hβc structure [75]. Interaction of GM-CSF with GMRα and hβc 
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within the structure were consistent with previous mutagenesis studies that reported the 
functional importance of GM-CSF D112 interaction with GMRα, and GMRα residues Y248 and 
R302 interaction with GM-CSF. Similarly E21 of GM-CSF hydrogen bonds with Y421 of hβc, 
consistent with the key importance of this residue in GM-CSF binding and function. 
 
Additionally, an unexpected novel higher-order dodecamer complex was observed in the crystal 
lattice (Appendix 1). The GMR dodecamer assembled via a novel interaction site, termed Site 4, 
which brought together the membrane proximal GMRα and βc domains from two adjacent 
hexameric complexes.  
 
A cell line model in the murine T cell line, CTL-EN, was established to investigate the 
functional relevance of the Site 4 interface. Both WT and mutated GMR were expressed in this 
in vitro system that importantly lacked endogenous mGMR/mIL3R. This ensured that 
interspecies receptor interactions did not confound functional activity of GMR receptor mutants. 
Mutation of residues on hβc at the dodecamer interface did not alter high affinity binding 
suggesting that a GMR hexamer is sufficient for high affinity binding. While high affinity 
binding is retained in dodecamer interface mutants a reduction in GM-CSF mediated 
proliferation was observed, along with greatly reduced tyrosine phosphorylation. This suggests 
that following a high affinity GMR hexamer forming that dodecamer formation is required for 
full GM-CSF receptor activation (Figure 4). Dodecamer assembly can provide the close 
proximity required between two JAK-2 molecules bound to hβc on adjacent hexamers, allowing 
transphosphorylation and subsequent downstream signal transduction to occur. Interestingly, we 
did not observe the formation of intermolecular covalent di-sulphide bridges that had been 
observed in cell-surface receptor studies. 
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Model of GM-CSF signal transduction. The low-affinity complex consists of GM-CSF bound to GMRa. Interaction 
with free hβc forms the high affinity hexamer complex. Dodecamer (or higher-order) complexes form by lateral 
aggregation of hexamer complexes to form the fully competent signalling complex. JAK2 associated with hβc (red 
sphere) is able to dimerize and transphosphorylate in the dodecamer complex but not in the hexamer (Appendix 1). 
 
 
Ultimately, the findings presented in this thesis revealed the mechanism of GMR assembly and 
determined it’s stoichiometry. The nature of the individual GMR components in the absence of 
ligand, the low affinity binding and high affinity GM-CSF binding complexes was shown, and 
subsequently enabled the GMR ternary complex structure to be solved. This structure revealed a 
novel mechanism of activation where GMR hexamers oligomerize into dodecameric complexes. 
Using appropriate in vitro cell line systems the dodecamer interface was shown to be required for 
activation of hβc associated JAK-2 and signal transduction. The structural determination of the 
GMR and the observed dodecameric complex formation revealed the mechanism of how GMR 
assembly enables the activation of hβc associated JAK-2. The GMR dodecamer interface may 
offer a new therapeutic target for the development of neutralising molecules for GM-CSF 
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(GM-CSF) is a pleiotropic cytokine that controls the
production and function of blood cells, is dere-
gulated in clinical conditions such as rheumatoid
arthritis and leukemia, yet offers therapeutic value
for other diseases. Its receptors are heterodimers
consisting of a ligand-specific a subunit and a bc
subunit that is shared with the interleukin (IL)-3 and
IL-5 receptors. How signaling is initiated remains an
enigma. We report here the crystal structure of the
human GM-CSF/GM-CSF receptor ternary complex
and its assembly into an unexpected dodecamer or
higher-order complex. Importantly, mutagenesis of
the GM-CSF receptor at the dodecamer interface
and functional studies reveal that dodecamer forma-
tion is required for receptor activation and signaling.
This unusual form of receptor assembly likely applies
also to IL-3 and IL-5 receptors, providing a structural
basis for understanding their mechanism of activa-
tion and for the development of therapeutics.
INTRODUCTION
A common feature of cytokine receptor activation is ligand-
induced receptor aggregation involving the homo or heterodi-
merization of two or more receptor components and their
assembly into a fully functional signaling complex. Structural
data for heterodimeric receptor families that utilize a common
binding and signaling subunit such as the IL-2 and IL-6 re-
ceptor systems have provided unique insights into their func-
tional activation (Boulanger et al., 2003; Wang et al., 2005;
Stauber et al., 2006). The GM-CSF, IL-3, and IL-5 family of
receptors remains the last major group of class I hemato-
poietic receptor systems to be structurally and functionally
elucidated.
The GM-CSF, IL-3, and IL-5 family of cytokines regulates the
survival, proliferation, differentiation, and functional activation
of hematopoietic cells (Guthridge et al., 1998) with GM-CSF
also controlling dendritic cell (Mellman and Steinman, 2001)
and T cell function (Barouch et al., 2002), thus linking innate
and acquired immunity. While on the one hand GM-CSF offers
therapeutic promise to bolster antitumor immunity (Sun et al.,
2002; Fleetwood et al., 2005) and innate immunity for the treat-
ment of Crohn’s disease (Korzenik et al., 2005), on the other
hand abnormalities in GM-CSF production or receptor function
have been implicated in multiple pathologies such as rheumatoid
arthritis (Cook et al., 2001), juvenile myelomonocytic leukemia
(Birnbaum et al., 2000), chronic myelomonocytic leukemia (Ram-
shaw et al., 2002), and alveolar proteinosis (Dirksen et al., 1998).
Furthermore, the GM-CSF receptor may also be important in the
pathogenesis of chronic myeloid leukemia and myeloprolifera-
tive diseases by propagating survival and proliferation signals
promoted by the abnormal expression of Bcr-Abl and JAK2
mutations, respectively (Wilson-Rawls et al., 1996; James et al.,
2005). The receptors for GM-CSF, IL-3, and IL-5 are expressed
at very low levels (100–1000 per cell) on the surface of hematopoi-
etic cells and comprise a cytokine-specific a subunit and the bc
subunit that is common to all three receptors (Guthridge et al.,
1998). Each a subunit binds cytokine with low affinity (KD = 0.2–
100 nM) but the presence of bc converts this to high affinity
(KD = 100 pM) causing dimerization of both subunits and receptor
activation (Stomski et al., 1996). Structure-function studies of
GM-CSF, IL-3, and IL-5 and their receptors have noted regions
of importance for ligand binding and biological activity; however
the composition, assembly, and underlying mechanisms of
receptor activation have remained elusive.
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Although GM-CSF receptor activation follows general rules that
invoke receptor dimerization and tyrosine transphosphorylation
of the cytoplasmic domains (Schlessinger, 2000), it is not clear
how this is achieved. The GM-CSF receptor does not have intrin-
sic tyrosine kinase activity but associates with the tyrosine kinase
JAK2, which is required for bc transphosphorylation and the initi-
ation of signaling and biological activity. The cytoplasmic do-
mains of both GMRa and bc are essential for receptor activation
(Sakamaki et al., 1992; Muto et al., 1995), but it appears that
mainly bc associates with JAK2 (Brizzi et al., 1994; Quelle et al.,
1994; Lilly et al., 2001). Since the crystal structure of isolated bc
revealed a dimer in which the membrane-proximal domains
were 120 Å apart (Carr et al., 2001), a distance too great to allow
transphosphorylation of bc by their associated JAK2 kinases, it
has remained an enigma how activation of the GM-CSF, IL-3,
and IL-5 family of receptors could be achieved. We show here
that the crystal structure of the GM-CSF ternary complex assem-
bles into an unexpected dodecamer arrangement. Functional
analyses show that this dodecamer or higher-order complex
brings two bc dimers into close proximity and provides for the
functional dimerization and activation of the GM-CSF receptor.
RESULTS
The Structure of the GM-CSF Receptor Complex
Reveals a Hexameric Assembly
We have determined the structure of the GM-CSF ternary com-
plex revealing a 2:2:2 hexamer consisting of two bc chains, two
GMRa chains, and two GM-CSF molecules (Figure 1). This dif-
fers from the 2:1:1 stoichiometry (2 bc: 1 GMRa: 1 GM-CSF)
Figure 1. Structure of the GM-CSF Receptor Ternary Complex
GM-CSF is highlighted in blue and GMRa in yellow. One monomer of bc is shown in magenta (chain a) and the other in green (chain b). Labels correspond to
domain names. Orthogonal views show how the complex would sit on the membrane surface. The bottom panel shows the view of the receptor when looking
toward the membrane and the top panel shows a side-on view with the molecule sitting on a membrane surface. Observed N-linked carbohydrates are shown as
sticks. Disordered peptides that connect the C termini of each chain to the membrane are shown as dashed lines. This and the following figures were prepared
with PyMOL (DeLano, 2002).
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we observed in solution (McClure et al., 2003). This is likely to be
a result of differences in the total protein concentration at which
the complex is formed as we observe a protein concentration-
dependent shift in molecular weight and hence stoichiometry
of GM-CSF receptor complex (Figure S1 and Table S2 available
online). The 2:1:1 complex probably represents a relatively sta-
ble intermediate in the assembly of higher-order 2:2:2 GM-CSF
receptor complexes. The structure adopted by GM-CSF in the
ternary complex appears very similar to the structure of the iso-
lated cytokine (Rozwarski et al., 1996). We also observe the
same intertwined bc homodimer previously seen in the structure
of the isolated bc subunit (Carr et al., 2001). In our case the dimer
is generated by a crystallographic two-fold axis that runs through
the center of the hexameric complex. A comparison of the bc
chain in the complex compared to the structure of the isolated
molecule (Carr et al., 2006) reveals that domain 4 has rotated
3! toward the crystallographic diad that runs through the center
of the hexameric complex (Figure S2). The hinge region about
which the rotation has occurred is located close to domain 1 in
the linker region connecting domains 3 and 4, although the
conformation of the linker region closely resembles that seen in
the isolated molecule. Each bc chain consists of two cytokine
receptor homology modules (CRMs), which in turn consist of
two fibronectin type III (FnIII) domains. The GMRa chain consists
of an N-terminal ‘‘knob’’ domain followed by one CRM. However,
we only observe good electron density for the C-terminal FnIII
domain of GMRa (GMRa domain 2). Although the electron
density for N-terminal FnIII domain (GMRa domain 1) is of poorer
quality, it was sufficient to recognize core b sheet enabling
a partial model to be built and refined.
GM-CSF Interactions with GMRa—Site 1
GM-CSF binds to the elbow region defined by domains 1 and 2
of GMRa, reminiscent of the binding mode seen in other class I
cytokine receptors (Wells and de Vos, 1996). There is a small
interaction surface between GM-CSF and GMRa domain 2 of
"240 Å2 per molecule with a surface complementarity of 0.66,
a value within the range of normal protein-protein interaction
surfaces (Figure 2, Site 1). Additional surface area would be pro-
vided by domain 1. The loop residues 241 to 251 and 299 to 305
of GMRa interact with residues 11 to 23 (helix A) and residues
112 to 118 (helix D) of the cytokine. This is consistent with muta-
genesis studies showing that D112 of GM-CSF interacts with
GMRa (Hercus et al., 1994b) and that GMRa residues Y248
and R302 are important for GM-CSF binding to GMRa (Rajotte
et al., 1997; Haman et al., 1999).
GM-CSF Interactions with bc—Site 2
Recruitment of bc to the GM-CSF:GMRa binary complex con-
verts the GM-CSF binding to high affinity and leads to receptor
activation (Hayashida et al., 1990; Bagley et al., 1997). Surpris-
ingly, our structure reveals a composite GM-CSF binding site
at the elbow region between domain 1 (A-B and E-F loops) of
one bc chain and domain 4 (B-C and F-G loops) of the second
bc chain (Figure 2, Site 2), an arrangement not seen previously
in cytokine-cytokine receptor complex structures (see Discus-
sion). The involvement of these loops in cytokine binding is
consistent with previous mutagenesis data (Lock et al., 1994;
Woodcock et al., 1994, 1996; Murphy et al., 2003). The interac-
tion at Site 2 buries "570 Å2 of surface area per molecule with
a surface complementarity value of 0.62. Helix A of GM-CSF
nestles into a surface crevice of bc formed by the E-F loop (res-
idues 100 to 107) of bc domain 1 and the B-C (residues 360 to
369) and F-G (residues 417 to 423) loops of domain 4 (Figure 2).
All the loops of bc that interact with cytokine adopt conforma-
tions very similar to that seen in isolated bc. In bc domain 1,
Y39 of the A-B loop forms pi-pi interactions with Y421 in the
F-G loop of domain 4. Residues V104, V105, and T106 of the
E-F loop of domain 1 nestle into a hydrophobic pocket formed
by helices A and C of GM-CSF. The side chain of the adjacent
F103 residue is sandwiched between E-F and A-B loops of
domain 1 stabilizing the conformation of this region in the Site
2 interface. D107 potentially forms a salt bridge interaction
with K72 of GM-CSF. Y365 and H367 of the B-C loop of domain
4 are positioned on either side of E21 of GM-CSF. In the F-G loop
of bc domain 4, Y421 hydrogen bonds with E21 of GM-CSF (Fig-
ure 2, Site 2). These observations are consistent with mutagen-
esis studies showing that the principal cytokine interaction with
bc occurs through a conserved glutamate in helix A of GM-
CSF (E21) (Lopez et al., 1992; Hercus et al., 1994a), IL-3 (E22)
(Barry et al., 1994), or IL-5 (E13) (Tavernier et al., 1995) with
E21 of GM-CSF making direct contact with bc (McClure et al.,
2003) and with alanine substitution of bc at Y39, F103, Y365,
H367, I368, or Y421 abolishing GM-CSF binding (Lock et al.,
1994; Woodcock et al., 1994, 1996; Murphy et al., 2003). Phenyl-
alanine substitution of Y421 ablates high-affinity binding of
GM-CSF and IL-3 (Figure S3), highlighting the importance of
the phenolic hydroxyl group in ligand binding.
Interactions between GMRa and bc—Site 3
Domain 2 of GMRa forms an extensive interaction with domain 4
of bc resulting in "680 Å2 of buried surface area per molecule
with a surface complementary value of 0.52. The interface,
involving residues 231, 232, 259, 266–270, and 280–286 of
GMRa and residues 350, 353, 366–369, 389–400, and 418 of
bc, is predominantly hydrophobic with a rim of charged residues
(Figure 2, Site 3). We previously reported two surface hydropho-
bic patches, denoted H1 and H2, in our crystal structure of bc
domain 4 and speculated that they might be involved in interac-
tion with other parts of bc and GMRa, respectively (Rossjohn
et al., 2000). The structure reported here shows that residues
in H1 contact the A-B loop of bc domain 1 whereas residues of
H2, located at the edge of the beta strands D and E of bc domain
4, are involved in the formation of the interface with GMRa. The
Site 3 interface provides additional interacting surfaces between
GMRa and bc, thereby enhancing the overall binding affinity of
GM-CSF for its receptor.
The GM-CSF Receptor Complex Assembles
into a Dodecamer
The crystal lattice generates an unexpected dodecamer
complex, an assembly not previously observed in structures of
cytokine receptor complexes, consisting of two hexameric com-
plexes related by a crystallographic two-fold axis (Figure 3A).
Intriguingly, the dodecamer assembles in a head-to-head orien-
tation bringing the C-terminal tails of neighboring bc domain 40s
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Figure 2. Peeled-away Interaction Surfaces between Components of the GM-CSF Receptor and Comparison of Related Class I Heteromeric
Cytokine Receptor Systems
(A) The surfaces are colored by residue property: blue is basic and red is acidic. Residues involved in the interfaces are labeled. The top panel shows how bc
interacts with GM-CSF (Site 2), the right middle panel shows the interaction between cytokine and GMRa (Site 1), and the bottom panel shows the interaction
surfaces between bc and GMRa (Site 3). The composite nature of the GM-CSF binding Site 2 surface of bc is highlighted by a cartoon of the bc:GM-CSF inter-
action shown to the left of the Site 2 surfaces. A detailed view of GM-CSF E21 and interacting residues of bc is shown to the right of the Site 2 surfaces.
(B) Ribbon representation of the GM-CSF receptor complex. The panel shows a blown-up view of part of the ternary complex in the same orientation presented in
the top panel of Figure 1. Also shown is the likely location of the GMRa knob domain.
(C) The IL-6 receptor complex (Boulanger et al., 2003). For clarity only the unique components of the hexameric complex are shown with the exception of the
second gp130 molecule where the N-terminal domain interacts with the cytokine molecule.
(D) The IL-2 receptor complex (Wang et al., 2005). Related receptor components in each of the three systems shown in (A)–(D) are highlighted by the same color.
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and GMRa domain 20s into close proximity, suggesting a physio-
logical relevance to the assembly (Figure 3B). The interaction
surface, that we term Site 4, is large with "770 Å2 being buried
per hexamer with major contributions between bc domain 4 of
each hexamer ("520 Å2 per molecule) and the rest contributed
from an interaction between the GMRa of one hexamer and bc
domain 4 of the other. The mostly polar interface involves resi-
dues 260 and 261 of GMRa and residues 346–354, 357, 359,
362, and 430–435 of bc with a high surface complementarity
value of 0.63. The bc domain 4 dodecamer interface includes
the mutated N-linked glycosylation site, N346Q. Complex sugar
chains are readily accommodated at the interface with only the
first couple of sugars emanating from N346 located at the inter-
face while the rest protrude out into solution (Figure S4).
Dodecamer Complex Provides a Mechanism
of Activation for JAK2 Associated with bc
The JAK/STAT pathway is the principal signal transduction path-
way used by cytokine receptors. JAK activation occurs by
ligand-induced dimerization and transphosphorylation of recep-
tor-bound JAK molecules that subsequently phosphorylate the
receptor itself, STATs, and other signaling molecules recruited
to the receptors (Rawlings et al., 2004). JAK2 activation is
a feature of GM-CSF receptor activation (Quelle et al., 1994;
Watanabe et al., 1996) and plays a critical and nonredundant
role in GM-CSF signaling (Watanabe et al., 1996; Parganas
et al., 1998). Although JAK2 has been seen to specifically asso-
ciate with bc (Brizzi et al., 1994; Soldi et al., 1997; Lilly et al., 2001)
its association with GMRa is much less clear (Quelle et al., 1994).
Figure 3. The Dodecamer Complex
(A) View of the dodecamer when looking toward the membrane surface. Coloring as in Figure 1 with second hexamer in lighter shade. (A model of the complete
domain 1 of GMRa [labeled aD1] was superimposed onto the partial model derived from the crystallographic data.) Also shown is the likely location of the GMRa
knob domain. In the lower panel a simplified version of the upper panel highlights the arrangement of chains and domains. The chains of bc are labeled a to d and
domains denoted with a ‘‘D.’’
(B) Side-on (with respect to the membrane) view of the complex, highlighting peeled-away interaction surfaces between GMRa domain 2 and bc domain 4 of each
hexamer (Site 4).
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This is an important point as the selective association of JAK2
with bc would support the notion that juxtaposition of neighbor-
ing bc domain 40s as seen in the dodecamer complex (but not the
hexameric complex) (Figure 3B) would be required for JAK2
transphosphorylation and subsequent receptor activation.
First, we coimmunoprecipitated JAK2 with each receptor sub-
unit using CTL-EN cell lines stably expressing GMRa alone
(Figure 4A) or coexpressing GMRa and bc (Figure 4B) and ob-
served that only bc coimmunoprecipitated JAK2. Second, we
used the human erythroleukemic TF-1 cell line that endoge-
nously expresses both receptor subunits and proliferates in re-
sponse to GM-CSF to perform reverse experiments where
JAK2 immunoprecipitation brought down bc but not GMRa
(Figure 4C). Furthermore, following stimulation with GM-CSF,
immunoprecipitation of bc brought down GMRa as well as phos-
phorylated JAK2, indicating that the JAK2 preassociated with
bc only becomes phosphorylated after cytokine stimulation
(Figure 4C). Finally, we studied human monocytes, a key effector
cell type of the immune system and also observed JAK2 associ-
ation with bc but not with GMRa (Figure 4D). Association of JAK2
with bc was observed in the absence of GM-CSF stimulation,
and JAK2 binding and phosphorylation were upregulated follow-
ing GM-CSF treatment. Similar results were observed with cells
from a patient with acute myeloid leukemia and from purified
human neutrophils (Figure S5). The exclusive association of
JAK2 with bc suggests that GMRa:bc heterodimerization is not
sufficient for receptor activation and that JAK2 activation by
GM-CSF requires functional bc dimerization as provided by the
dodecamer.
Interfering with Site 4 Profoundly Affects
Receptor Signaling
The dodecamer structure makes two important predictions that
have physiological consequences for how GM-CSF engages its
receptor and activates intracellular signaling. First, disruption of
the Site 4 interaction is predicted to disturb dodecamer assembly
and impede biological responses. Second, such disruption of
Site 4 interactions should have little impact on hexamer assembly
and so high-affinity binding should remain intact. We tested
these possibilities by first mutating specific bc residues in Site
4 that were identified in the structure to make contact between
hexamers. CTL-EN/IL3Ra/GMRa cells were stably transfected
with plasmids encoding wild-type or mutant bc (Figure 5A) and
then sorted for bc expression. The resulting stable pools
were assayed for GM-CSF- and IL-3-mediated proliferation
(Figure 5B). All cell lines showed an equivalent response to mu-
rine IL-2 (data not shown) that was used to normalize the prolifer-
ation responses. Mutation of residues 430–436 (M1) reduced
Figure 4. Association of JAK2 with bc but Not GMRa
(A) JAK2 does not associate with GMRa in the CTL-EN/IL3Ra/GMRa cell line. CTL-EN/IL3Ra/GMRa were lysed and immunoprecipitated with antibodies specific
for GMRa, for JAK2, or for an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2 or GMRa.
(B) JAK2 associates with bc but not GMRa in the CTL-EN/IL3Ra/GMRa/bc cell line. CTL-EN/IL3Ra/GMRa/bc were lysed and immunoprecipitated with antibodies
specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecipitates were analyzed by western blotting using an antibody specific for JAK2.
(C) Phosphorylated JAK2 associates with bc but not GMRa in the hematopoietic cell line TF-1. TF-1 cells starved of GM-CSF for 18 hr were treated with 0 or
150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa, bc, JAK2, or an irrelevant control antigen. Immunoprecip-
itates were analyzed by western blotting using antibodies specific for GMR, bc, or phosphorylated JAK2.
(D) JAK2 associates with bc but not GMRa in normal human monocytes and is phosphorylated only in the presence of GM-CSF. Cells were treated with 0 or
150 ng/ml GM-CSF for 5 min then lysed and immunoprecipitated with antibodies specific for GMRa or bc. Immunoprecipitates were analyzed by western blotting
using antibodies specific for GMRa, bc, total JAK2, and phosphorylated JAK2 (pJAK2).
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proliferation in response to GM-CSF (50-fold) and IL-3 (450-fold).
Restoration of the buried tryptophan residue at 434 (M2)
increased GM-CSF and IL-3 function, suggesting that the
W434A substitution in M1 caused some degree of structural
perturbation contributing to the loss of function. Mutation of res-
idues 347–352, alone (M3) or combined with mutation of residues
354 and 362 (M5), had no effect on GM-CSF-mediated prolifera-
tion but caused a modest reduction in IL-3-mediated proliferation
(10-fold). Combination of M2 and M3 (M4) virtually abolished
proliferation in response to GM-CSF and IL-3, but additional mu-
tation of residues 354 and 362 (M6) partially restored GM-CSF
Figure 5. Mutation of bc at the Dodecamer
Interface Reduces GM-CSF- and IL-3-Medi-
ated Cell Proliferation and Signaling
(A) Dodecamer interface of one hexamer showing
Site 4 residues colored in orange, Site 3 residues
colored in gray, and the remaining residues col-
ored yellow for GMRa and magenta (domain 4a)
or green (domain 1d) for bc. The alanine substitu-
tions of Site 4 residues are listed under the figure
and some of the mutated residues are labeled.
(B) GM-CSF- and IL-3-mediated cell proliferation
is reduced by mutation of bc Site 4 contact resi-
dues. Proliferation of cells expressing wild-type
bc (filled circle), bcM1 (filled diamond), bcM2
(open diamond), bcM3 (open square), bcM4 (filled
square), bcM5 (open triangle), or bcM6 (filled trian-
gle) in response to GM-CSF (left panel) or IL-3
(right panel) was normalized against the prolifera-
tion of each cell line in response to murine IL-2.
Each point is determined in triplicate and error
bars represent one standard deviation. Represen-
tative data are shown from multiple experiments.
(C) GM-CSF- and IL-3-mediated cell signaling is
reduced by mutation of bc Site 4 contact residues.
CTL-EN/IL3Ra/GMRa cells expressing wild-type
bc or the bc M1, M4, or M6 mutants were stimu-
lated for 5 min with GM-CSF (upper panel) and
IL-3 (lower panel) at 0, 0.15, 1.5, 15, or 150 ng/ml.
Cells were lysed, immunoprecipitated with anti-
body specific for bc, then analyzed by western
blotting using an anti-phosphotyrosine antibody
(phos-Tyr) or an antibody specific for bc (Total
bc). Cell lysates were analyzed by western blotting
using antibodies specific for phosphorylated
JAK2 (phos-JAK2) or phosphorylated STAT5
(phos-STAT5).
and IL-3 function (Figure 5B). Importantly,
the strongest effect was observed with
M4 that encompassed both targeted
regions of the large area that forms Site
4 (Figure 5A). The IL-3 response is consis-
tently more sensitive to mutation of Site 4
residues in bc than the GM-CSF re-
sponse, but the overall hierarchy in mu-
tant function is conserved between the
two cytokines. CTL-EN cell lines express-
ing the bc mutants support high-affinity
binding sites for GM-CSF and IL-3 (Table
S3), indicating that functional bc Sites 2
and 3 are retained by these mutants and that they are expressed
on the cell surface. The reduced proliferation observed for cells
expressing bcM1, bcM4, and bcM6 was accompanied by
a greatly reduced ability of GM-CSF and IL-3 to stimulate tyrosine
phosphorylation of bc, JAK2, and STAT5 (Figure 5C) and a sub-
stantial loss of colony-forming capacity (bcM1) in bone marrow
cells stimulated with GM-CSF (Figure S6). Functional disruption
of Site 4 required multiple mutations, probably reflecting the large
surface area of this protein-protein interface. Together, these
data indicate that Site 4 residues predicted from the structure
to be essential for dodecamer formation affect GM-CSF receptor
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activation. Furthermore, our results show that high-affinity bind-
ing (and hexamer assembly) is not sufficient for biochemical or
functional receptor outputs and suggest that formation of
a higher-order dodecamer complex is an obligate step for full re-
ceptor activation.
To determine the physiological significance of the dodecamer
complex we generated antibodies specific to a portion of bc
(residues 427–440) within Site 4 and assessed their ability to in-
terfere with normal GM-CSF functions. Affinity-purified anti-
bodies against the bc Site 4 peptide recognized the immunizing
peptide as well as the soluble extracellular domains of bc
(Figure S7). We first examined GM-CSF upregulation of CD11b
in neutrophils, a key component of the CD11b/CD18 (Mac-1) in-
tegrin responsible for integrin activation, neutrophil adhesion,
leukocyte extravasation, and phagocytosis (Fagerholm et al.,
2006). Significantly, anti-bc Site 4 antibodies inhibited GM-
CSF-mediated upregulation of CD11b expression in human
neutrophils (Figure 6A). Furthermore, anti-bc Site 4 antibodies
inhibited GM-CSF-mediated colony formation from bone mar-
row cells of a patient with chronic myelomonocytic leukemia
(CMML), a condition where myeloid cells display a hypersensitive
response to GM-CSF (Figure 6B). These results indicate that
Site 4 is involved in normal as well as in immunopathological
functions mediated by GM-CSF.
DISCUSSION
We present here the structure of a ligand:receptor complex in the
GM-CSF/IL-3/IL-5 family of receptors and provide structural and
functional evidence for an unexpected form of cytokine receptor
assembly, namely a dodecamer, that can explain for the first time
how these receptors are activated. The structure of the GM-CSF
receptor complex reveals a hexamer with a stoichiometry of 2
GM-CSF:2 GMRa:2 bc, in an arrangement analogous to other
heteromeric cytokine receptors and using three sites of interac-
tion (Figure 2). Site 1 is formed largely by helix D of GM-CSF
interacting with domains 1 and 2 of GMRa. Site 2 is largely pro-
vided by helix A of GM-CSF interacting with a composite bc sur-
face comprising the A-B and E-F loops of domain 1 from one bc
chain and the B-C and F-G loops of domain 4 of the second bc
chain. This elbow region resembles the ligand-binding interface
conserved in the simpler two-domain hematopoietin receptors,
despite domains 1 and 4 being noncontiguous. The composite
nature of the interface formed between GM-CSF and the bc di-
mer is highly unusual. In other ternary cytokine-cytokine receptor
complexes different regions of the cytokine interact with just one
receptor chain (Figure 2). More generally, we haven’t been able
to identify known examples of nonobligate heterotrimers that
involve an obligate dimer in which different surfaces of each
component interact with each other. The key to the Site 2 inter-
action is a hydrogen bond formed between E21 of GM-CSF and
Y421 in bc that is consistent with mutagenesis studies that
highlight the importance of these residues for GM-CSF binding
and function (Hercus et al., 1994a; Woodcock et al., 1996).
Mutagenesis studies suggest that structurally similar interac-
tions are likely to exist between Y421 of bc and E22 of IL-3 and
E13 of IL-5 (Barry et al., 1994; Tavernier et al., 1995: Woodcock
et al., 1996). Site 3 is formed between domain 2 of GMRa and
domain 4 of bc and serves to stabilize the cytokine-mediated
heterodimerization.
We observed a higher-order dodecamer complex composed
of two hexamers that interact through a Site 4 surface and bring
the membrane-proximal domains of bc and GMRa into close
proximity (Figure 3). The functional significance of the dodeca-
mer complex is supported first by the observation that JAK2,
which is essential for GM-CSF signaling, is associated with bc
and not GMRa (Figure 4). This could be seen in transfected cells,
in hemopoietic cell lines that respond to GM-CSF using endoge-
nous GM-CSF receptors, and, most importantly, in primary
human monocytes and neutrophils, essential leukocytes that
participate in immunity. Thus JAK2-associated bc as a homo-
dimer in the unliganded receptor (Muto et al., 1996; Stomski
et al., 1996; Carr et al., 2001) or as a heterodimer with GMRa in
the hexamer complex (Figure 1) would be too far apart ("120 Å)
to transphosphorylate the receptor. The dodecamer structure (Fig-
ure 3) on the other hand, brings JAK2-associated bc close enough
("10 Å) to allow functional dimerization and transphosphorylation
of the receptor and initiation of signal transduction. Second,
Figure 6. Antibodies to bc Site 4 Inhibit
GM-CSF-Mediated Functions in Normal
Cells and in Leukemic Cells
(A) Affinity-purified antibodies to bc Site 4 residues
inhibit upregulation of CD11b in human neutro-
phils treated with GM-CSF. Histograms shows
relative fluorescence for CD11b staining on neu-
trophils either unstimulated (black) or GM-CSF-
stimulated in the presence of nil (red) or 4 mg/ml
(blue) of affinity-purified bc Site 4 antibody. Prein-
cubation with 1 mg/ml of an irrelevant control
antibody (dashed line) had no effect on CD11b
expression by unstimulated (black) or GM-CSF-
stimulated (red) neutrophils.
(B) Affinity-purified antibodies to bc Site 4 residues
inhibit GM-CSF-stimulated colony formation by
bone marrow cells from a patient with chronic
myelomonocytic leukemia (CMML). Bone marrow
mononuclear cells (1 3 105) from a patient with CMML were plated in 2 ng/ml GM-CSF plus medium (Nil), or plus 10 mg/ml bc Site 4 antibody (Site 4 Ab), or plus
0.5 mg/ml of a control bc antibody (Control Ab). Data show average of triplicate plates and error bars represent the standard error of the mean (SEM). The two-
tailed p value was generated using an unpaired t test.
Cell 134, 496–507, August 8, 2008 ª2008 Elsevier Inc. 503
97
Appendix 1: Publications arising
several mutants across the Site 4 interface decreased biological
activity and signaling with M4 showing an almost complete elim-
ination of function while not affecting high-affinity binding (Fig-
ure 5). Third, antibodies directed against part of bc Site 4 signif-
icantly reduced GM-CSF-mediated upregulation of the integrin
CD11b in human neutrophils and stimulation of the growth and
differentiation of leukemic cells (Figure 6).
Assembly of the dodecamer complex also promotes the inter-
action of two GMRa chains. While bc is the principal signaling
component of the GM-CSF/IL-3/IL-5 receptor family, it is clear
that the cytoplasmic domains of alpha chains are essential for
signal transduction (Muto et al., 1995; Lia et al., 1996; Lilly
et al., 2001). The observation that GMRa lacking a cytoplasmic
domain acts in a dominant-negative fashion (Lia et al., 1996)
indicates that the signaling complex must contain at least two
GMRa chains. In the dodecamer complex the GMRa cytoplas-
mic tails are "30 Å from the bc cytoplasmic tails of each neigh-
boring hexamer (Figure 3A), thus also providing a structural
explanation for how the cytoplasmic domain of GMRa can par-
ticipate in signaling.
In analyzing the role of Site 4 in receptor activation we focused
largely on two regions of bc, residues 344–365 and 427–438,
because their side chains are located in close proximity on the
surface of bc (Figure 5A). Interestingly, alanine substitution mu-
tants targeting only one of these regions at a time had little im-
pact on GM-CSF function (Figure 5B). The mutations with the
greatest effect on GM-CSF function, M4 and M6, encompassed
both regions of Site 4, suggesting that many residues in Site 4
contribute to the function of this interacting surface.
While we have not examined the effect of bc Site 4 mutations
on IL-5 function, the IL-5 dimer can be docked into our dodeca-
mer structure (Figure S8), suggesting that IL-5 is capable of
assembling a dodecamer complex. This particular assembly may
also allow the simultaneous incorporation of different cytokines
bound to the cognate alpha chain, potentially explaining how
stimulation of cells with IL-3 or IL-5 can result in phosphorylation
of the GM-CSF receptor (Woodcock et al., 1997). The structural
and functional data shown here support a model of GM-CSF/IL-
3/IL-5 receptor activation where the hexamer complex provides
for high-affinity cytokine binding but the dodecamer complex is
required for receptor activation and signal transduction (Fig-
ure 7). Interestingly, the different mutations of bc at the Site 4
interface greatly reduced signaling and function not only from
GM-CSF but also from IL-3 (Figure 5), suggesting that dodeca-
mer formation may be a conserved mechanism utilized by the
whole GM-CSF/IL-3/IL-5 receptor family. As such it may offer
new avenues to interfere with receptor activation and facilitate
the development of new molecules, which by simultaneously
blocking GM-CSF, IL-3, and IL-5 function may be of clinical
use in diseases where all these cytokines play a pathogenic role.
EXPERIMENTAL PROCEDURES
Expression and Purification of Receptor Components
Soluble human GM-CSF was produced in Escherichia coli (Hercus et al.,
1994a). The soluble extracellular domains of GMRa or bc were expressed in
Sf21 insect cells and purified by affinity chromatography (McClure et al., 2003).
Structure Determination of the Complex
Ternary complex consisting of GM-CSF, sGMRa, and sbc was concentrated
to 5 mg/ml in 10 mM HEPES (pH 7.0). The best crystals were grown from a so-
lution containing 100 mM HEPES buffer (pH 7.0), 6% (v/v) PEG3350, 0.2 M pro-
line at 20!C using the hanging drop technique. The crystals belonged to the
space group P6322 with unit cell dimensions a = b = 166.4 Å and c = 212.2 Å.
Diffraction data were collected on the BioCARS beamline 14-BM-C at the
Advanced Photon Source (Chicago, IL, USA) (Table S1). The structure was de-
termined by molecular replacement using the known structure of isolated bc
(Carr et al., 2001) and refined at 3.3 Å resolution (Supplemental Data).
Mutagenesis and Generation of Cell Lines
Mutations of bc were generated by site-directed mutagenesis using the Al-
tered site system (Promega). Wild-type and Site 4 mutant bc cDNAs were
subcloned into the expression vector pRcCMVpuro (Woodcock et al., 1997).
Murine CTL-EN cells (Jenkins et al., 1999) stably expressing human IL3Ra
and GMRa chains (CTL-EN/IL3Ra/GMRa) were grown routinely in RPMI
1640 medium supplemented with 10% v/v FCS, 2 mM glutamine, 50 mM mer-
captoethanol, and 100 U/ml mIL-2. TF-1 cells were maintained as previously
described (Hercus et al., 1994a).
CTL-EN/IL3Ra/GMRa cells (5 3 106) were electroporated with 20 mg of
pRcCMVpuro DNA encoding wild-type or Site 4 mutant bc at 960 mF with
270 V and selected in 2–5 mg/ml puromycin 48 hr after transfection. Following
selection, pools of cells were sorted for bc expression by flow cytometry using
indirect immunofluorescence staining as previously described (Woodcock
et al., 1996) on a FACSAria (Becton Dickinson). Cells were starved of growth
Figure 7. Model of Signal Transduction
The low-affinity complex consists of GM-CSF bound to GMRa. Interaction with free bc forms the high-affinity hexamer complex. Dodecamer (or higher-order)
complexes form by lateral aggregation of hexamer complexes to form a fully competent signaling complex. JAK2 associated with bc (shown as red spheres) is
able to dimerize and transphosphorylate in the dodecamer complex but not in the hexamer complex.
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factor overnight prior to use, and for biochemical studies, starve medium
included 0.5% v/v FCS.
Receptor Binding Assays
Radio-iodinated GM-CSF and IL-3 binding assays to CTL-EN/IL3Ra/GMRa
cell lines stably expressing wild-type bc or bc Site 4 mutants were as previously
described (Woodcock et al., 1994). COS cells were cotransfected with plas-
mids encoding GMRa and IL3Ra together with wild-type or bc Site 2 mutants
by electroporation and saturation binding assays with radio-iodinated cytokine
carried out in 24 well plates as previously described (Woodcock et al., 1996).
Dissociation constants were determined using Prism (Graphpad Software).
Cell Proliferation Assays
Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type bc or bc
Site 4 mutants were incubated (1 3 104 cells per well) with growth factors
over a range of concentrations for 40 hr. Cells were pulsed with 0.25 mCi/
well of [6-3H]-thymidine (GE-Healthcare) for 4 hr, harvested onto glass fiber fil-
ters, and counted in liquid scintillation fluid on a Top Count NXT (Perkin Elmer).
Immunoprecipitations and Immunoblotting
Human mononuclear cells from normal donors were isolated by Ficoll-Hypa-
que density-gradient centrifugation and resuspended in PBS containing
0.1% human albumin (CSL). CTL-EN/IL3Ra/GMRa and CTL-EN/IL3Ra/
GMRa/bc cells were lysed and immunoprecipitated using 4H1 anti-GMRa
monoclonal antibody (Stomski et al., 1998), 1C1 anti-bc monoclonal antibody
(Stomski et al., 1996), anti-JAK2 monoclonal antibody (Cell Signaling), or
12CA5 anti-influenza hemagglutinin monoclonal antibody. Samples from 2 3
107 cells were subjected to western blotting with antibodies specific for
GMRa or total JAK2. Human monocytes, starved TF-1 cells, or starved CTL-
EN/IL3Ra/GMRa/bc cells were stimulated with 0 or 150 ng/ml GM-CSF for
5 min, lysed, and immunoprecipitated using 4H1, 1C1, anti-JAK2, or 12CA5
monoclonal antibodies. Samples were subjected to western blotting with
antibodies specific for GMRa, bc, total JAK2, or tyrosine-phosphorylated
JAK2. Starved CTL-EN/IL3Ra/GMRa cell lines stably expressing wild-type
bc or bc Site 4 mutants were stimulated with 0, 0.15, 1.5, 15, or 150 ng/ml
GM-CSF or IL-3 for 5 min, lysed, and immunoprecipitated using the 1C1
anti-bc monoclonal antibody. Samples of bc immunoprecipitates were sub-
jected to western blotting with 1C1 anti-bc or 4G10 anti-phosphotyrosine
monoclonal antibodies (Upsate Cell Signaling Solutions). Samples of cell ly-
sates were subjected to western blotting with antibodies specific for phos-
phorylated JAK2 or phosphorylated STAT5.
Generating and Functional Testing of Polyclonal Antibodies
against bc Site 4
Antibodies directed to bc Site 4 were generated by immunizing New Zealand
white rabbits with a peptide (EWSEARSWDTESVL) spanning residues 427–
440 of bc (Mimotopes) and conjugated to keyhole limpet antigen. Peptide-spe-
cific polyclonal antibody was affinity purified using the EWSEARSWDTESVL
peptide coupled to Sepharose. CD11b expression on neutrophils was moni-
tored as previously described (Guthridge et al., 2006) but included a 30 min
preincubation with antibody at 4!C followed by a 30 min incubation with
15 ng/ml GM-CSF at 37!C. The 12CA5 monoclonal antibody was used as
a negative control. Bone marrow colony assays where performed as previ-
ously described (Ramshaw et al., 2002) with the 1C1 monoclonal antibody
used as a negative control.
ACCESSION NUMBERS
Atomic coordinates and structure factors have been deposited in the Protein
Data Bank with accession code 3CXE.
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The Structure of the GM-CSF Receptor 
Complex Reveals a Distinct Mode of 
Cytokine Receptor Activation 
Guido Hansen, Timothy R. Hercus, Barbara J. McClure, Frank C. Stomski, Mara Dottore, 
Jason Powell, Hayley Ramshaw, Joanna M. Woodcock, Yibin Xu, Mark Guthridge, William 
J. McKinstry, Angel F. Lopez, and Michael W. Parker 
 
Supplemental Experimental Procedures 
Expression and Purification of Receptor Components 
Soluble human GM-CSF was produced in Escherichia coli and purified by anion exchange 
chromatography and reversed phase HPLC (Hercus et al., 1994). DNA fragments encoding 
the soluble extracellular domains of GMRα (sGMRα) or βc (sβc) were cloned into the 
pIBV5-His expression vector (Invitrogen) and transfected into Sf21 insect cells using 
Cellfectin (Invitrogen). Permanently transfected Sf21 cell lines were selected by incubation 
with Blasticidin at 50 µg/ml (Invitrogen) and maintained in serum-free ExCell 420 medium 
(JRH Biosciences) at 27°C. Soluble receptors were purified from conditioned medium by 
affinity chromatography (McClure et al., 2003). 
Human βc contains three N-linked glycosylation sites and elimination of the third site 
at N346 by glutamine substitution has previously been demonstrated to improve the 
diffraction properties of crystallized sβc (Gustin et al., 2001). We expressed and purified sβc 
N346Q from Sf21 cells and observed a modest reduction in molecular weight compared to the 
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wild-type sβc but no difference in its ability to form a ternary complex with sGMRα and GM-
CSF (results not shown). 
 
Crystallization of the Complex  
Ternary complex consisting of GM-CSF, sGMRα and sβc N346Q was isolated by gel 
filtration chromatography using a Superdex 200 column (26mm x 600mm, GE Healthcare) 
operated at 2 ml/min at 4°C with 150 mM NaCl, 50 mM sodium phosphate pH 7.0, as running 
buffer. For crystallization the complex was concentrated to 5 mg/ml in 10 mM HEPES pH 
7.0. A number of crystal forms of the wild-type ternary complex were grown but none 
diffracted beyond 8 Å resolution using synchrotron radiation. We subsequently grew a 
number of crystal forms of the ternary complex using the sβc N346Q construct. However, 
only one out every 100 crystals diffracted beyond 4 Å resolution. Complete details of the 
crystallization trials will be published elsewhere. Briefly, using the hanging drop technique, 
crystals appeared after 1 week and grew to full size (up to 0.8 x 0.8 x 0.4 mm) within 2 weeks 
The best crystal was obtained mixing 1 µl of ternary GM-CSF receptor complex at a 
concentration of ~5 mg/ml with 1 µl reservoir solution containing 100 mM HEPES buffer pH 
7.0, 6% (v/v) PEG3350, 0.2 M proline at 20ºC. The crystal belonged to the space group P6322 
with unit cell dimensions a = b = 166.4 Å and c = 212.2 Å.  
 
Structure Determination of the Complex  
Diffraction data were collected at 100 K and recorded on an ADSC Quantum-315 CCD 
detector on BioCARS beam line 14-BM-C at the Advanced Photon Source (Chicago, USA). 
The wavelength was set to 0.9 Å. Data were processed using MOSFLM and SCALA (CCP4, 
1994) (Table S1). The best crystal diffracted to a resolution of 3.3 Å. The structure was 
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determined by molecular replacement using PHASER (Storoni et al., 2004). The search 
models were GM-CSF βc chain (Carr et al., 2001; PDB id: 1GH7) and GM-CSF (Rozwarski 
et al., 1996; PDB id: 2GMF). Molecular replacement solutions for GM-CSF βc and GM-CSF 
gave Z-scores of 51.6 and 6.3 to a resolution of 3.3 Å, respectively. Difference electron 
density maps calculated with phases obtained after a few rounds of refinement clearly showed 
unexplained density close to domain 4 of the βc chain. A homology model of domain 2 of the 
alpha chain (Chris Bagley, unpublished results) was built into this density. (The choice of 
which alpha chain domain to build into the density was straight forward as it was interacting 
with domain 4 of βc, the membrane proximal domain of that chain, and thus the correct 
choice had to be the membrane proximal alpha chain domain 2). The model was completed by 
iterative cycles of manual rebuilding using COOT (CCP4, 1994) and refinement with 
REFMAC (Murshudov et al, 1997). In the final refinement steps the βc model was replaced 
by a better quality structure that just became available (Carr et al., 2006; PDB id: 2GYS). 
During the final refinement step each subunit was treated as a rigid body for the purposes of 
TLS (translation, libration and screw rotation tensors) refinement to account for overall 
differences in displacements between the molecules and anisotropy in the data (Winn et al., 
2001; Painter and Merritt, 2006). Despite the low resolution of our data, the availability of 
refined structures of two of the components (βc dimer at 2.7 Å resolution (Carr et al., 2006) 
and GM-CSF at 2.4 Å resolution (Rozwarski et al., 1996), combined with rigidity of the 
structural modules (< 1.75 Å rmsds from their unliganded structures), suggests we have a 
more accurate model than the resolution would indicate. For example, electron density 
corresponding to the F-G loop in domain 4 of βc, which includes the essential residue Y421, 
indicated a different conformation of this loop from that described in the original structure of 
βc (Carr et al., 2001), although the initial maps were calculated using this model. Instead our 
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interpretation agrees with that in the more recently refined higher resolution structure (Carr et 
al., 2006).  
The final model includes residues 25-436 of βc. The sequence of the published 
structure of βc, a variant of the one used in this work, has a six residue insertion in the C-D 
loop of domain 3. Density for parts of this loop were not observed in the published structure 
(Carr et al., 2006) but is well defined in the complex. Additionally, several loops including 
residues 157 to 161 (B-C loop of domain 1 in both chains), residues 349 to 351 (A-B loop in 
domain 4, chain A) and residues 361 to 368 (B-C loop in domain 4, chain A) were missing in 
the published structure but are well defined in our model. As observed in the apo structure of 
βc, two carbohydrate chains are covalently linked to N58 (built as NAG-NAG-MAN) and 
N191 (built as NAG). 
The model of GM-CSF starts at residue 14 and ends at residue 118. Although electron 
density for GMRα is generally weaker in comparison to the rest of the structure, large parts of 
domain 2 could be traced (residues 218 - 316) including a portion of a carbohydrate chain 
covalently linked to N229 (modeled as NAG). In general the main chain of GMRα in this 
region is well defined by electron density. Density modification, sharpening of structure 
factors and calculation of composite omit maps did not lead to any significant improvement of 
electron density maps. Although the electron density for N-terminal FnIII domain (GMRα 
domain 1) is of poorer quality, it was sufficient to build a partial polyalanine model including 
a two-stranded beta-sheet. A homology model of the complete GMRα domain 1 could be 
superimposed onto the partial structure. SDS-PAGE gels of washed crystals confirm that all 3 
domains of GMRα are present indicating the N-terminal knob domain is disordered in the 
crystals. 
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The stereochemical quality of the final model correlates well with structures at similar 
resolutions with 96.8% residues in the allowed regions of the Ramachandran plot and only 18 
residues in the disallowed regions. Other stereochemical parameters are all better than or 
within the allowed ranges defined by PROCHECK (Laskowski et al., 2003). 
 
Immunoprecipitations and Immunoblotting 
Human monocytes, neutrophils, mononuclear cells from an acute myeloid leukaemia patient, 
starved TF-1 cells, or starved CTL-EN/IL3Rα/GMRα/βc cells were stimulated with 0 or 10 
ng/ml GM-CSF for 5 min and lyzed in NP40 lysis buffer (10 mM Tris-HCl (pH 7.4), 137 mM 
NaCl, 10% v/v glycerol, 1% v/v Nonidet P-40) containing 2 mM phenylmethylsulfonyl 
fluoride, 4 mM sodium vanadate, 10 mM sodium fluoride, 10 mM β-glycerol phosphate, 5 
µg/ml leupeptin (Sigma), 8.5 µg/ml aprotinin (Sigma). Lysates were immunoprecipitated 
using 4H1 anti-GMRα monoclonal antibody (Stomski et al., 1998), 1C1 anti-βc monoclonal 
antibody (Stomski et al., 1996), anti-JAK2 monoclonal antibody (Cell Signaling) or 12CA5 
anti-influenza hemagglutinin monoclonal antibody as a negative control. Immune complexes 
were captured on Protein A-Sepharose beads, washed extensively in lysis buffer and eluted by 
boiling in SDS sample buffer. Samples from 2-4x107 cells were fractionated on 7.5% v/v 
SDS-PAGE and analyzed by Western blotting with 1 µg/ml 4H1, 1 µg/ml 1C1, 1 µg/ml anti-
JAK2 monoclonal antibody or anti-phospho-JAK2 polyclonal antibody (Cell Signaling) at a 
dilution of 1:1000. Bound antibodies were detected using appropriate horseradish peroxidase-
coupled anti-mouse or anti-rabbit secondary antibodies (Pierce) and enhanced 
chemiluminescence (GE-Healthcare). 
Starved CTL-EN/IL3Rα/GMRα cell lines stably expressing wild-type βc or βc Site 4 
mutants were stimulated with 0, 0.01, 0.1, 1 or 10 ng/ml GM-CSF or IL-3 for 5 min and the 
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cells lyzed in NP-40 lysis buffer. Lysates were immunoprecipitated using 1C1 anti-βc 
monoclonal antibody then fractionated on 7.5% v/v SDS-PAGE and analyzed by Western 
blotting with 1 µg/ml 4G10 anti-phosphotyrosine monoclonal antibody (Upstate Cell 
Signaling Solutions) or 1 µg/ml 1C1. Samples of cell lysate were fractionated by SDS-PAGE 
and analyzed by Western blotting with anti-phospho-JAK2 polyclonal antibody or 1 µg/ml 
anti-phospho-STAT5 monoclonal antibody (Zymed). 
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Supplemental Data 
Intermolecular Disulfide bonds in the GM-CSF Receptor Complex 
IL-3, IL-5 and GM-CSF receptors have been shown to undergo covalent dimerization of their 
respective α chains with βc in the presence of their cognate ligand and this appears to be 
important for receptor activation (Stomski et al., 1996; Stomski et al., 1998). Modeling 
studies suggested the disulfide forms between domain 1 of βc and the knob domain of the α 
chain. It is not possible to homology model the knob region into the crystal structure of the 
hexamer complex so that it gets sufficiently close to domain 1 of the βc chain. However, the 
knob domain can be fitted snugly between domain 1 of GMRα  and domain 1 of βc from the 
second hexamer molecule in the dodecamer structure (Figure 3A) providing further credence 
for the physiological relevance of the latter structure. This suggests a role for the knob in 
stabilizing the higher order signaling complexes for receptor signaling. 
 
Stoichiometry of the GM-CSF Receptor Ternary Complex 
We previously characterized the formation of the soluble GM-CSF receptor ternary complex 
with a 2:1:1 stoichiometry comprising two βc chains, one GMRα chain and one GM-CSF 
molecule (McClure et al., 2003). These studies utilized protein concentrations in the low 
micromolar range but considerably higher protein concentrations (~30 µM) were used for 
preparation of material used in crystallization studies. We investigated the impact of protein 
concentration on the stoichiometry of the GM-CSF receptor complex. Purified soluble βc was 
titrated alone or in the presence of equimolar soluble GMRα and a 1.5x molar excess of GM-
CSF and the mixture fractionated by size exclusion chromatography (Figure S1). The elution 
time of the ternary complex (TC) was markedly influenced by total protein concentration 
unlike the GMRα:GM-CSF binary complex (BC) or free βc. The estimated molecular weight 
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of the ternary complex (Table S2) at protein concentrations > 5.4 µM is consistent with a 
2:2:2 complex comprising two βc chains, two GMRα chains and two GM-CSF molecules. 
The estimated molecular weight of the ternary complex formed at 1.1 µM is consistent with a 
2:1:1 complex as previously described (McClure et al., 2003). Thus the 2:1:1 complex most 
likely represents a relatively stable intermediate in the assembly of the higher order 2:2:2 GM-
CSF receptor complex. The analogous IL-6 receptor system also exists as either a 2:1:1 
complex (2 gp130 (equivalent to βc): 1 IL-6Rα: 1 IL-6) or a 2:2:2 complex. It has been 
argued that both models are correct with the differences reflecting a mechanism by which 
complex receptor systems can respond to differing cytokine concentrations (Hermanns et al., 
2005). 
 
Docking of IL-5 dimer onto Dodecameric Complex Model 
IL-5 is unique amongst cytokines utilizing βc in that it forms a disulfide-linked dimer 
whereby helix D of one chain combines with helices A, B and C of the other chain so that 
each four helix bundle of the dimer resembles the bundle observed in the monomeric GM-
CSF and IL-3 molecules. The possibility that IL-5 exerts its biological activity through both 
monomers has been supported by the observation that engineered dimers of mouse IL-3 
display increased biological activity (Ishino et al., 2004). An obvious question arises: can the 
IL-5 dimer dock onto the dodecamer complex where the GM-CSF “dimers” bind? The IL-5 
dimer was superimposed onto GM-CSF in the dodecamer complex structure (Figure S8). 
Because GM-CSF packs as a head-to-tail dimer in the complex whereas the IL-5 dimer 
assembles as a head-to-head dimer (with respect to the N-termini), the superposition results in 
one IL-5 monomer pointing out into solution. Attempts were made to dock the IL-5 dimer 
into the dodecamer complex so that both monomers interacted with βc molecules, assuming 
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that at least one of the essential E13 residues interacts with domain 4 of βc in similar fashion 
to how GM-CSF interacts with the same region. No convincing docking solution in which the 
IL-5 dimer interacting with both βc chains of the dodecamer could be identified. An IL-5 
monomer was then superimposed onto GM-CSF in the hexameric complex and a dodecamer 
complex generated using the twofold axis observed in the IL-5 dimer, but the distance 
between equivalent βc cytoplasmic tails would be approximately 100 Å, too far apart for 
signaling to occur. Thus the IL-5 dimer likely functions as a monomer in the receptor 
complex without compromising dodecamer formation. This suggestion is in agreement with 
the findings that the IL-5 dimer binds its alpha chain in a 1:1 ratio (Devos et al., 1993) and 
that engineered IL-5 monomers stimulate cell proliferation in IL-5 receptor positive cells with 
a dose dependence similar to wild-type (Li et al., 1997). 
110
Appendix 1: Publications arising
  
Figure S1. Stoichiometry of the GM-CSF Receptor Complex 
Purified sβc N346Q was titrated (1.1 – 10.9 µM) alone or mixed with equimolar sGMRα and 
a 1.5x molar excess of GM-CSF, adjusted to 50 µl with 150 mM NaCl, 50 mM sodium 
phosphate pH 7 and incubated at 25°C for at least 1 hr. Samples were chromatographed on a 
SMART system using a Superdex 200PC column (3.2 mm x 300 mm, GE Healthcare) as 
previously described (McClure et al., 2003). Elution time and area of eluted peaks was 
determined using the instruments software. The molecular weight of the eluted ternary 
complex (TC) and binary complex (BC) was estimated using the protein components as 
internal molecular weight standards as previously described (McClure et al., 2003) (Table 
S2). Chromatograms show sβc N346Q alone (A), or mixed with equimolar sGMRα and a 
1.5x molar excess of GM-CSF (B). Inset graphs plot the area of the peaks in min.mAU for 
ternary complex (TC), binary complex (BC) and free sβc (sβc) versus the elution time of each 
peak in minutes. Elution position of molecular weight standards is shown above each panel. 
 
Figure S2. Comparison of Apo and Complexed βc Structures 
The apo structure (Carr et al., 2006) is in light grey and the complex structure in magenta. The 
figure highlights a 3º rotation of domain 4 on complex formation. 
 
Figure S3. Critical role for the Phenolic Hydroxyl Group of βc Tyr421 in High Affinity 
GM-CSF and IL-3 Binding  
Scatchard plots of 125I-labelled GM-CSF or IL-3 binding to COS cells expressing GMRα 
(left) or IL3Rα (right) with wild type βc (filled square) or the Y421F (open circle), Y421A 
(open triangle) βc mutants. The dashed line indicates the high affinity binding component for 
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wild type βc and the solid lines represents the line of best fit for the Y421F and Y421A 
mutants βc as determined using Prism (Graphpad Software). 
 
Figure S4. Accommodation of N-linked Glycosylation at βc N346 Position in Dodecamer 
Interaction 
Ribbon pictures of Site 4 showing two different complex sugar chains, denoted in stick 
fashion, linked to the glycosylation site at N346. The view and coloring scheme is the same as 
shown in Figure 3B. The key to the different sugar models is shown in the right panels. N-
acetyglucosamine residues are shown as green squares and mannose residues shown as red 
circles. The sugar chains are readily accommodated in the Site 4 interface without disturbing 
it. 
 
Figure S5. Association of JAK2 with βc but not GMRα in Human AML and Normal 
Neutrophils 
(A) JAK2 associates with βc but not GMRα in mononuclear cells from a patient with acute 
myeloid leukaemia (AML). Cells were treated with 0 or 10 ng/ml GM-CSF for 5 min then 
lyzed and immunoprecipitated with antibodies specific for GMRα, βc, JAK2 or for an 
irrelevant control antigen. Immunoprecipitates were analyzed by Western blotting using 
antibodies specific for JAK2. 
(B) JAK2 associates with βc but not GMRα in normal human neutrophils. Purified 
neutrophils were treated with 0 or 10 ng/ml GM-CSF for 5 min then lyzed and 
immunoprecipitated with antibodies specific for GMRα or βc. Immunoprecipitates were 
analyzed by Western blotting using antibodies specific for GMRα, βc, total JAK2 and 
phosphorylated JAK2 (pJAK2). 
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Figure S6. Reduction in GM-CSF Stimulated Colony Formation in Cells Transduced 
with the βcM1 Mutant 
HEK293T cells were co-transfected with the pEQEco packaging plasmid (Persons et al., 
1998) and a bicistronic retroviral construct (Guthridge et al., 2006) encoding GMRα and 
either wild type or M1 mutant βc using Lipofectamine. Retroviral supernatant was harvested 
after three days and used to transduce fetal liver cells from βc-/-/βIL3-/- mice in the presence of 
50 ng/ml SCF. Transduction efficiency was quantified using flow cytometry to assess GMRα 
expression and 1x105 transduced cells were plated in 0.3% agar in a cocktail of cytokines (IL-
6+G-CSF+SCF+EPO) or 10 ng/ml GM-CSF and incubated for 14 days. The histogram shows 
the number of colonies per 1x105 cells plated and the bars represent the standard error of the 
mean. 
 
Figure S7. Generating Polyclonal Antibodies against βc Site 4 
(A) Dodecamer interface of one hexamer showing Site 4 residues colored in orange, Site 3 
residues colored in gray and the remaining residues are colored yellow for GMRα and 
magenta (domain 4a) or green (domain 1d) for βc. 
(B) The M1 peptide corresponding to βc residues 427-440 (colored in cyan) and including 
some of the Site 4 contact residues was synthesized and used to raise antibodies. 
(C) Samples of sβc were fractionated on 10% v/v SDS-PAGE and analyzed by Western 
blotting using crude pre-immune serum (Pre), M1 peptide immune serum (Imm) or M1 
peptide affinity purified immune serum (AP) at a dilution of 1:1000. Bound antibodies were 
detected using horseradish peroxidase-coupled anti-rabbit secondary antibodies (Pierce) and 
enhanced chemiluminescence (GE-Healthcare). 
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Figure S8. IL-5 Docking onto the GM-CSF Receptor Dodecamer Complex 
Structural superposition of the IL-5 dimer onto one of the GM-CSF molecules in the complex. 
Shown are (A) side and (B) top views. The cartoon below explains why the IL-5 dimer does 
not superimpose on the GM-CSF “dimer”. 
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Table S1  Data Collection and Refinement Statistics 
 
  GM-CSF Receptor Complex
Data collection  
Space group P6322
Cell dimensions  
    a, b, c (Å) 166.6, 166.6, 213.1
    α, β, γ (°)  90, 90, 120
Resolution (Å) 3.3 (3.5-3.3)
Rmerge 7.7 (62.1)
I / σI 17.7 (2.3)






Rwork / Rfree (%) 27.0 / 31.7
No. atoms 5127
B-factors after TLS refn (Å2)  
    All atoms 122.71
    GM-CSF-alpha 126.34
    GM-CSF-beta 122.22
    GM-CSF 120.77
R.m.s. deviations  
    Bond lengths (Å) 0.013
    Bond angles (°) 1.5
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Table S2 Calculated Molecular Weight of Ternary Complex 
Concentration of sβc N346Q        Estimated Molecular Weight 
µM TC BC 
   
1.1 156,000 60,000 
2.2 169,000 57,000 
3.3 185,000 57,000 
4.3 197,000 57,000 
5.4 200,000 56,000 
6.5 204,000 55,000 
8.7 209,000 54,000 
10.9 217,000 54,000 
 
Molecular weight of components; 
GM-CSF = 13,700 
sGMRα = 40,700 
sβc N346Q dimer = 97,400 
Predicted Molecular Weights; 
1:1 (α:GM) Binary Complex (BC) = 54,400 
2:1:1 (β:α:GM) Ternary Complex (TC) = 151,900 
2:2:2 (β:α:GM) Ternary Complex (TC) = 206,300 
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Table S3 GM-CSF and IL-3 Binding Affinities of βc Site 4 Mutants 
   
               GM-CSF Binding                 IL-3 Binding 
       
βc Mutant  n Kd (pM) Receptors/cell n Kd (pM) Receptors/cell 
       
βc wild type 8  70-200  3300-11100 4  35-145  360-2200 
βcM1 7  35-100  700-2200 2  50-80  240-360 
βcM2 4  190-600  7600-23000   n.d.  n.d 
βcM3  1  300  5100 2  60-120  420-1800 
βcM4 1  200  2200 2  150-200  1000-1100 
βcM5  1  40  400 2  90-170  970-1120 
βcM6 1  150  2150 2  89-91  100-240 
 
Summary of Scatchard analysis of 125I-labelled GM-CSF or IL-3 binding to CTL-
EN/IL3Rα/GMRα cells expressing wild type or mutant βc. 
n = number of experimental determinations, n.d.= not determined 
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